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ABSTRACT 
 
MEHUL S. SUTHAR:  Molecular Pathogenesis of the Sindbis-group virus strain AR86 
           (Under the direction of Mark T. Heise, Ph.D.) 
 
  Sindbis virus infection of mice has provided valuable insight into the viral and host 
factors that contribute to virus-induced neurologic disease.  In an effort to further define the 
viral genetic elements that contribute to adult mouse neurovirulence, the virulent Sindbis-
group virus strain AR86 was compared to the closely related (22 single amino acid coding 
differences and the presence or absence of an 18 amino acid sequence in nsP3), but avirulent 
Girdwood strain.  Detailed mapping studies identified three major determinants in the 
nonstructural region at nsP1 538 (Ile to Thr; avirulent to virulent), an 18 amino acid deletion 
in nsP3 (positions 386-403), and nsP3 537 (Opal to Cys; avirulent to virulent), as well as a 
single determinant in the structural genes at E2 243 (Leu to Ser; avirulent to virulent) that 
were essential for AR86 adult mouse neurovirulence.  Of these four virulence determinants, 
we found that the virulence determinant at nsP1 538 plays a particularly important role.  This 
determinant has been shown to regulate viral nonstructural processing, viral RNA synthesis, 
and play a major role in regulating adult mouse neurovirulence.  Analysis of the effect of the 
nsP1 538 determinant on modulating the host antiviral response demonstrated that an 
attenuating mutation at nsP1 538 resulted in enhanced type I interferon induction.  While 
most alphaviruses have been shown to inhibit type I interferon induction through virus-
induced host cell shutoff, we demonstrated that the Sindbis-group virus strain AR86 inhibits 
type I interferon induction through an additional mechanism by inhibiting the activation of 
interferon regulatory factor 3 (IRF-3), a key mediator of type I interferon induction.  In an 
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effort to extend these findings, we examined virus interactions with the type I interferon 
induction signaling pathway.  We found that although AR86 genomic RNA is efficiently 
recognized by retinoic-acid inducible gene I (RIG-I), a host cytoplasmic sensor of viral 
dsRNA, AR86 virus actively antagonized IRF-3 activation induced from an exogenous 
source of dsRNA.  Furthermore, the viral nonstructural proteins (nsPs), when expressed 
independently of virus infection, inhibited RIG-I and melanoma-differentiation-associated 
gene 5 (Mda5), a related host cytoplasmic sensor of viral dsRNA, signaling.  Strikingly, co-
expression of the viral nsPs proteins led to the loss of RIG-I, Mda5, and IRF-3 expression in 
a manner that was dependent on the nsP2 protease.  These results demonstrate that the viral 
nonstructural proteins specifically antagonize the type I interferon induction signaling 
pathway and suggest that the virus may directly target components of the type I interferon 
induction signaling pathway.  The results from these studies have provided significant insight 
into the viral and host factors that mediate virus-induced disease and have advanced our 
understanding of the mechanisms underlying alphavirus pathogenesis. 
 
 
 v 
 
 
 
 
 
This thesis is dedicated to my wife, Sucheta,  
Who has  helped me maintain a positive attitude 
 and supported me throughout 
 
And to my mother, father, and brothers 
For their support and encouragement 
 
And this would not be possible without Maharaj and Swami, 
For giving me a second chance at life 
 vi 
 
 
 
 
 
ACKNOWLEDGEMENTS 
 
There are so many people that I would like to thank for helping me complete my thesis.  
First, I would like to thank my mentor, Mark T. Heise, for taking me on as his first student 
and providing me with constant support and encouragement.  I would like to thank my 
committee members for providing me with valuable ideas on my research.   I would like to 
thank the present and past members of the Heise Lab.  I would like to individually thank 
Reed Shabman, Tem Morrison, Cathy Cruz, and Jason Simmons for help with experiments, 
reagents, and valuable scientific discussions.  I would like to thank all of the past and present 
members of Johnston and White laboratories.  I would like to thank the Carolina Vaccine 
Institute.  I would like to thank all of my collaborators, including Dr. Charlie Rice and Dr. 
Joe Marcotrigiano.  Finally, I would like to thank all of my family and friends who have 
made my time in graduate school fun and worthwhile.   
 
 
 
 
 vii 
 
 
 
 
 
TABLE OF CONTENTS 
 
LIST OF TABLES....................................................................................................................xi 
LIST OF FIGURES.................................................................................................................xii 
LIST OF ABBREVIATIONS ................................................................................................xiv 
 
Chapter 
I.  INTRODUCTION................................................................................................................ 1 
OVERVIEW OF ALPHAVIRUSES ............................................................................... 2 
Genetics and Epidemiology of Alphaviruses............................................................. 2 
Genome Organization and Virus Life Cycle ............................................................. 6 
Viral Particle ........................................................................................................ 6 
Virus attachment and entry .................................................................................. 7 
Viral RNA Synthesis.......................................................................................... 10 
Virus assembly and budding.............................................................................. 13 
ANIMAL MODELS TO STUDY HUMAN-DISEASE ASSOCIATED WITH 
ALPHAVIRUS INFECTIONS...................................................................................... 14 
Virus-induced bone/joint disease............................................................................. 14 
Alphavirus-induced neurologic disease ................................................................... 17 
Sindbis virus....................................................................................................... 18 
TRSB/TR339 ............................................................................................... 19 
 viii 
SV and NSV................................................................................................. 21 
AR86............................................................................................................ 24 
Venezuelan Equine Encephalitis virus............................................................... 26 
Semliki Forest virus ........................................................................................... 29 
VIRUS MODULATION OF THE HOST TYPE I INTERFERON INDUCTION....... 34 
Type I interferon signaling pathway........................................................................ 34 
Host factors limiting alphavirus replication....................................................... 38 
Alphavirus evasion of type I interferon ............................................................. 39 
Alphavirus modulation of type I interferon ....................................................... 40 
DISSERTATION OBJECTIVES .................................................................................. 42 
REFERENCES .............................................................................................................. 44 
II.  AN ARTHRALGIA ASSOCIATED SINDBIS VIRUS EXHIBITS ENHANCED 
REPLICATION IN MURINE JOINT AND MUSCLE TISSUE........................................... 74 
ABSTRACT................................................................................................................... 75 
KEYWORDS................................................................................................................. 76 
INTRODUCTION ......................................................................................................... 77 
RESULTS ...................................................................................................................... 81 
DISCUSSION................................................................................................................ 85 
ACKNOWLEDGMENTS ............................................................................................. 92 
REFERENCES .............................................................................................................. 93 
III.  IDENTIFICATION OF ADULT MOUSE NEUROVIRULENCE DETERMINANTS 
OF THE SINDBIS VIRUS STRAIN AR86 ......................................................................... 109 
ABSTRACT................................................................................................................. 110 
 ix
MATERIALS AND METHODS................................................................................. 114 
RESULTS .................................................................................................................... 118 
DISCUSSION.............................................................................................................. 126 
ACKNOWLEDGMENTS ........................................................................................... 132 
REFERENCES ............................................................................................................ 133 
IV.  A VIRULENCE DETERMINANT AT NSP1 538 MODULATES TYPE I 
INTERFERON INDUCTION BY THE SINDBIS-GROUP VIRUS STRAIN AR86......... 150 
ABSTRACT................................................................................................................. 151 
INTRODUCTION ....................................................................................................... 152 
MATERIALS AND METHODS................................................................................. 156 
DISCUSSION.............................................................................................................. 165 
ACKNOWLEDGEMENTS......................................................................................... 168 
REFERENCES ............................................................................................................ 169 
V.  THE SINDBIS VIRUS NONSTRUCTURAL PROTEINS ANTAGONIZE TYPE I 
INTERFERON INDUCTION BY INHIBITING RIG-I AND IRF-3 ACTIVITY .............. 185 
ABSTRACT................................................................................................................. 186 
INTRODUCTION ....................................................................................................... 187 
MATERIALS AND METHODS................................................................................. 190 
RESULTS .................................................................................................................... 194 
DISCUSSION.............................................................................................................. 200 
ACKNOWLEDGEMENTS......................................................................................... 203 
REFERENCES ............................................................................................................ 204 
VI.  DISCUSSION................................................................................................................ 222 
 x
Girdwood virus-induced arthralgia in mice ................................................................. 223 
The genetic determinants of the adult mouse neurovirulent AR86 virus .................... 225 
AR86 virus antagonism of type I IFN induction ......................................................... 231 
REFERENCES ............................................................................................................ 237 
 
 xi
LIST OF TABLES 
Table 2-1:  Girdwood virulence in mice. .............................................................................. 100 
 
Table 3-1.  Amino acid sequence comparison between AR86 and Girdwood. .................... 137 
 
 
 
 
 xii
LIST OF FIGURES 
Figure 2-1:  Relative specific infectivity of the Girdwood clone (G100), 
Girdwood natural isolate and TRSB. ..................................................................96 
 
Figure 2-2:  The Girdwood clone displays similar in vitro growth kinetics 
as that of the natural isolate. ...............................................................................98 
 
Figure 2-3:  Girdwood infected mice show more severe disease signs than 
TR339. ..............................................................................................................101 
 
Figure 2-4:  Girdwood exhibits tropism for bone and joint-associated 
connective tissues..............................................................................................103 
 
Figure 2-5:  Girdwood exhibits enhanced replication in peripheral tissues 
as compared to TR339. .....................................................................................105 
 
Figure 3-1:  Both the nonstructural and structural genes of AR86 contain 
neurovirulence determinants. ............................................................................138 
 
Figure 3-2:  Mutational analysis of neurovirulence determinants within the 
nonstructural genes of AR86. ...........................................................................140 
 
Figure 3-3:  AR86 neurovirulence determinants within the nonstructural 
genes. ................................................................................................................142 
 
Figure 3-4:  AR86 neurovirulence determinants within the structural 
genes. ................................................................................................................144 
 
Figure 3-5:  Identification of the major determinants of neurovirulence 
within AR86......................................................................................................146 
 
Figure 3-6:  In vitro and in vivo growth analysis of virulent and attenuated 
viruses. ..............................................................................................................148 
 
Figure 4-1:  The mutant S340 virus induces more type I IFN in cell 
culture. ..............................................................................................................175 
 
Figure 4-2:  The mutant S340 virus induces a robust type I IFN response 
in vivo................................................................................................................177 
 
Figure 4-3:  The mutant S340 virus exhibits similar kinetics of host cell 
transcription shutoff as compared to wild-type S300 virus. .............................179 
 
Figure 4-4:  The mutant S340 virus shuts off host cell translation with 
similar kinetics as the wild-type S300 virus. ....................................................181 
 xiii 
 
Figure 4-5:  The mutant AR86 virus induces earlier IRF-3 activation. .................................183 
 
Figure 5-1:  RIG-I is more efficient in responding to AR86 viral RNA than 
Mda5. ................................................................................................................208 
 
Figure 5-2:  AR86 virus blocks poly-(I:C)-mediated IRF-3 activation. ................................210 
 
Figure 5-3:  The AR86 nsPs inhibit RIG-I and Mda5 mediated IFN-β 
promoter activity. ..............................................................................................212 
 
Figure 5-4:  The AR86 nsPs inhibit constituitively active RIG-I mediated 
IFN-β promoter activity. ...................................................................................214 
 
Figure 5-5:  The protease function of nsP2 is critical in antagonizing RIG-I 
and Mda5 mediated IFN-β promoter activity. ..................................................216 
 
Figure 5-6:  AR86 nsPs inhibit MAVS/IRF-3 signaling pathway.........................................218 
 
Figure 5-7:  Expression of AR86 nsPs induces the loss of RIG-I, Mda5, 
and IRF-3 expression. .......................................................................................220 
 
 
 
 
 xiv
LIST OF ABBREVIATIONS 
BFC  Barmah Forest virus complex 
CARD  Caspase recruitment domain 
IFN  Interferon 
IRF-3  Interferon Regulatory Factor-3 
i.c.  Intracranial 
kDa  Kilodalton 
Mda5  Melanoma-differentiation-associated gene 5 
NSV  Neuroadapted Sindbis virus 
nsP  nonstructural protein 
NF-κB  Nuclear factor kappa B 
PAMP  Pathogen-associated molecular patterns 
POGD  Pogosta virus disease 
PRR   Pattern recognition receptors 
RIG-I  Retinoic-acid inducible gene I 
RRV  Ross River virus 
RRVD  Ross River virus disease 
SFV  Semliki Forest virus 
SFC  Semliki Forest complex 
SINV  Sindbis virus 
SLC  Sindbis-like complex 
SIRS  Systemic Inflammatory Response Syndrome 
VEE  Venezuelan Equine Encephalitis virus 
  
 
 
 
 
CHAPTER ONE 
INTRODUCTION 
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OVERVIEW OF ALPHAVIRUSES 
 
Genetics and Epidemiology of Alphaviruses 
 Alphaviruses are mosquito-borne viruses containing a positive-sense single-stranded 
RNA genome and are members of the Togaviridae family.  Most alphaviruses are found 
within an enzootic cycle in nature, cycling between a mosquito vector and a principle 
vertebrate reservoir host, consisting of a small mammal or bird.  Occasionally, alphaviruses 
are transmitted through the bite of a mosquito to large mammal hosts, such as horses, 
turkeys, and humans, resulting in an epizootic transmission cycle.  Infection of large mammal 
hosts can be divided into two categories based on the outcome of disease (281).  New World 
alphaviruses are generally associated with fever, moderate to severe encephalitis, and 
occasionally resulting in fatal disease (249).  Old World alphaviruses are generally associated 
with fever, rash, and debilitating and often persistent polyarthritis (145, 249).   
 New World alphaviruses are primarily found in North and South America and 
compose of three main virus members, Venezuelan Equine Encephalitis (VEE), Eastern 
Equine Encephalitis (EEE), and Western Equine Encephalitis (WEE) viruses.  VEE is found 
within an enzootic cycle between Culex species of mosquitoes and a small mammal, 
primarily the cotton rat, spiny rat, and opossums (44, 75, 76, 92, 93, 229, 279).  One theory is 
that viral mutations within the enzootic transmission cycle can result in a crossover to the 
epizootic cycle resulting in a broader mosquito host range and infection of large mammal 
hosts, such as humans and horses (29, 30, 94, 280).  Infection with enzootic strains of VEE in 
equines and humans are generally avirulent, with the exception of a few reported cases of 
human fatalities, however, epizootic strains are virulent and do cause significant disease 
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(189, 275).  In particular, subtype IAB and IC viruses have been estimated to cause between 
19-83% mortality in equines and less than 1% in humans, with 4-14% showing neurologic 
symptoms (26, 64, 189, 228, 275).  Most recently, a major outbreak of VEE was reported in 
1995 in Venezuela and Colombia, causing disease in nearly 75,000-100,000 individuals and 
a case fatality rate of 0.7% (4, 5, 284, 284).     
EEE virus is maintained within an enzootic cycle by Ornitophillic species of 
mosquitoes and a narrow host range of Passerine birds (180).  During the enzootic cycle, the 
virus becomes available to other mosquito species, otherwise known as the “bridge vector,” 
that have broader feeding preferences and can result in transmitting the virus to hosts, such as 
horses and humans (109).   Although EEE virus has a low incidence rate within the Americas 
(8.2 cases per year within the United States), it is the most pathogenic of the encephalitic 
alphaviruses, causing between 35-70% mortality, with children and the elderly being most 
susceptible (1, 28, 36).   
Similar to EEE virus, WEE virus is maintained by a bird/mosquito enzootic cycle and 
is a significant equine pathogen.  WEE virus was first isolated from equines suffering 
encephalomyelitis during an outbreak in 1931 in the San Joaquin Valley (175).  An estimated 
6,000 equines showed signs of neurologic disease and approximately 3,000 equines 
succumbed to infection (175).  WEE virus is thought to have evolved from a recombination 
event between a Sindbis-like virus and EEE virus that probably occurred between 1,300 and 
1,900 years ago (103, 283).  Finally, similar to VEE and EEE virus, WEE virus poses a 
significant threat to humans due to possibility of transmission via the aerosol route (206).  
 Old World alphaviruses can be found throughout most of the world, including Africa, 
Asia, Australia, and Europe.  Similar to the New World alphaviruses, Old World 
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alphaviruses are maintained in nature either by a mosquito/bird or mosquito/large vertebrate 
host cycle.  Old World alphaviruses can be divided up into three main groups based on their 
antigenic complexes, namely Semliki Forest complex (SFC), Bharma Forest complex (BFC), 
and Sindbis-like virus subcomplex (SLC) within the WEE virus complex (204).   
The SFC consists of several viruses that are significant causes of human polyarthritis 
and rash.  Ross River virus (RRV), which is endemic to Australia, spread to the island of Fiji 
causing a major outbreak in 1979 (6, 21, 66).  On  the island of Fiji alone, an estimated 
500,000 individuals were infected and about 50,000 patients showed symptoms of severe 
pain in one or more joints, rash, and fever (6, 21, 66, 258).  Chikungunya virus (CHIKV), 
another SFC virus, was first isolated in 1952-53 during an epidemic in Tanzania (162, 168, 
210).  Similar to RRV, CHIKV causes severe and debilitating polyarthritis, headache, fever, 
and rash within 2-4 days from initial infection (31, 32).  Since the initial discovery of 
CHIKV, several small-scale outbreaks have been reported in India and Africa.  However, in 
February 2006, a major outbreak of CHIKV was reported on the island of Reunion (54).  In a 
matter of 6-9 months, the virus spread rapidly and reached epidemic proportions in East 
African countries bordering the Indian Ocean and reaching as far as India and Sri Lanka (2, 
3, 235).  In India alone, as of October 2006, nearly 1.25 million suspected cases have been 
reported, although this maybe underestimated due to likelihood of misdiagnosing patients 
with similar symptoms from dengue virus infection (3, 25, 205, 224).   
The BFC consists of one member, Barmah Forest virus (BFV), and is the second most 
common mosquito-born disease in Australia.  The incidence rate has been reported to be 
lower than that of RRV and appears to be geographically restricted along the Australian 
coastline (108).  However, BFV has the potential to pose a serious public health risk due to 
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its similarities to RRV and its ability to replicate in greater than 73 species of mosquitoes 
(184).   
 The Sindbis-like subcomplex consists of the prototype strain of Sindbis virus (SINV) 
AR339 and several related strains.  AR339 was isolated in Egypt in 1952 from a pool of 
Culex species of mosquitoes (256).  Sindbis and Sindbis-like viruses are widespread and can 
be found throughout Africa, Europe, Asia and Australia (204).   However, clinical disease 
associated with SINV infection is common in geographically restricted areas, such as South 
Africa, Egypt, and Northern Europe (145).  The broad distribution of SINV is primarily due 
to bird migrations patterns, which serve as the major blood source for vector mosquitoes, and 
the availability of competent mosquito reservoir hosts (onithophilic mosquitoes of the genra 
Culex, Culiseta) (65, 163).  Similar to EEEV, the epizootic cycle involves introduction of the 
virus to the Aedes sp. of mosquitoes to serve as the “bridge vector” (50).   
 It was not until 1963 in Johannesburg, South Africa, that the first SINV was isolated 
from a 45-year-old woman suffering from debilitating arthralgia in several joints, 
maculopapular rash on the trunk and limbs, and fever (166).  Comparative studies of this new 
strain of SINV, named GirdwoodS.A., was found to be antigentically closely related to 
another SINV strain, AR86, which was isolated from a pool of Culex species of mosquitoes 
near the same area 9 years earlier (166, 285).   
 In 1982, Ockelbo virus was isolated in central Sweden from a pool of Culiseta 
mosquitoes and found to be the etiological agent for the Sindbis-like human symptoms 
afflicting the area for the past 15 years (187).  The Ockelbo82 isolate cross-reacted with 
convalescent sera from patients with symptoms of Ockelbo disease and found to be closely 
related to SINV (187).  Similar diseases were reported in eastern Finland and the Karelian 
 6 
region of the former Soviet Union and were later termed “Pogosta disease” and “Karelian 
fever”, respectively (145).  Endemic outbreaks of Pogosta disease are typically found to 
occur at a frequency of every 7 years and between late July and early October (34, 140).  
While the exact reason for this cyclical pattern is not yet known, environmental effects and 
herd immunity in tetranoid birds are thought to play a contributing role (34).  Similar 
frequencies are thought to occur with Ockelbo disease and Karelian fever (145).  The last 
Pogosta disease outbreak occurred in the fall of 2002 in Finland and one study reported that 
approximately 11% of serum samples from a case study tested positive for antibodies against 
Pogosta virus, with the highest reported cases from western Finland (15%) to the lowest in 
northern Finland (6%) (146).  Another study reported that nearly 50% of Pogosta virus 
infected patients with joint symptoms lasted for greater than 12 months (139).  Currently 
there is no vaccine against SINV infections and the only therapy is supportive.   
 
Genome Organization and Virus Life Cycle 
Viral Particle  
Alphaviruses are plus-strand RNA viruses with a genome of approximately 11.7 kilobases in 
length.  The viral RNA consists of a methylated cap on the 5’ end and a polyadenylated tail 
at the 3’ end.  The RNA is encapsidated with a single capsid protein arranged with 
icosahedral surface symmetry consisting of a triangulation number of 4 (T=4) (193).  The 
virion is enclosed within a lipid-protein envelope consisting of a lipid-bilayer derived from 
the host cell plasma membrane and two envelope glycoproteins (E2 and E1) protruding from 
the surface.  The E2-E1 glycoprotein’s form 80 trimeric spikes that are involved in receptor 
interaction and fusion, respectively (reviewed in reference (249)).    
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Virus attachment and entry   
Alphaviruses have a broad host range which include infecting vertebrate (mammals and 
birds) and invertebrate (mosquito vectors) hosts, as described in detail earlier.  Within each 
of the hosts, the virus is able to infect a variety of cell types, including but not limited to 
dendritic cells, muscle cells, connective tissues, and neurons.  Similarly, within cultured 
cells, most alphaviruses are able to infect a variety of cell types with fairly high efficiencies.  
This indicates that there maybe one or more receptors and co-receptors mediating alphavirus 
infectivity.  Early studies from Wang et al. revealed a 67 kiloDalton (kDa) high-affinity 
laminin protein as a receptor for SINV entry in mammalian cells (276).  This protein was 
found to be highly conserved in mammals and mosquitoes and expressed in a variety of cell 
types, which may partially explain the very broad host range of alphaviruses.  Furthermore, 
Wang et al. also identified a distinct 63 kDa protein in chicken cells as a major receptor for 
SINV, suggesting differences in receptor usage between mammalian and avian host species 
(276).  Ubol and Griffin identified two proteins (110 kDa and 74 kDa), primarily expressed 
on neural cells at birth, believed to serve as a receptor for SINV (270).  However, expression 
of these proteins was found to be short-lived after birth.  In 4-day old mice, expression 
decreased dramatically, which may explain the age-related susceptibility of SINV infection 
in mice (270).  The identity of these putative attachment receptors has not yet been 
determined.  Furthermore, recent work by La Linn et al. identified the collagen-binding α1β1 
integrin as a receptor for RRV, however, its use as a receptor appears to be limited to BFV 
and RRV and complete inhibition of virus infection, as measured by antibody specific for the 
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α1β1 integrin, was not achieved (141).  This suggests that α1β1 integrin is not the only 
receptor for RRV.    
 Identification of attachment receptors for alphaviruses has been complicated by the 
fact that most alphaviruses rapidly adapt in cell culture to interact with glycosaminoglycans, 
specifically heparan sulfate, and act as an attachment receptor.  Acquisition of this adaptation 
has a tendency to occur after continuously passaging virus in cultured cells (135).  While 
binding heparan sulfate increases the efficiency of infection in cultured cells, this adaptation 
has detrimental effects on the virulence of the virus (22, 134).  Klimstra et al. has 
demonstrated that two C-type lectins, DC-SIGN (for DC-specific ICAM-3 grabbing non-
integrin) and L-SIGN (for liver/lymph node-specific ICAM-3 grabbing non-integrin), 
expressed specifically on dendritic cells and on specialized liver and lymph node endothelial 
cells, respectively, can be used as co-receptors for SINV (133).  Treating cells with inhibitors 
to DC-SIGN or L-SIGN, such as yeast mannan, EDTA, or antibody considerably reduced 
infectivity (133).  C-type lectins contain a carbohydrate recognition domain that can bind 
carbohydrate structures in a Ca++ dependent manner (295).  Based on this feature, Klimstra 
et al.. also discovered that viruses grown in mosquito cells, more efficiently bind to DC-
SIGN or L-SIGN expressing cells as compared to virus grown in mammalian cells (133).  
This finding suggests that carbohydrate modifications on the viral glycoproteins alter the 
efficiency of virus to bind to DC-SIGN or L-SIGN.  Furthermore, it has been demonstrated 
that mosquito-grown RRV virus, which has simple glycans on the glycoproteins, infect 
dendritic cells with higher efficiencies than mammalian-grown virus consisting of complex 
glycans (133, 237).     
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 Alphaviruses are thought to deliver their genome RNA into the host cell cytoplasm of 
a cell through one of two pathways, direct fusion of the virion with the host cell plasma 
membrane or receptor-mediated endocytosis (38, 42, 55, 114, 131).  This has been a subject 
of significant controversy in the literature.  In the pathway involving direct fusion with the 
cell plasma membrane, it is believed that the first event triggering fusion is interaction of the 
E2 glycoprotein with a receptor at the cell surface (63).  This interaction triggers a structural 
rearrangement of the heterodimeric E2-E1 glycoprotein spikes (176), resulting in fusion with 
the cell plasma membrane at neutral pH and the subsequent release of the virion genome 
RNA into the cytoplasm (194).  These studies were completed using the SINV strain AR339 
and several laboratory strain variants.  Early studies demonstrated that fusion occurred 
independent of the endocytosis pathway by using lysosomotropic weak bases, such as 
chloroquine and ammonium chloride and a temperature-sensitive Chinese hamster ovary 
mutant cell line defective in its ability to acidify endosomes (38, 42, 52).  However, a 
conflicting report from Glomb-Reinmund and Kielian demonstrated that SINV and SFV 
fusion occurs in the endosome in a pH-dependent manner (88).  Studies by Flynn et al. 
demonstrated that the E2-E1 glycoprotein spikes undergo structural rearrangement at neutral 
pH (63), while Meyer et al. demonstrated that the structural rearrangements could be 
mimicked in vitro by treatment with low pH, brief exposure to heat, or treatment with a 
reducing agent (176).  Furthermore, Abell and Brown demonstrated that thiol-disulfide 
exchange reactions were integral to the fusion event, which has been shown to disrupt the 
rigid E1 glycoprotein associations, a step which is suggested to directly follow the structural 
protein rearrangement (7). 
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 In regards to the receptor-mediated endocytosis fusion pathway, studies were initially 
conducted using SFV and later studies directly compared SINV to SFV.  Early studies, 
demonstrated that SFV enters the cell through a receptor-mediated endocytosis pathway 
(114, 167, 290).  Using a liposome-based fusion assay to analyze alphavirus entry, studies 
showed that fusion was pH-dependent and required cholesterol and sphingolipids (130, 185, 
289).  Studies with SFV have shown that the virus is first internalized upon receptor-
recognition at the cell surface, followed by uptake into a relatively neutral pH containing 
endocytic compartment, delivery to an early endosome with an acidic pH, transition to a late 
endosome with a lower pH, and fusion between the viral membrane and the lysosomal 
membrane, and finally delivery of the viral genome into the cytoplasm (114, 230).  Similar to 
studies with SINV, conformational changes were also observed with SFV structural proteins 
upon low pH treatments, however unlike SINV, virions exposed to low pH were able to fuse 
directly to the plasma membrane, suggesting treatment with an acidic pH is all that is 
required to trigger the fusion event (33, 85, 272, 273, 290).   
 Interestingly, both competing groups agree that the structural rearrangement induced 
by exposure to low pH results in the formation of E1 homotrimeric proteins (194, 272).  
Isolation and crystallization of these trypsin-resistant E1 trimeric proteins revealed that five 
of these trimers assemble to form a fusion pore (85, 288).  These fusion pores are believed to 
facilitate cell penetration (194, 288).   
 
Viral RNA Synthesis   
Upon successful entry and uncoating, the genomic RNA is immediately translated by the host 
cell translation machinery.  The first of the viral proteins that are translated are the viral 
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nonstructural proteins, producing one of two polyproteins, nsP123 or nsP1234.  The larger 
polyprotein is produced by read-through of an opal termination codon located between nsP3 
and nsP4.  While most alphaviruses encode for an opal termination codon proximal to the 3’ 
end of the nsP3 gene, the SINV strain AR86 and the prototype SFV strain SFV4 carry a 
sense codon (241, 255).  Translation readthrough of the opal termination codon occurs at a 
frequency of about 5-20%, thus limiting the quantities of the nsP4 protein relative to the 
other nonstructural proteins (158, 160).   
 The nonstructural coding region encodes for four nonstructural proteins.  
Nonstructural protein 1 (nsP1) is involved in capping newly synthesized genomic and 
subgenomic viral RNA’s by functioning as a guanine-7-methyltransferase and 
guanylyltransferase (8).  In addition, nsP1 has been shown to be tightly bound to host cell 
membranes and is palmitoylated (9, 142, 199).  NsP2 is a multifunctional protein exhibiting 
papain-like thiol proteolytic activity (105), nucleoside triphosphatase activity (208, 271), and 
helicase activity (89).  The nsP2 protease is responsible for cleaving the various nonstructural 
polyprotein precursors and, as a result, plays an important role in regulating viral RNA 
synthesis.   
The nucleoside triphosphatase activity initiates the viral RNA capping process by 
cleaving the γ-β 5’triphosphate bond from newly made viral RNAs followed by the addition 
of a methylated cap by nsP1 (8, 271).  NsP2 also is believed to play a major role in regulating 
virus-host interactions.  NsP2 has been found to be important in regulating virus-induced host 
translation and transcription shutoff (77, 90).   Approximately 50% of nsP2 is found within 
the nucleus of infected cells, however, its role in the nucleus is not well understood (90, 200, 
209).   
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NsP3 is a phosphorylated protein that plays an essential role in viral minus-strand and 
subgenomic RNA synthesis, however, the functions of nsP3 are not well defined (148, 201, 
277).  The N-terminus of nsP3 is highly conserved amongst alphaviruses while the C-
terminus varies in length and sequence (136, 249).  Virus-host interaction studies have shown 
that nsP3 interacts with several host proteins, however, the importance of these interactions 
are not well understood (43, 72).  In addition, studies have found that nsP3 aggregates to 
form dynamic spherule complexes within the cytoplasm (72).   
The nsP4 protein is highly conserved amongst alphaviruses and functions as the viral 
RNA-dependent RNA polymerase and was found to possesses terminal adenylyltransferase 
activity (249, 261).  NsP4 is also found to be tightly regulated within infected cells, in that 
excess nsP4 is highly unstable and shown to rapidly degrade by the N-end rule pathway (48).   
Virus minus-strand RNA synthesis is initiated when nsP4 is cleaved from the nascent 
nonstructural polyprotein at the nsP3/nsP4 site by the nsP2 protease and associates with 
nsP123 to form the nsP123-nsP4 complex (150-152, 239, 277).  This viral replication 
complex forms on the cytoplasmic side of endosomes and lysosomes and is capable of 
binding viral genome RNA and synthesizing 49S minus-strand RNA (70, 74, 149, 218).  
Subsequent cleavage at the nsP1/nsP2 site forms a short-lived nsP1-nsP23-nsP4 replication 
complex capable of minus-strand and plus-strand synthesis.  The final cleavage event at the 
nsP2/nsP3 site forms the stable nsP1-nsP2-nsP3-nsP4 replication complex that is active in 
genomic plus-strand RNA synthesis and recognition of the internal 26S promoter in the 
minus-strand template to initiate 26S subgenomic RNA synthesis (239, 253).  It is thought 
that cleavage of the nsP2/nsP3 serves to halt minus-strand RNA synthesis and amplify 26S 
subgenomic RNA synthesis.  Minus-strand RNA synthesis occurs early during infection, 
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requires ongoing protein synthesis, and typically ceases between 3-6 hours post-infection 
while plus-strand RNA synthesis is ongoing for the remainder of the viral life cycle (152, 
223).   
 
Virus assembly and budding   
The subgenomic RNA is translated to make the structural genes.  The structural proteins are 
translated as a single polyprotein and the capsid protein, which is the first protein translated, 
is processed from the nascent polyprotein by the autoprotease activity of the capsid protein 
(11, 104, 173).  Once the capsid protein is released, an exposed signal peptide in pE2 
translocates the pE2-6k-E1 polyprotein into the lumen of the ER (24, 79, 80).  Following 
insertion into the ER membrane, a host signal peptidase is believed to cleave pE2 from pE2-
6K-E1 polyprotein (159).  This cleavage event exposes a signal sequence on the N-terminus 
of 6K and leads to ER membrane translocation of the 6K-E1 polyprotein (174).   While in the 
ER, the E1 protein is folded into its mature metastable conformation by changes in disulfide 
bonding (183).  In addition, PE2 heterodimerizes with E1 to form the premature viral 
glycoprotein followed by formation of the glycoprotein spike, consisting of three sets of the 
PE2-E1 heterodimer (20).  During transport through the secretory pathway to the plasma 
membrane, fatty acid modifications and oligosaccharide modifications are added to the 
glycoproteins (as reviewed in reference (249) and PE2 is processed by the host endoprotease 
furin to form the mature E2 glycoprotein (222, 296). 
 Budding is initiated by oligomerization of the capsid protein and encapsidation of the 
viral genome RNA.  Selection of the viral genome RNA occurs by interaction of a packaging 
signal within nsP1 or nsP2, which varies depending on the strain of alphavirus, along with a 
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stretch of 68 amino acid residues in the capsid protein (71, 84, 286, 287).  One-to-one 
interactions between the cytoplasmic tail of the E2 glycoprotein spike and the capsid protein 
initiates assembly of the capsid core (as reviewed in reference (81).  Once fully assembled, 
the virion contains 240 copies of the capsid protein and 240 copies of the E2 and E1 
glycoproteins in the envelope (193).  The mature virion buds from the plasma membrane and 
into the extracellular space.  
 
ANIMAL MODELS TO STUDY HUMAN-DISEASE ASSOCIATED WITH 
ALPHAVIRUS INFECTIONS 
 
Virus-induced bone/joint disease 
 Old world alphaviruses are a general cause of infectious rheumatic complaints, 
including severe arthritis, arthralgia, and myalgia (98, 145).  Ross River virus, Sindbis group 
viruses, Chikungunya virus, O’nyong-nyong virus, and Mayaro virus are recurrent problems 
in Australia, Southern Africa, Northern Europe Asia, and South America where they cause 
several hundred to several thousand reported cases of disease each year (2, 3, 145, 252, 257).  
Of note, Mayaro virus is the only arthralgia-inducing alphavirus located in the Americas 
(259). However, many of these viruses, including RRV, O’nyong-nyong, and CHIKV, are 
also capable of emerging in new locales and causing epidemics on a massive scale, as 
illustrated by an outbreak of RRV disease (RRVD) in the South Pacific in 1979-80 that 
affected 50-60,000 individuals just on the island of Fiji (6, 66, 106), an outbreak of O’nyong-
nyong in the 1960’s that caused upwards nearly two million cases of infectious 
arthritis/arthralgia (292), and currently an outbreak of CHIKV of epidemic proportions 
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affecting individuals residing in East African countries bordering the Indian Ocean, India, 
and Sri Lanka (2, 3, 54, 235).  
 Disease manifestations vary among arthritogenic alphaviruses.  RRVD is 
characterized by rheumatic manifestations characterized by arthritis in several joints and 
constitutional effects, including fever, myalgia, and general fatigue (106).  The rheumatic 
manifestations can range from mild pain in one or more joints to tenderness and swelling 
with restricted movement (106).  Sindbis virus-induced disease can generally be 
characterized as arthralgias with pain in and around tendons and other tissues surrounding the 
joint.  In particular, Pogosta disease (POGD), Ockelbo disease, and Karelian fever disease 
are characterized by fever, rash, arthralgia (139, 269).   
Though alphavirus-induced arthridities are generally found to be acute and self-
limiting (145, 252), the rheumatic symptoms can be severe and are often debilitating.  In 
many reported cases of alphavirus-induced arthridities, a subset of patients complain of 
chronic pain and sometimes loss of function in one or more limbs (145).  Approximately 
50% of patients showing typical signs of RRVD experience additional symptoms of 
headache, lethargy, and maculopapular rashes (66, 106).  Whether these symptoms are 
directly related to virus infection or other factors is not well understood.   
 Although alphavirus-induced arthridities can be extremely severe, the mechanisms 
underlying alphavirus-induced arthritis/arthralgia in humans are not well understood.  Direct 
viral replication in and around affected joints and connective tissues are thought to contribute 
to disease.  This is largely based on studies of individuals suffering from RRVD, where viral 
nucleic acid or antigen have been recovered from synovial aspirates (68, 243).  In the case of 
patients suffering from POGD, skin biopsies and blood samples have tested positive for viral 
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nucleic acid and infectious virus from patients showing symptoms of POGD (140).  It is 
believed that individuals suffering from chronic arthralgia, who previously tested positive for 
IgM or IgG antibodies to Pogosta virus (POGV), Ockelbo virus, or RRV is due to viral 
persistence in and around joints, connective tissues, or surrounding muscle (144, 186, 188, 
243).   
 While attempts at recovering POGV from human synovial fluids have been 
unsuccessful, it is thought that virus persistence within the synovium contributes to 
prolonged joint symptoms often seen with a majority of individuals (146).  This is supported 
by the finding that IgM specific antibodies can be detected several months to years after 
initial onset of symptoms (144).  However, an IgM specific antibody response typically 
wanes 1-2 weeks after initial exposure to an antigen and correlates with an increase in an IgG 
specific antibody response.  Therefore, it is unclear as to how a persistent POGV in a human 
can lead to a persistent IgM antibody response that can be detected several months after 
initial infection.  Way et al. has shown that RRV is capable of persisting in macrophages, a 
predominate cell type present in synovium effusions recovered from RRVD patients (278).  
However, RRV has not been isolated from patients several months or years after the initial 
onset of RRVD and the mechanism of persistence is not well understood.   
 Although the immune response to alphavirus-induced arthralgia/arthritis in humans 
has also not been well characterized, studies with RRVD and POGD patients have provided 
limited, but significant, insight into the immune response to virus infection.  Synovium 
effusions from RRVD patients were found to be mainly composed of macrophages, CD4+ T 
cells, B cells, and monocytes (68, 69, 110, 243).  IFN-γ, mainly produced by natural killer 
(NK) cells and T cells, has also been shown to be present in synovial effusions, although its 
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role in recovery from RRVD is not well understood (213).  Histological examination of 
maculopapular rashes from recovering RRVD patients were composed mainly of infiltrating 
CD8+ T cells, suggesting a role for lymphocytes in resolution of virus infection (67).  In 
addition, examination of skin lesions from POGD patients revealed pronounced 
lymphohistocytic inflammatory infiltrates and lymphoblast-like cells (17).   
 In order to better understand the pathogenesis of arthritogenic alphaviruses, improved 
animal models would be useful for dissecting the pathogenesis of these diseases.  To date, 
two mouse models have been reported for studying the pathogenesis of alphavirus-induced 
arthritis and myositis.  Heise et al. found that the SINV strain AR86 replicates in bone and 
joint associated connective tissues of adult mice (111).  However, no virus-induced disease 
was observed, thus limiting the potential of this model for studying the pathogenesis of 
SINV-induced arthritis/arthralgia.  Morrison et al. recently reported a mouse model to study 
RRV-induced arthritis and myositis (182).  In this study, RRV was found to replicate in bone, 
joint, and skeletal muscle tissues.  Furthermore, macrophages, NK cells, CD4+ and CD8+ T 
cells were detected in skeletal muscle of RRV-infected mice, which is similar to synovial 
effusions and skin biopsies from patients suffering RRVD, suggesting that the mouse model 
reflects a valid system for studying RRV pathogenesis (243).  However, for alphaviruses 
such as SINV, which cause arthralgias without overt inflammation, the RRV mouse model is 
likely to be of limited use in understanding the pathogenesis of virus-induced arthralgias.  
Therefore, improved animal models are needed if advances are to be made in studying the 
mechanisms underlying alphavirus-induced arthralgia.   
 
Alphavirus-induced neurologic disease 
 18 
Sindbis virus   
While infection of mice with SINV causes arthralgia in humans, infection of mice provides 
an excellent model for studying virus-induced neurologic disease.  The outcome of SINV 
infection in mice has been well characterized and found to correlate with the age and strain of 
the animal, virus dose, route of inoculation, and the virus strain (99, 100, 143, 267).  
Infection of neonatal mice with most SINV strains result in a lethal disease characterized by 
elevated levels of proinflammatory cytokines and high viral titers in the muscle, brain and 
serum, without causing overt encephalitis (134, 263, 264).  Increasing the age of the animal 
or infecting with an attenuated mutant virus results in a shift from the systemic disease 
towards a central nervous system (CNS)-specific disease (262).  However, infection in adult 
mice is limited in that most Sindbis-group viruses are avirulent in mice greater than 14 days 
of age, with the notable exceptions of the neuroadapted Sindbis virus (NSV) and the Sindbis-
group virus strain AR86, which are lethal in adult mice (101, 214, 241).   
 Most laboratory variants of SINV have originated from the original SINV strain 
AR339, with the notable exception of AR86 and Girdwood.  The AR339 strain of SINV was 
first isolated in 1952 from a pool of Culex pipiens and C. univittatus mosquitoes near Egypt, 
Cairo (aptly named after the Sindbis district from where it was isolated) (256).  Although the 
exact passage history of the AR339 strain from when it was isolated is not known, it is 
believed to have been passaged 8 times in suckling mouse brains (personal communication 
R.E. Johnston) and further propagated by laboratories through either chicken embryo 
fibroblasts or baby hamster kidney cells, giving rise to several laboratory strain variants, such 
as HRsp (small plaque), HRlp (large plaque), SB, or SB-RL, or were additionally passed 
through neonatal and weanling mouse brains (14, 19, 101, 285).  One such virus was NSV, 
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which was passed serially six times by intracranial inoculations of alternating passages 
between neonatal and weanling mouse brains (101).  Klimstra et al. constructed an infectious 
cDNA clone for AR339 by assembling the consensus sequences of several laboratory 
variants and eliminating several predicted cell-culture adaptated mutations.  The predicted 
sequence is believed to be very close to the original AR339 isolate, prior to propagation in 
cell culture.  The virus produced from the infectious clone is was called TR339 and is known 
as the prototypic SINV strain (135).   
 Two notable low cell culture passaged Sindbis-group virus isolates are AR86 and 
Girdwood.  AR86 virus was isolated from a pool Culex mosquitoes near Johannesburg, South 
Africa in 1955 (285).  Girdwood virus was recovered from a human patient near 
Johannesburg, South Africa suffering from febrile illness, rash, and arthritis and has the 
distinction of being one of the first Sindbis viruses to be isolated from a human case (166).  It 
was immediately clear from antigenicity tests that Girdwood was closely related to AR86 and 
sequencing revealed that these two strains differed by only 22 single amino acid coding 
changes plus an 18 amino acid deletion in nsP3 (166, 241).   
 This next section on SINV pathogenesis describes three murine models to study 
SINV-induced neurologic disease.  TRSB and TR339 virus infection of newborn mice have 
served as models to study virus-induced systemic inflammatory response syndrome (SIRS).  
SV (the strain of NSV prior to neuroadaptaion) and NSV infection of adult mice have served 
as models to study nonfatal and fatal virus-induced encephalitis, respectively.  Finally, AR86 
infection of adult mice has served as a model to study virus-induced neurologic disease.  
 
TRSB/TR339   
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Early reports with a virulent strain of AR339 virus in newborn mice showed high levels of 
replication in the CNS, robust induction of type I interferon (IFN), and it was believed that 
the infected mice were succumbing to infection from a fatal acute encephalitis (207, 238).  
Two laboratory strain variants of AR339, Toto1101 or HRSP, were found to be attenuated in 
newborn mice and showed virus-specific IgG antibody production seven days after infection, 
which correlated with virus clearance (164, 203, 238).  Studies with the TRSB strain, derived 
from an infectious cDNA clone for the SB strain, showed a lack of encephalitis and a more 
systemic inflammatory response (263).  Several reports attributed these differences in 
virulence and immune response to mutations within the E2 and E1 glycoproteins (134, 263).   
 In support of this, Klimstra et al. demonstrated that virus passaged repeatedly in cell 
culture attenuated virulence because the virus readily adapted to using heperan sulfate as an 
attachment receptor (135).  These adaptive mutations were linked to the E2 and E1 
glycoproteins (135). Therefore, the differences in virulence between various the laboratory 
strains is most likely attributed to their passage history.  Klimstra et al. also suggested that 
SINV strains that are more closely related to the consensus sequence of AR339 cause a lethal 
systemic inflammatory response, while attenuated laboratory strain variants cause an 
encephalitic disease in neonatal mice (134).  Comparing infection of neonatal mice with 
TRSB and an attenuated mutant TRSB (TRSB-114) virus, which contains a cell-culture 
adapted mutation in the E2 glycoprotein at position 114, found that TRSB infected mice 
caused a lethal disease with no overt signs of virus-induced encephalitis, while the mutant 
TRSB-114 was attenuated in virulence and showed signs of encephalomyelitis (263).  
Further characterization of TRSB infected mice showed virus replication in several tissues, 
induction of proinflammatory cytokines, including type I IFN and tumor necrosis factor-α 
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(TNF-α), and induction of the stress hormones corticosterone and adrenalcorticotropin-
releasing hormone (ACTH) (262).   
Studies with TR339 showed similar virus localization and immune response in 
newborn mice, showing strong induction of proinflammatory cytokines, including type I IFN, 
TNF-α, IFN-γ, IL-12(p40), and IL-6, and induction of a stress response (134).  Based on the 
similarities to LPS-treatment in newborn mice, it is believed the TR339 or TRSB infected 
mice are most likely dying from SIRS.  
 Virulence studies by Tucker et al., using two laboratory strains of SINV (TE and 
TES), found that an Arg to Gly (virulent) change at E2 position 172 was an important 
virulence determinant in newborn mice (265).  The mechanism of this determinant is 
believed to correlate with kinetics of viral RNA synthesis, penetration and infection of 
neuronal cells, and viral growth in the CNS (265).  Furthermore, sequence comparison 
between AR339 and NSV revealed that a His at position 55 in the E2 glycoprotein in 
combination with the Gly at position 172 in E2 are important virulence determinants in 
newborn and weanling mice (164, 267).   
 
SV and NSV   
The laboratory adapted SINV strain SV causes fatal disease in newborn mice and nonfatal 
encephalitis in adult mice (207).  In contrast, NSV, causes acute fatal encephalitis in adult 
mice (101).  These two SINV laboratory strains have served to study the molecular 
pathogenesis of virus-induced acute nonfatal and fatal encephalitis.  Infection of adult mice 
with SV causes acute nonfatal asymptomatic encephalitis.  After an i.c. inoculation, SV 
replicates primarily in neurons in the brain and the spinal cord.  Virus  replication peaks by 
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day 2 and detectable infectious virus is cleared by day 7.  Perivascular cuffing in the CNS, 
representing infiltrating mononuclear inflammatory cells, are first observed between day 3 
and 4, and peak by day 8 (169).  The infiltrating inflammatory cells consisted mainly of 
CD4+ and CD8+ T cells, B cells, and macrophages/microglia (179, 212).  SV infection also 
resulted in the induction of several proinflammatory cytokines, including IL-6, IL-1β, and 
TNF-α.  Cytokine induction was found to correlate with a Th1 immune response, 
characterized by low levels of IL-4, high levels of IL-10 producing CD4+ T cells, and 
induction of IL-12, IL-2, and IFN-γ (212).   
 The appearance of virus-specific neutralizing antibodies correlated with clearance of 
infectious virus from the CNS (156).  Although infection of adult scid/CB17 mice with SV 
exhibit nonfatal persistent infection, infectious virus was readily cleared by administering 
virus-specific monoclonal antibodies to the E2 glycoprotein.  In vitro studies of viral 
persistence in primary neuronal cultures were shown to be cleared of virus upon treatment 
with neutralizing E2-specific monoclonal antibodies (156). In contrast, adoptive transfer of 
sensitized T cells into SV-infected scid/CD17 mice had no effect on persistence.  
Interestingly, SV-infected µMT mice, which lack functional B cells, showed clearance of 
infectious virus in a tissue-specific manner.  While virus in the brain showed intermediate 
clearance in µMT and µMT mice depleted for CD8+ T cells, the spinal cord exhibited 
clearance similar to that seen in wild-type C57BL/6 mice.  Because virus was cleared from 
the spinal cord in the absence of antibody and the fact that no µMT-infected mice showed 
clinical signs of infection, this suggested an additional mechanism of viral clearance from 
neurons in a noncytolytic manner.  Using a  double-promoter expressing virus, it was 
demonstrated that interferon-γ contributed to the noncytolytic clearance of virus from 
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neurons (23).  Additional studies confirmed this observation in two different persistently 
infected neuronal cell lines (35).  The mechanism underlying IFN-γ mediated neuronal 
clearance is not well understood, however, it is believed to induce antiviral factors that alter 
the efficiency of virus production in infected neurons (35). 
 In contrast to SV-infected adult mice, NSV-infected mice displayed clinical signs that 
are characteristic of an acute encephalitis, such as ruffled fur, hunched posture, and hind limb 
paralysis.  Mice typically succumb to NSV-induced disease between 6-11 days post-infection 
with an average mortality rate between 80-100%, depending on the strain of the mouse (101, 
118).  From an intranasal route of inoculation, NSV replicates in neurons within the olfactory 
region and spreads to the brain along neuronal tracts.  By day 4, NSV antigen and viral RNA 
was shown to disseminate into large foci in the brain and virus appears to primarily localize 
to neurons (260).  Following an i.c. inoculation, NSV infects neurons primarily in the 
hippocampal gyrus, the adjacent white matter, and the cerebral cortex (132).  Regardless of 
the route of inoculation, NSV causes significant neuronal loss.   
 To understand the immune components involved in fatal NSV infection, Griffin et al. 
passively transferred immune sera, spleen cells, or  lymph node cells (LNC) from mice 
surviving nonfatal NSV infection and found that only immune sera significantly protected 
mice from a lethal challenge of NSV (101).  This study suggested that virus-specific IgG or 
IgM antibodies play an important role in protection against NSV infection, similar to the 
observations with persistent SV infection.  Infection of mice depleted of CD4+ T cells 
revealed reduced hippocampal damage and fewer infiltrating macrophages while mice 
depleted of CD8+ T cells showed more extensive hippocampal damage and greater 
infiltrating macrophages (132, 211).  These results suggest that T cells may play an important 
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role in contributing to mortality following NSV infection.  This is supported by work from 
Rowell et al.. that showed TCR-/- (α and β/δ) mice, CD4-/-, and CD8-/- mice displayed 
reduced virulence from NSV infection (211).  In addition, nearly all of the IFN-γ knockout 
mice were protected from NSV infection.  This study demonstrates a role for immune-
mediated pathology to virus-induced fatal encephalitis.  Furthermore, this result also 
demonstrates an alternative role for IFN-γ during fatal encephalitis, as compared to its role 
during nonfatal encephalitis.   
 To identify the genetic determinants of virulence within SV and NSV, initial studies 
using a panel of monoclonal antibodies to E1 and E2 showed that the E2 and E1 
glycoproteins were altered during neuroadaptation with NSV and suggested this region of the 
genome was important for virulence in adult mice (247).  Subsequent studies identified a His 
at position 55 in the E2 glycoprotein as major determinant of NSV adult mouse 
neurovirulence (164, 267).  In addition to its importance as a virulence determinant in 
newborn mice, Gly at position 172 in the E2 glycoprotein appeared to play a minor role in 
adult mouse virulence (265).  The mechanism underlying the His 55 determinant is not yet 
completely understood, however, E2 His 55 was shown to correlate with improved binding 
and entry into neuronal cells (266), increased levels of viral replication (51), and the ability 
to overcome the protective effect of bcl-2 overexpression in neurons (155, 157).   
 
AR86   
Previous studies from our laboratory with AR86 have demonstrated that a Thr at position 538 
in nsP1, plays an important role in adult mouse neurovirulence.  Replacing this Thr of AR86 
with an Ile, found in most Sindbis-group viruses, attenuates virulence in adult mice, while 
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introduction of the Thr into a non-neurovirulent laboratory strain of SINV leads to an 
increase in neurovirulence (112).  Introduction of the attenuating Ile at position 538 in nsP1 
did not adversely affect viral growth, as viruses that contained this change replicated at least 
as well as wild-type AR86 virus both in cell culture and in the brains of infected animals 
(112).  Furthermore, the presence of an Ile at nsP1 538 accelerated processing of the 
nonstructural polyprotein precursor nsP123 and showed earlier induction of viral 26S RNA 
synthesis (113). 
 In an effort to further define the viral determinants that contribute to adult mouse 
neurovirulence, mapping studies were conducted between the neurovirulent Sindbis-group 
virus strain AR86 and the closely related but avirulent Girdwood strain.  This study identified 
four major genetic determinants of adult mouse neurovirulence within the SV AR86 (254).  
These determinants localized to the nonstructural coding region, at nsP1 position 538 
(Ile=non-neurovirulent, Thr=neurovirulent), at nsP3 positions 386-403 (18 amino acid 
deletion= neurovirulent), and at nsP3 position 537 (Opal termination codon=non-
neurovirulent, Cys=neurovirulent), as well as one change in the structural coding region at 
E2 position 243 (Leu=non-neurovirulent, Ser=neurovirulent).  Although the attenuating 
mutations result in a loss of virulence, in vitro replication kinetics were not adversely 
affected and the attenuated mutant AR86 viruses were able to establish infection in the brain 
and spinal cord as efficiently as the virulent wild-type AR86 virus (254).   
 While the attenuated and virulent viruses appear to establish infection within the CNS 
with similar efficiency, at late times post-infection the wild-type AR86 virus continues to 
replicate throughout the brain while the attenuated mutant S363 virus, containing the four 
attenuating determinants in the AR86 background, was cleared (254).  This suggests that the 
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mutant S363 virus may be controlled more effectively by the host immune response than the 
wild-type AR86 virus.  This is supported by the observations that the mutant S363 virus 
induces higher levels of inflammation within the brain than wild-type AR86 virus (Suthar 
M.S. and Heise M.T., unpublished data).  Furthermore, while the mutant S363 virus shows 
no mortality in wild-type C57BL/6 mice, this virus causes 100% mortality in RAG-/- mice, 
suggesting that the adaptive immune response is required to protect against the mutant S363 
virus-induced disease (Suthar M.S. and Heise M.T., unpublished data).  This is further 
supported by preliminary studies where the mutant S363 virus induced higher levels of CD8+ 
T cells and macrophages at late times post-infection as compared to the wild-type AR86 
virus (Suthar M.S. and Heise M.T., unpublished data).  These results were further 
corroborated by the finding that introduction of the attenuating Ile at nsP1 538, led to more 
type I IFN induction both in vivo and in vitro as compared to wild-type AR86 virus.   
 
Venezuelan Equine Encephalitis virus   
VEE virus infection in equines and humans can be grouped based on their virulence, with the 
avirulent viruses generally causing no overt signs of infection and virulent viruses causing 
fairly high mortality in equines (20-80%) and febrile illness associated with neurologic 
disease in humans.  The avirulent viruses are generally associated with the enzootic subtypes 
IE, II, III, IV, while the virulent viruses are generally associated with the epizootic subtypes 
IAB and IC (as reviewed in reference (282)).  Experimental infection with VEE virus in the 
laboratory has been shown to cause fatal disease in several mammalian species (37, 236, 
274).  Early studies in guinea pigs revealed that the epizootic strains (with the exception of 
ID) caused fatal disease while enzootic  strains were avirulent (120, 227).  VEE viral 
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pathogenesis has been studied extensively in the mouse model using the subtype IAB 
Trinidad donkey strain (TRD).  This strain was isolated in 1943 from the brain of a donkey 
and was passaged once in a guinea pig brain followed by 13 passages in embryonated 
chicken eggs (178).  Infection of mice with the TRD virus results in a fatal disease, 
regardless of the age, strain, or route of inoculation, although mice infected from the 
intranasal or intracranial routes appear to more rapidly succumb to virus-induced disease (40, 
137, 138, 248).  Infection of adult mice with TRD virus causes encephalomyelitis, similar to 
infections seen in humans and equines (137).      
 Following peripheral inoculation of VEE virus in adult mice, disease progression is 
characterized in two phases, a lymphoid phase and a CNS phase (39, 45, 96).  Immediately 
after a footpad inoculation, VEE virus migrates to and replicates in the draining popliteal 
lymph node.  Studies by Macdonald et al. have demonstrated using viral replicons that 
following a subcutaneous inoculation in the footpad, Langerhan cells, which reside in the 
skin, are readily infected (165).  Extensive replication in the lymph node likely seeds a high-
titered viremia by 18 hours post-infection, followed by virus infection in several vascularized 
organs, including spleen, thymus, heart, lung, kidney, liver, and adrenal glands (39).  
Detectable VEE virus in the serum begins to wane upon production of VEE-specific IgM 
responses by 72 hours post-infection (39).  The CNS phase is characterized by virus entry 
into the CNS and extensive replication in neurons and astrocytes (232).  A robust immune 
response within the CNS leads to high levels of inflammation in the brain and immune-
mediated pathology (39, 231).  Virus infection of the peripheral nervous system is believed to 
be seeded from virus that is circulating in the blood or through infection of olfactory or 
dental neuronal tissues (45, 96).  Removal of the olfactory bulb or neuroepithelium by 
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surgery or chemical disruption, did not prevent VEE virus from entering the CNS from an 
intranasal route of inoculation, suggesting other peripheral nervous system pathways by 
which the virus can gain entry into the CNS (40). 
 It has become apparent through several studies that both viral and host factors 
contribute to VEE virus-induced encephalitis.  Infection of mice with an attenuated VEE 
virus, such as TC-83, leads to a protective immune response (41, 245).  In contrast, infection 
with virulent VEE virus leads to a fatal and cytotoxic immune response in the CNS.  Greider 
et al. identified three attenuating mutations within the E2 and E1 glycoproteins which were 
defective in spreading to the draining lymph node (DLN), producing a high titer viremia, or 
efficiently invading the CNS (96).  These virulence determinants localized to E2 Lys at 
position 76, E2 Lys at position 209, E2 Asn at position 239, and E1 Thr at position 272 (96).   
 The host innate and adaptive immune responses have been shown to be important in 
controlling VEE virus infection.  Cytokine expression analysis within the DLN upon a 
footpad inoculation with wild-type VEE virus (V3000) showed elevated levels of IFN- γ, IL-
6, IL-12, IL-10, and TNF-α (95).  Several lines of evidence have demonstrated the 
importance of type I IFN in protecting mice from virulent VEE virus infection and disease.  
Infection of IRF-1-/- mice, IRF2-/- mice, IFN-α/βR-/- mice with virulent VEE virus exhibited 
rapid kinetics of death and enhanced viral tropism (97, 233, 291).  However, infection of 
mice treated with pegylated IFN-α prior to infection with VEE virus showed a reduction in 
virulence (161).   
 The host adaptive immune response has been shown to be important in protection 
from lethal VEE virus infection.  Vaccination of mice with attenuated VEE mutant viruses 
(V3032 and TC-83) have shown near complete protection against a lethal challenge with 
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wild-type VEE virus, further demonstrating a protective immune response induced by 
attenuated mutants of VEE virus (46, 107, 121).  In these studies, protection from the lethal 
challenge administered s.c. or by aerosol was due to a combination of virus-neutralizing IgG 
antibodies in the serum and  mucosal IgA responses.   
 
Semliki Forest virus   
SFV has been shown to experimentally infect several different mammalian species, including 
rabbits, guinea pigs, hamsters, mice, and rats (27, 57).  Infection of mice with SFV has been 
well characterized and shown to result in one of three disease outcomes—acute encephalitis, 
demyelinating meningoencephalo-myelitis, or persistent infection of the central nervous 
system.  SFV-induced disease in the murine model depends on the strain of the virus and age 
and strain of the mouse.  All known strains of SFV cause a lethal disease in neonatal and 
suckling mice (15, 62). The age-dependent susceptibility is observed in mice greater than 14 
days of age, in which most SFV strains, including A7, and A7(74), and  are avirulent (15, 62, 
195).  However, the prototype SFV strain SFV4 (derived from an infectious clone) and L10 
strain are virulent in adult mice (18, 83, 87).   
 The SFV AR2066 strain was isolated from a pool of Aedes argenteopunctatus 
mosquitoes in Namancurra, Mozambique and was subsequently passaged seven times 
intracerebrally in suckling mice giving rise to the A7 strain (170).  The A7 strain was further 
selected from plaques in monolayers of primary chicken embryo cells resulting in the A7(74) 
strain (27, 251).  SFV was originally isolated in 1942 from a pool of mosquitoes in Uganda 
and was passaged intracerebrally eight times in adult mice followed by two passages through 
the brains of suckling mice to give rise to the L10 strain (102).  The prototype SFV SFV4 
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strain was derived from an unknown number of passages in BHK cells of the L10 strain, 
resulting in decreased virulence in adult mice as compared to the original L10 strain (87, 
181). 
 Following peripheral inoculation in adult mice, SFV replicates in smooth, skeletal, 
and cardiac muscles (57).  A transient high titer viremia is seeded by 24 hours post-infection 
and subsequently leads to neuroinvasion (59).  The viremia is controlled and eventually 
cleared by 4 days post-infection by a combination of  virus-specific IgM and IgG antibody 
responses (59).  Interestingly, the virulent (SFV4 and L10) and avirulent (A7 and A7(74)) 
strains are able to efficiently enter the CNS, suggesting attenuation of the avirulent strains 
occurs once the virus enters the CNS (18, 191, 197, 198).  The mechanism of neuroinvasion 
by SFV has been well characterized.  Early studies by Pathak et al. suggested virus enters the 
brain from the blood by passing across cerebral endothelial cells (197).  Fazakerley et al. 
confirmed this finding in neonatal and adult mice by observing scattered perivascular foci of 
viral RNA around cerebral capillaries early during infection (59).  Furthermore, SFV may 
enter the CNS by infecting endothelial cells causing increased permeability of the blood-
brain barrier (244).  Following intranasal inoculation, SFV is believed to enter through the 
olfactory neuronal pathway in an age-dependent manner (125, 191).   
 Several lines of evidence demonstrate that the age-dependent virulence of the A7 or 
A7(74) strains correlate with the maturity of CNS cells.  In neonatal mice, A7(74) is able to 
enter, producing the perivascular foci, and spread from these foci unhindered throughout the 
brain (59, 190).  However, in adult mice, A7 or A7(74) viruses replicate slower and reach 
lower peak titers than the virulent SFV4 or L10 viruses (59, 190, 191).  In situ hybridization, 
immunocytochemistry, and electron microscopy of A7(74)-infected adult mouse brains show 
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restricted patterns of virus localization, mostly appearing as small perivascular foci (18, 59, 
191, 195, 198).  The restricted spread within the CNS has been shown to be independent of a 
maturing adaptive immune response, in that, nu/nu adult mice, which lack T cells, and SCID 
adult mice, which lack T and B cells, displayed similar patterns of virus localization as 
compared to wild-type mice (12, 59).  Similar results have been reported in mice lacking a 
functional type I interferon pathway (191).  These studies suggest that the defect in viral 
spread in adult mice is due to alteration in virus infection and/or replication in maturing 
neurons, however, the mechanism restricting A7 or A7(74) viral replication in the CNS is not 
well understood.   
 Viral and cellular factors may contribute to the observed restriction in viral 
replication, including altered expression of a developmentally regulated neuronal receptor or 
a developmentally regulated change in neurons that influences the outcome of a productive 
viral infection.  As mentioned earlier, Ubol et al. identified a putative neuronal receptor for 
the closely related SINV and showed that expression of the receptor diminished with the age 
of the mouse (270).  However, the receptor for SFV has not been identified and have thus 
limited the studies on this front.  On the other hand, pretreatment of adult mice with 
aurothiolates, which induce smooth endoplasmic membrane production in neurons, followed 
by infection with the avirulent A7(74) virus caused increased replication, virulence, and 
displayed similar virus dissemination within the CNS as compared to the virulent L10 virus 
(171, 172, 226).   
 Furthermore, electron microscopic studies of CNS cells from adult mice infected with 
A7(74) indicated a defect in virion maturation.  Within these CNS cells, large viral core 
aggregates, later identified as viral capsid protein, form in the cytoplasm (59, 196).  In 
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contrast to the adult mice, neonatal mice infected with A7(74) show normal virion formation 
in CNS cells (59).   
 Studies by Scallan et al. implicated a role for the antiapoptotic factor bcl-2 in limiting 
viral replication and delaying virus-induced apoptosis (225).  However, studies by Murphy et 
al. showed that SFV-infection induced apoptosis in three cell lines over-expressing bcl-2 
with comparable kinetics to cells normally expressing bcl-2 (91).  Furthermore, it was shown 
that SFV overcomes bcl-2 over-expression by proteolytic cleavage and inactivation of bcl-2 
(91).  The viral function which mediates this activity has not been identified.  In addition, the 
biological significance of this finding is controversial in that staining for bcl-2 in the CNS of 
adult rats revealed a lack of bcl-2 expression in neurons, the main culprit in restricting viral 
spread of the avirulent SFV strains in the CNS (219).   
 Infection of mice with avirulent strains of SFV causes focal demyelinating 
meningoencephalomyelitis and represents a viral model to study multiple sclerosis (MS) in 
humans (16, 251).  The demyelinating lesions occur in focal areas in the white matter of the 
CNS and are believed to be caused by the host immune response and direct infection of 
oligodendrocytes (83, 251).  In support of this, infection of SCID mice, nu/nu mice, or 
immunosuppressive therapy, including treatment with cyclophosphamide, γ-irradiation, and 
cycloleucine, resulted in viral persistence in the CNS without overt signs of cytopathic effect 
or demyelination (13, 61, 82, 119).  Reconstitution of nu/nu mice with spleens from nu/+ 
littermates or recovery of immunosuppresed mice abrogated viral persistence and resulted in 
demyelination (13, 58, 82).  Furthermore, adoptive transfer studies into immunosuppresed 
mice, infection of nude mice (T-cell deficiency), and administration of anti-CD4 or anti-CD8 
antibodies in wild-type mice demonstrated the demyelination was due to a pathogenic 
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immune response and, for the most part, mediated by CD8+ T cells (60, 83, 250).  Studies by 
Keogh et al. demonstrated that Th1 CD4+ T cells play an important role in controlling SFV 
infection in a manner that does not contribute to virus-induced neuropathology (128).  
Infection of mice deficient for IL-12, a Th1 promoting cytokine, with SFV A7 showed no 
effect on demyelination, increase in neuronal necrosis, higher virus brain titers, and reduced 
IFN-γ production as compared to wild-type mice (128).  In contrast, infection of mice 
deficient for IL-4, a Th2 promoting cytokine, showed reduced demyelination, lower virus 
brain titers, less severe neuronal necrosis, and higher levels of IFN-γ production as compared 
to wild-type mice (128).  In addition, infection of mice genetically deficient in expression of 
IFN-γ indicated that IFN-γ plays an important role in mediating neuronal necrosis and little, 
if any, role in mediating virus-induced demyelination (129).   
 Based on sequences of the virulent and avirulent SFV strains and the availability of a 
full-length infectious clone (SFV4), several studies were initiated to identify the genetic 
determinants of SFV virulence.  Early studies identified two determinants of adult mouse 
virulence within the E2 glycoprotein consisting of a Val to Ile at position 37 and Asn to Ser 
at position 212 (221).  Tuittila et al. identified the nsP3 gene as the major virulence factor in 
SFV4 (268).  Within the nsP3 gene, the opal termination codon to an arginine codon at 
position 469 was found to be a major virulence determinant.  Furthermore, several amino 
acid changes within nsP3, namely Val to Ile at position 11,  Ala to Glu at position 48, Gly to 
Ala at position 70, Leu to Phe at position 201, Asp to Asn at position 249, Thr to Ala at 
position 435, and Phe to Leu at position 442 were important virulence determinants (268).  
Introduction of the Arg codon at position 469 and specific combinations of two of the 
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remaining seven amino acids in nsP3 into the avirulent A7(74) strain fully conferred adult 
mouse virulence (268).   
 
VIRUS MODULATION OF THE HOST TYPE I INTERFERON INDUCTION 
 
Type I interferon signaling pathway 
 The innate and adaptive arms of the immune system play critical roles in controlling 
virus replication, viral clearance, and establishing long-term protection from re-infection.  
Although the adaptive immune response is critical, this response is ultimately determined by 
the innate immune response.  Type I IFN is the first line of defense for a host cell infected 
with a virus and is responsible for deterring virus replication and spread within the host.   
 Interferons were first discovered by Isaacs and Lindenmann in a study that identified 
a host factor that was induced upon treatment of cells with heat-inactivated influenza A virus 
(117).  This factor was shown to interfere with establishing influenza A virus infection in 
cells, and thus this interference factor was aptly termed “interferons.”  An immense amount 
of research has been conducted on characterizing interferons since this initial observation.  
Interferons can be grouped into three subsets, type I, II, and III (as reviewed in reference 
(202)).  Type I IFNss are comprised of seven classes, IFN-α, IFN-β, IFN-δ, IFN-ε, IFN-κ, 
IFN-τ, and IFN-ω.  Type I IFNs can be induced and secreted by most cell types.  Type II IFN 
is comprised mainly of IFN-γ and is mainly secreted by T cells and NK cells.  Type III IFNs 
are a new set of IFN genes that include IFN-λ1, IFN-λ2, and IFN-λ3 (otherwise known as IL-
29, IL-28A, and IL-28B, respectively).  Not much is known about the cell types that 
primarily produce Type III IFN, however, comparisons have been made to IFN-α/β, and have 
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been shown to be induced to comparable levels and kinetics as that of IFN-α/β (192).  The 
remainder of this review will focus on virus-host interactions with type I IFN, mainly IFN-
α/β.   
 In humans and mice, there are 13 and 14 subclasses of IFN-α, respectively, and only 
one class of IFN-β (202).  In a virally-infected cell, IFN-β is the first type I IFN to be 
induced.  Secreted IFN-β binds to its receptor on uninfected and infected cells, leading to 
activation of signaling pathways that result in the synthesis of IFN-α and interferon-
stimulated genes (ISG).  Type I IFNs can be induced in response to RNA virus infection 
through two distinct pathways, recognition of viral RNA by toll-like receptors (TLRs) or 
cytosolic receptors (177).   
 TLRs are a type of pattern recognition receptors (PRRs) and recognize conserved 
pathogen specific molecules that are often referred to as pathogen-associated molecular 
patterns (PAMPs).  To date, 13 different TLRs have been identified in humans and mice (10).  
Of these 13, TLR3, TLR7, and TLR8 are responsible for sensing viral RNA and inducing a 
proinflammatory cytokine response, particularly type I IFN (10).  TLR3 is expressed in 
myeloid dendritic cells (mDCs), NK cells, neuronal cells, and astrocytes, and is thought to  
recognize double-stranded RNA (dsRNA) within the endosomal compartment (47, 234).  In 
contrast, TLR7 is expressed in mDCs and plasmacytoid DCs (pDCs), B cells, and monocytes 
and TLR8 is expressed in NK cells, T cells, B cells, and monocytes (10).  Both TLR7 and 
TLR8 recognize single-stranded RNA molecules present in the endosomal compartment (49, 
242).  While TLR7 and TLR8 immune effects require the adaptor protein MyD88 for 
signaling, TLR3 signals through Toll/IL-1 receptor (TIR)-domain-containing adaptor 
inducing IFN-β (TRIF) in a MyD88-independent manner (10).  MyD88-mediated signaling 
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activates IRF-7 and NF-κB leading to the induction of IFN-α and ISGs.  In contrast, TLR3 
signals through TRIF to activate IRF-3 and NF-κB leading to the induction of IFN-β.   
 While TLR signaling depends on the presence of ssRNA or dsRNA in the endosomal 
compartment, dsRNA in the cytoplasm is recognized by a newly identified set of RNA 
helicases retinoic acid inducible gene-I (RIG-I) and melanoma differentiation antigen 5 
(Mda5) (126, 294).  These sensory molecules are found in nearly every cell type analyzed, 
except for pDCs (127).  RIG-I and Mda5 contain two caspase recruitment domains 
(CARDS), helicase domain, and a repressor domain (RD) (217, 294).  The repressor domain 
has only been identified in RIG-I and has not yet been identified in Mda5.  RIG-I is normally 
found in an inactive conformation where the RD is interacting with the CARD domains.  
Upon binding the RNA substrate, a conformational change occurs that releases the RD 
domain and exposes the CARD domain and leads to in RIG-I multimerizing (217).  This 
complex then signals through the CARD domains to the mitochondrial associated protein 
IPS-1, otherwise known as MAVS, Cardif, and VISA (122).  This interaction recruits the 
“noncononical” kinases IκB kinase-ε (IKKε) and TANK-binding kinase-1 (TBK1).  These 
kinases phosphorylate IRF-3 at serine residues located between 386 and 403.  This, in turn, 
leads to the formation of IRF-3 homodimers and translocation into the nucleus.   
 IPS-1 is also activates the NF-κB signaling pathway through interactions with Fas-
associated death-domain protein (FADD) and receptor-interacting protein (RIP-1) or by 
direct recruitment of the inhibitory kappa B kinases (IKK), IKKα and IKKβ (122, 293).  IPS-
1 association with FADD and/or RIP-1 is thought activate IKK and cause the 
phosphorylation of the NF-κB inhibitor protein, Iκβα, leading to its ubiquitination, 
degradation, and release of free NF-κB, which subsequently translocates to the nucleus.  
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 Activation of these signaling pathways results in the formation of the enhancesome 
consisting of IRF-3, NF-κB, CBP/p300, and ATF-2/c-Jun.  The enchancesome binds to the 
promoter region of the IFN-β gene and activates its transcription (115).   
 In addition to the recognition of viral dsRNA by TLR3 and RIG-I/Mda5, two other 
well characterized dsRNA-dependent interferon-inducible pathways are the 2-5A 
oligoadenylates synthetase/RNaseL and the protein kinase R (PKR) pathways.  In response to 
IFN, host cells synthesize proteins encoded by ISGs.  One such pathway is the 2-5A system 
which is composed of two types of enzymes:  2-5A oligoadenylates synthetases (OAS) and 
RNaseL.  After activation by dsRNA, 2-5A OAS catalyzes ATP to produce 2’5’-linked 
oligoadenylates (2-5A) that can range from dimers to 30mers (as reviewed in reference 
(124)).  The 2-5A substrates bind to and activate RNaseL, a potent endoribonuclease which 
specifically cleaves cellular and viral single-stranded RNA substrates and effectively limiting 
virus replication, inhibiting cell proliferation, and inducing apoptosis. 
 PKR was one of the first identified dsRNA-dependent interferon-inducible enzymes 
(as reviewed in reference (147)).  PKR is normally found within the cytoplasm of most cells 
in an inactive state.  Upon binding dsRNA substrates PKR homodimerizes and undergoes 
autophosphorylation.  Activated PKR phosphorylates the α subunit of eIF2 thereby inhibiting 
of host protein synthesis.  The effects of PKR can also lead to induction of apoptosis or 
promote cell survival and this is mediated by association with TRAF and activated IKK (86).  
 As described in detail below, type I IFN induction and the antiviral response induced 
through type I IFN signaling play important roles in controlling virus replication in the host.  
This next section describes alphavirus interactions with the host type I IFN response with 
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focus on three main topics:  Host factors limiting alphavirus replication, viral evasion of type 
I IFN, and alphavirus modulation of type I IFN. 
 
Host factors limiting alphavirus replication   
The direct role of the host type I IFN response to alphavirus infection has been directly 
analyzed using mice genetically deficient in type I IFN-α/β receptors (IFN-α/βR-/-).  These 
mice are unresponsive to type I IFN and exhibit increased susceptibility to a number of 
viruses, including alphaviruses ((97, 116, 215, 220, 240).  While infection of adult wild-type 
129Sv/Ev mice with TR339 causes no morbidity or mortality, infection of adult IFN-α/βR-/- 
mice causes 100% mortality with rapid kinetics of death (average survival time is between 2-
3 days postinfection) (215).  Infection of the knockout mice exhibited increased viral 
replication and increased tropism for tissues that normally do not harbor high levels of 
replication, including the stomach, pancreas, intestines, and heart.  Furthermore, DCs derived 
from IFN-α/βR-/- mice exhibit increased susceptibility to alphavirus infection (215, 237).   
 Interferon-stimulated genes have also been shown to play an important role in 
controlling alphavirus infection.  Microarray analysis of SINV-infected brain tissue showed 
that several host antiviral response genes were upregulated, including IRF-1, IRF-7, Stat1, 
and ISG15 (123).  Interestingly in this study, PKR and the coupled 2-5A synthetase/RNaseL 
genes were not found to be upregulated.  In support of this finding, Ryman et al. 
demonstrated that PKR/RNase/Mx-1 did not play a major role in controlling virus 
replication, in that mice deficient in PKR, RNaseL, and Mx-1 (triply-deficient [TD]) did not 
exhibit any increased tissue tropism, virus dissemination or virulence (216).  This suggested 
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that an alternative pathway dependent on the IFN-α/β receptor was important in controlling 
virus replication.   
 In a study to identify host genes responsible for conferring age-dependent resistance 
to SINV infection, ISG12 was identified and shown to extend average survival time in 
neonatal mice infected with SINV (143).  The mechanism by which ISG12 functions to delay 
death in neonatal mice is not currently understood, however, ISG12 expression was found to 
be expressed at higher levels in CNS tissues of infected weanling mice  as compared to 
neonatal mice.   
 ISG-15 was recently reported to protect mice from infection with a virulent SINV 
(153, 154).  Using a recombinant SINV expressing ISG15 from a second subgenomic 
promoter, IFN-α/βR-/- mice, were protected from a lethal dose while wild-type virus caused 
greater than 90% mortality (153, 154).  Furthermore, infection with the recombinant SINV 
expressing ISG15 reduced virus replication in several tissues in infected IFN-α/βR-/- mice.  
Infection of ISG15-/- mice with wild-type SINV showed increased virulence, while infection 
of these mice with the recombinant SINV expressing ISG15 exhibited reduced virulence 
(154).  While the mechanism of the antiviral activity of ISG15 during SINV infection is not 
understood, it is thought to function as a cytokine or increase stability of host proteins 
through direct conjugation.  
 
Alphavirus evasion of type I interferon  
 Successful transmission of alphaviruses from the mosquito vector to the human host is 
believed to be a complex process involving delivery of virus to the host,  establishing virus 
infection, and dissemination of virus.  Upon delivery of the virus from the mosquito vector, it 
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is believed that alphaviruses likely interact with mDCs in the skin.  Shabman et al. 
discovered that infection of mDCs with virus derived from mosquito cells showed 
considerably reduced type I IFN induction compared to infections with virus derived from 
mammalian cells (237).  Furthermore, passage of the mosquito grown virus over mammalian 
cells followed by infection of mDCs restored the type I IFN induction phenotype, strongly 
suggesting nongenetic viral factors as playing an important role in modulating type I IFN 
induction.   
 
Alphavirus modulation of type I interferon  
 Most alphaviruses induce shutoff of host macromolecular synthesis in mammalian cells 
(249).  This shutoff mechanism is believed to be employed by alphaviruses to suppress the 
host antiviral response.  Infection of vertebrate cells has been shown to induce shutoff at the 
level of host transcription and translation and are thought to be two independent events (90).  
Two viral proteins, nsP2 and capsid (C), have been shown to important regulators of host cell 
macromolecular synthesis.   
 Mutational analysis within the carboxy- terminus of nsP2 revealed its functions in 
virus-induced host cell translation and transcription shutoff (90).  Specifically, an amino acid 
change from a Pro to Leu at position 726 in nsP2 significantly reduced the efficiency of 
virus-induced host translation shutoff and correlated with an increase in type I IFN induction 
and upregulation of  ISGs mRNA production (73).  In addition, ablating the nsP2/3 cleavage 
site altered kinetics of virus-induced host transcription shutoff without affecting host 
translation shutoff  and resulted in the induction of type I IFN (90), similar to that seen with 
the mutation at nsP2 position 726.  This result suggested that mature nsP2 was required for 
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the shutoff of host cell transcription.  In support of this, Garmashov et al. demonstrated that 
expression of nsP2 alone inhibited RNA polymerase I and RNA polymerase II-dependent 
transcription and this was independent of the protease and helicase functions of nsP2 (77).  
Furthermore, overexpression of nsP2 caused cytotoxic effects in host cells and this was 
believed to be mediated by nsP2-inhibition of host cell transcription (77).   
 The role of the viral C protein in shutoff of host cell macromolecular synthesis has 
been a source of controversy.  Early studies with SFV suggested a role for C protein in host 
shutoff by two key observations:  i) increased expression of C protein during infection 
inversely correlated with shutoff of host protein synthesis (53) and ii)  PKR phosphorylation 
during infection correlated with expression of the C protein (56).  It was this later study by 
Favre et al. that demonstrated that expression of C protein at high concentrations induced 
phosphorylation of PKR, phosphorylation of the α subunit of eIF2, and in turn lead to shutoff 
of host protein synthesis (56).  Using a cell-free translation system, it was demonstrated that 
purified C protein added to cytoplasmic extracts triggered phosphorylation of PKR and 
eIF2α.  However, C protein did not co-immunoprecipitate with PKR, suggesting that C 
protein maybe involved in interactions with host cell proteins that can influence the 
activation of PKR.   
 Recent studies by Garmashova et al. reported that the C protein from New World 
alphaviruses, such as VEEV and EEEV, plays an important role in host transcription shutoff, 
whereas Old World alphaviruses, such as SINV and SFV, host transcription shutoff depends 
on the nsP2 protein and not the C protein (78). These studies also indicated the N-terminal 
portion of the C protein from VEEV or EEEV was important and independent of the RNA 
binding domain or protease function.  Most of the C protein is found within the cytoplasm of 
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infected cells, therefore, these studies imply that C protein may block transcription through 
effects on nuclear export of host mRNA and rRNA or degradation of host mRNA and rRNA 
in the cytoplasm.   
 Infection of IFN-α/βR-/- mice with several VEE strains found that virulence was 
associated with the determinants within the 5’UTR and glycoproteins (246).  Interestingly, 
epizootic VEE strains were found to be more IFN resistant than enzootic VEE strains.  
Studies by White et al. identified a single change at nucleotide 3 (G to A) within the 5’UTR 
that modulated sensitivity to IFN-α/β (291).  While infection of wild-type mice with the 
attenuating mutation at nt 3 showed no mortality, infection of IFN-α/βR-/- mice exhibited 
100% mortality and mice died with similar kinetics as those infected with wild-type VEE.  
While both viruses exhibited strong induction of type I IFN, the virus containing the 
attenuating mutation showed enhanced sensitivity to type I IFN.  While the mechanism of 
this virulence determinant is not understood, it is believed that it maybe affecting viral RNA 
synthesis, virus-induced host shutoff, or efficiency of viral nonstructural protein synthesis.   
  
 DISSERTATION OBJECTIVES 
 SINV infection of mice has provided  valuable insight into the viral and host factors 
that contribute to virus-induced neurologic disease.  Specifically, the Sindbis-group virus 
strain AR86 infection in mice provides an excellent viral pathogenesis model.  Infection of 
adult mice with AR86 virus causes a lethal disease characterized by a severe neurologic 
disease (112, 241, 254), uncontrolled virus replication and spread within the CNS (112, 254), 
and an apparent lack on inflammation in the CNS (Suthar, M.S. and Heise, M.T., 
unpublished).  Furthermore, AR86 virus can be manipulated at the molecular level with the 
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use of the full-length infectious clone and a well-established alphavirus-reverse genetic 
system  (242).   
 As mentioned earlier, AR86 virus was found to be closely related to the Sindbis-
group virus strain Girdwood (166).  In contrast to AR86 virus, Girdwood virus is avirulent in 
adult mice however, and perhaps most importantly, Girdwood virus establishes infection in 
the CNS as well as that of AR86 virus.  These two viruses differ by only 22 amino acid 
coding changes plus an 18 amino acid deletion in nsP3 between positions 386-403 found in 
AR86 virus.   
 The viral and host factors involved in AR86 virus pathogenesis are not well 
understood.  Previous studies by Heise et. al identified a unique amino acid at nsP1 position 
538 as playing an important role in adult mouse neurovirulence (112).  Introduction of an 
attenuating Ile, which is found in most SINV, at this position reduced AR86 virulence, 
however, did not completely attenuate AR86 virulence (112).  This strongly suggested the 
presence of additional viral factors that contribute to AR86 adult mouse neurovirulence.  This 
provides a unique opportunity to use the Girdwood virus in order to identify the additional 
AR86 virulence determinants followed by studies aimed at uncovering the mechanism of 
these virulence determinants, with specific focus on characterizing viral interactions with the 
host immune response.  Therefore, the objectives of this dissertation are as follows: 
 1)  To identify the major determinants of AR86 adult mouse neurovirulence. 
 2)  To determine if the AR86 virulence determinant at nsP1 position 538 plays a role 
 in  modulating the host innate immune response, specifically type I IFN. 
 3)  To determine if the AR86 virus nonstructural proteins are interacting with the type 
 I IFN induction signaling pathway.    
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ABSTRACT 
Sindbis viruses, like many alphaviruses, cause rash, fever, and arthralgia in humans, 
however, the pathogenesis of alphavirus-induced arthritis/arthralgia is poorly understood.  
Therefore, a molecularly cloned Sindbis-group virus, Girdwood, that is associated with 
infectious arthralgia humans, was assessed for its ability to replicate in joint associated 
tissues and cause disease in a mouse model.  In 14 day-old mice, Girdwood exhibited tropism 
for periosteum, joint associated connective tissue, and tendons within the hind limbs.  
Furthermore, comparison of the Girdwood clone to TR339, a molecularly cloned Sindbis 
virus that represents an early, non-cell culture adapted strain of the original AR339 strain of 
Sindbis, showed that Girdwood virus caused more severe disease than TR339 following 
peripheral inoculation of 14 day-old mice.  Although both viruses exhibited similar levels of 
replication within the serum and CNS, the arthralgia associated Girdwood virus exhibited 
significantly higher viral titers  in bone and joint associated tissue and skeletal muscle as 
compared to TR339.  Therefore, this virus represents a useful tool for dissecting the viral 
molecular determinants that promote replication within joints and associated connective 
tissues.   
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INTRODUCTION 
 
 Old world alphaviruses are a common cause of infectious rheumatic complaints, 
including severe arthritis, arthralgia, and myalgia (Griffin, 2001; Laine et al., 2004).  Viruses 
such as Ross River virus (RRV), Sindbis viruses (SINV), and Chikungunya are recurrent 
problems in Australia, Southern Africa, Europe and Asia, where they cause several hundred 
to several thousand cases of disease each year (2006a; 2006b; Enserink, 2006; Laine et al., 
2004; Suhrbier and La Linn, 2004).  However, many of these viruses, including RRV, 
O’nyong-nyong, and Chikungunya virus, are also capable of emerging in new locales and 
causing epidemics on a massive scale, as illustrated by an outbreak of RRV disease in the 
South Pacific in 1979-80 that affected 50-60,000 individuals just on the island of Fiji 
(Aaskov et al., 1981; Fraser, 1986; Harley et al., 2001), an outbreak of O’nyong-nyong in the 
1960’s that caused upwards of nearly two million cases of infectious arthritis/arthralgia 
(Williams et al., 1965), and currently an epidemic of Chikungunya virus affecting individuals 
residing in East African countries bordering the Indian Ocean, India, and Sri Lanka (2006a; 
2006b; Enserink, 2006; Seneviratne and Perera, 2006).  
Though alphavirus-induced arthridities are generally acute and self-limited (Laine et 
al., 2004; Suhrbier and La Linn, 2004), the rheumatic symptoms can be severe and are often 
debilitating.  Furthermore, with many alphavirus-induced arthridities, a subset of patients 
complain of chronic pain and loss of function (Laine et al., 2004), though whether this is 
directly related to persistent virus infection or other factors is not well understood.  Disease 
manifestations also vary between alphavirus infections, with viruses such as RRV are 
generally associated with frank arthritis involving virus-induced inflammation (Fraser et al., 
1983; Hazelton et al., 1985; Soden et al., 2000), while SINV are generally associated with 
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arthralgia characterized by pain within tendons and other tissues surrounding the joint 
(Kurkela et al., 2005; Turunen et al., 1998). 
 Alphavirus-induced arthridities can be extremely severe, however, the mechanisms 
underlying alphavirus-induced arthritis and arthralgia in humans are not well understood.  
Direct viral replication and inflammation within and around affected joints and connective 
tissues are thought to contribute to disease.  RRV nucleic acid or antigen has been recovered 
from synovial aspirates of individuals suffering from RRV-induced infectious polyarthritis 
(Fraser et al., 1981; Soden et al., 2000).  Characterization of the inflammatory response 
within synovium effusions revealed that it mainly consists of macrophages, CD4+ T cells, B 
cells, and monocytes (Fraser et al., 1981; Fraser et al., 1983; Hazelton et al., 1985; Soden et 
al., 2000).  For Sindbis-group viruses, skin biopsies and blood samples have tested positive 
for viral nucleic acid and infectious virus has been recovered from patients showing 
symptoms of Pogosta disease, however, no virus has been recovered from joint-associated 
tissues (Kurkela et al., 2004). 
 In order to better understand the pathogenesis of arthritogenic alphaviruses, improved 
animal models would be useful for dissecting the pathogenesis of these diseases.  Currently, 
two mouse models have been described for studying the pathogenesis of alphavirus-induced 
arthritis and myositis.  Morrison et al. has recently characterized RRV infection in an adult 
mouse model to study virus-induced arthralgia/arthritis and myositis (Morrison et al., 2006).  
In this model, RRV shows tropism for bone, joint, and skeletal muscle from a peripheral 
route of inoculation.  Furthermore, infiltrating inflammatory macrophages, NK cells, CD4+ 
and CD8+ T cells were present in skeletal muscle of RRV-infected mice, which is similar to 
synovial effusions and skin biopsies from patients suffering from RRV-induced polyarthritis 
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(Soden et al., 2000), suggesting that the mouse model reflects a valid system for studying 
RRV pathogenesis.  However, for alphaviruses such as SINV, which cause arthralgias 
without overt inflammation, the RRV model is likely to be of limited use in understanding 
the pathogenesis of virus-induced arthralgia.  One study has shown that the Sindbis-group 
virus strain AR86 replicates within joint associated tissues of adult mice (Heise et al., 2000a).  
However, no virus-induced disease was observed, thus limiting the potential of this model for 
studying the pathogenesis of SINV-induced arthralgia.  Therefore, improved animal models 
are needed if advances are to be made in studying the mechanisms underlying alphavirus-
induced arthritis/arthralgia.   
 In this study, we report the characterization of a molecular clone for the Sindbis-
group virus, Girdwood, a virus originally isolated from a human suffering from virus-induced 
arthralgia (Malherbe et al., 1963).  Characterization of the cloned virus (G100) demonstrated 
similar in vitro and in vivo growth and virulence characteristics as compared to the natural 
Girdwood isolate.  Studies to evaluate Girdwood replication in 14 day-old mice, an age 
where Girdwood virus (G100) causes hind limb dysfunction without a lethal outcome, 
showed high levels of replication in periosteum, tendon, and joint-associated connective 
tissues.  Furthermore, direct comparison between the arthralgia associated Girdwood virus 
and the prototypic laboratory strain of SINV (TR339), which has not been associated with 
arthralgia, showed striking differences in both viral replication and disease induction.  While 
both G100 and TR339 showed similar levels of replication in neural tissues, G100 exhibited 
significantly higher titers in several peripheral tissues, including ankle joints and skeletal 
muscle.  In addition, G100 consistently caused more severe disease signs (hind limb 
dysfunction and weakness) than TR339, which suggest that the molecularly cloned G100 
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virus may prove to be a useful reagent for studying the pathogenesis of alphavirus-induced 
arthritis/arthralgia and for identifying viral genetic determinants that promote viral 
replication in joint and skeletal muscle tissues.   
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 RESULTS 
 
Characterization of the full-length infectious clone of the arthralgia associated Sindbis-
group virus Girdwood.  The Sindbis-group virus, Girdwood, was isolated from a human 
suffering from arthralgia (Malherbe et al., 1963) and is closely related to the arthralgia 
associated Northern European isolates of Sindbis virus, such as Ockelbo, Karelian Fever, and 
Pogosta (Laine et al., 2004; Shirako et al., 1991).  Our group has previously described the use 
of the full-length infectious clone of Girdwood in a study to map virulence determinants 
within the adult mouse virulent Sindbis-group virus strain AR86 (Suthar et al., 2005).  
However, given that Girdwood virus caused arthralgia in a human (Malherbe et al., 1963), 
we sought to investigate whether this virus might also be a useful reagent for studying the 
pathogenesis of alphavirus-induced arthralgia.  As a first step in this process, a detailed 
analysis was performed to ensure that the cloned virus was phenotypically identical to the 
disease associated natural isolate.  This was particularly important given that the infectious 
clone derived virus contained the 5’ and 3’ UTRs from the closely related Sindbis-group 
virus, AR86, which resulted in a single nucleotide change at position 16 (from a T to C) in 
the 5’ UTR and a single nucleotide change at position 11558 (from a T to a C) in the 3’ UTR 
(Suthar et al., 2005).    Both G100 and the natural isolate exhibited a large plaque size 
phenotype, in which the two viruses were indistinguishable (data not shown).  The specific 
infectivity (i.e. PFU per cpm as measured on BHK-21 cells) of the Girdwood clone and 
natural isolate were also compared (Fig. 1).  The clone derived virus and the natural isolate 
had comparable particle to PFU ratios.  Both viruses exhibited similar specific infectivities to 
TR339, a non-cell culture SINV that represents the prototypic AR339 strain of Sindbis, and 
all three were less than TRSB, a well characterized SINV that contains a cell culture 
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adaptation mutation in E2 (Arg at position 1) resulting in enhanced BHK-21 cell infectivity 
(Klimstra et al., 1998).   
The growth characteristics of the cloned virus was compared to the natural isolate by 
performing single- and multi-step growth curves in BHK-21 cells.  In the single-step growth 
assay, in which cells were infected at an MOI of 5.0, the infectious clone derived virus and 
the natural isolate displayed similar growth kinetics (Fig. 2A).  Furthermore, both viruses 
exhibited similar growth kinetics in a multi-step growth curve in which BHK-21 cells were 
infected at an MOI of 0.01 (Fig. 2B).  By 36 hours post-infection, both viruses reached 
comparable peak viral titers of approximately 106 -107 PFU/ml.   
Previous studies using the Girdwood infectious clone demonstrated that this virus was 
non-neurovirulent in mice greater than 4 weeks of age.  To further characterize the virulence 
of the Girdwood clone, suckling and adult mice were infected and the virulence was 
compared to that of the natural isolate (Table 1).  Overall, the infectious clone showed 
similar virulence properties to that of the natural isolate in 5, 8, 14, and 42 day-old mice.  
While infection of five-day-old mice exhibited 100% mortality, infection of 14-day-old mice 
with the clone G100 virus exhibited no mortality, however, mice exhibited moderate to 
severe morbidity, characterized by ruffled fur, hunched posture, and moderate to severe hind 
limb dysfunction (Fig. 3B).  In mice greater than 2 weeks of age, no mortality or morbidity 
was observed with either virus, confirming previously published studies (Suthar et al., 2005). 
The results from these studies demonstrate that the Girdwood clone exhibits similar in 
vitro and virulence properties as that of the natural isolate.  Furthermore, infection of 14 day-
old mice may serve as a non-lethal model to study virus-induced disease. 
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Girdwood virus exhibits tropism for bone and joint associated tissues in 14-day-old 
mice.  Peripheral inoculation of adult mice with AR86, which is closely related to Girdwood, 
demonstrated virus tropism and replication in bone and joint associated connective tissues 
(Heise et al., 2000a).  However, one limitation of these studies was that AR86 infection was 
restricted to older animals (greater than 6 weeks of age) mainly due to the fact that AR86 is 
neuroinvasive and lethal in younger mice (Suthar, M.S. and Heise, M.T., data not shown).  
Since SINV replication in joint associated tissues within the mouse becomes more restricted 
with age (Heise M.T., unpublished), we examined whether Girdwood would exhibit tropism 
for bone and joint associated tissue in younger animals.  In this study, 14-day-old mice, in 
which Girdwood showed moderate to severe hind limb dysfunction and no mortality, were 
infected with a modified Girdwood virus expressing green fluorescent protein (GFP) from a 
second subgenomic promoter.  GFP-positive cells were observed in the hind limbs at 24, 48, 
and 72 hours post-infection, however the most intense signal was observed at 48 hours post-
infection.  At 48 hours post-infection, virus-specific signal within the ankle joint and foot 
were observed within periosteum, joint associated connective tissues, and tendons (Fig. 4).  
These results, which were also confirmed by in situ hybridization (data not shown), 
demonstrate that Girdwood exhibits tropism for bone and joint-associated tissues in 14 day-
old mice.    
Girdwood virus replication in 14-day-old mice.   Based on the finding that Girdwood virus 
showed tropism for joint associated tissues, we compared Girdwood replication in 14 day-old 
mice to the molecularly cloned SINV, TR339, a non-cell culture adapted representative of 
the prototypic AR339 strain of SINV that is largely avirulent in mice greater than 11 days of 
age  and which has not been associated with arthralgia (Klimstra et al., 1998; Ryman et al., 
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2007).  Girdwood infection consistently caused more severe disease (DS= 3.0 on day 7), and 
exhibited greater than 30% weight differences by day 9 p.i. as compared to TR339 infected 
mice (DS=1.0 on day 7) (Fig. 3).   The Girdwood virus-induced disease was striking in that 
unlike the severe debilitating disease induced by the closely related, but adult mouse 
neurovirulent AR86 virus (Heise et al., 2000b), the hind limb disease induced by Girdwood 
infection was relatively moderate and mice eventually recovered (data not shown).   
Additional studies were performed to evaluate the sites and magnitude of Girdwood 
and TR339 replication in the infected mice.  Overall levels of virus replication were 
evaluated in ankle joint, muscle, spleen, serum, and CNS tissues of infected mice.  Consistent 
with previous studies with the Sindbis-group virus strain AR86, both G100 and TR339 
exhibited replication in joint associated tissues (Fig. 5).  Though both viruses showed 
equivalent levels of replication in the CNS, the arthralgia associated G100 virus had 
significantly higher titers in the ankle, skeletal muscle, and spleen (Fig. 5).  This suggests 
that determinants within the G100 virus promote enhanced growth in peripheral tissues, and 
further studies are required to identify these determinants and assess their role in virus-
induced disease.   
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DISCUSSION 
 Alphaviruses are a common cause of infectious arthridities worldwide, with several 
viruses, such as Chikungunya and RRV associated with large outbreaks of severe 
arthritis/arthralgia (Aaskov et al., 1981; Enserink, 2006).  Although alphaviruses are a 
significant cause of human disease, relatively little is known about the pathogenesis of 
alphavirus-induced rheumatic diseases.  We and others have described a mouse model of 
RRV-induced arthritis/myositis, however, unlike RRV, which causes inflammatory arthritis 
in humans, SINV, such as Ockelbo and Girdwood are associated with arthralgia (Harley et 
al., 2001; Laine et al., 2004; Morrison et al., 2006).  It is therefore likely that the 
pathogenesis of arthritis associated viruses, such as RRV will differ from arthralgia 
associated viruses such as the SINV.  With this in mind, we tested whether a molecularly 
cloned Sindbis virus that was found to cause arthralgia in a human would also replicate in 
bone and joint associated tissues and cause disease in a mouse model.   
 It is thought that direct virus replication within the affected joints contributes to the 
development of alphavirus-induced arthritis/arthralgia in humans.  This is largely based on 
studies with RRV, where viral RNA and viral antigen positive cells have been isolated from 
the knee joint and synovium effusions of afflicted individuals (Fraser et al., 1981; Soden et 
al., 2000).  In support of this, RRV has been shown to replicate to high levels in synovial 
tissues of infected mice and in hind limb skeletal muscle (Morrison et al., 2006), while the 
data presented here also demonstrates that joint associated tissues and skeletal muscle of 
mice are major sites of replication for the arthralgia associated Girdwood virus.  Perhaps 
most importantly, these results also demonstrate that the arthralgia associated Girdwood virus 
replicates to higher levels in joint and muscle tissues, than the prototypic TR339 strain of 
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SINV, which has not been linked to arthralgia in humans.  This result is particularly striking 
in that both viruses replicated to equivalent levels in the CNS, which suggests that Girdwood 
virus may either exhibit an enhanced tropism for extraneural tissues, or an enhanced ability 
to replicate in cells within these tissues.  Either of these possibilities may have an important 
impact on our understanding of the pathogenesis of alphavirus-induced arthralgia, since this 
would suggest that specific viral determinants contribute to the ability of arthralgia associated 
viruses to target to and/or replicate within joints associated or other connective tissues.  This 
would in turn raise the possibility of mapping the determinants within the cloned Girdwood 
virus that contribute to the enhanced replication within muscle and joint tissues.  The 
availability of molecularly cloned versions of Girdwood and TR339, which can be readily 
used to create a set of chimeras to map the determinants of bone/joint tropism, provides a set 
of tools that could be used significantly enhance our understanding of the viral and host 
factors that contribute the development of arthralgia following alphavirus infection.  
             The mechanisms underlying alphavirus-induced arthralgia are poorly understood, 
since the joint pain induced by SINV lacks the inflammatory infiltrates that presumably 
mediate the arthritic symptoms caused by viruses such as RRV (Harley et al., 2001; Rulli et 
al., 2005).  Infection of 14 day-old mice with Girdwood did result in a transient hind limb 
dysfunction which is similar to that seen with RRV-infected mice (data not shown; (Morrison 
et al., 2006).  Though we cannot rule out a role for neurologic effects, several lines of 
evidence suggest that this disease is due to direct viral replication within muscle and joint 
associated tissues within the limb, rather than virus-induced nerve damage within the CNS.  
This includes the transient nature of the disease, with infected mice recovering full use of 
their hind limbs after the resolution of the viral infection.  Though it is possible for mice to 
 87 
regain partial hind limb function following virus-induced damage of the CNS (Suthar et al., 
2005), it is unlikely that the affected animals would regain full function as rapidly as the 
those in our study if the hind limb dysfunction were simply due to nerve damage.  While 
Girdwood caused greater disease than TR339, both viruses replicated to similar levels in the 
CNS, but differed in their ability to replicate in joint and muscle tissue.  Furthermore, 
hematoxylin and eosin stained brain and spinal cord sections revealed no overt neuronal 
damage during the course of infection (data not shown).  This result supports the hypothesis 
that direct viral replication by the arthralgia associated Girdwood virus is responsible for the 
hind limb dysfunction, though additional studies are needed to address this issue in greater 
detail.  However, even if the hind limb disease proves to be due to virus-induced damage to 
the CNS, this mouse model should still be useful for identifying viral genetic factors that 
promote replication within joint associated tissues. 
      In summary, we have characterized a molecular clone of the arthralgia associated 
Girdwood virus for its ability to replicate in bone and joint associated tissues and cause 
disease in a mouse model.  Not only did Girdwood virus cause more severe disease than the 
non-arthralgia associated TR339 virus, but showed enhanced ability to replicate in bone and 
joint associated tissues and skeletal muscle.  This enhanced ability to replicate in bone and 
joint associated tissues and skeletal muscle may promote the induction of arthralgia by 
viruses such as Girdwood, while this difference in replication between TR339 provides an 
opportunity to identify viral determinants that promote replication in extraneural tissues, 
which has not previously been reported for alphaviruses. 
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MATERIALS AND METHODS 
 
Viruses and virus stocks.  Plasmids containing the viral cDNA are designated with the 
prefix “p” while the infectious virus derived from the cDNA clone does not contain the “p” 
designation; i.e., G100 represents virus derived from the plasmid pG100.  TRSB and TR339 
virus stocks were generously provided to us by the laboratories of Robert E. Johnston and 
William Klimstra.    
 Virus stocks were made as described previously (Suthar et al., 2005).  Briefly, viral 
cDNA plasmids were linearized with PmeI and used as templates for the synthesis of full-
length transcripts using SP6-specific mMessage Machine in vitro transcription kits 
(Ambion).  Transcripts were electroporated into BHK-21 cells grown in α-minimal essential 
medium (α-MEM:  10% fetal calf serum [Gibco], 10% tryptose phosphate broth [Sigma], and 
0.29 mg of L-glutamine per ml [Gibco]).  Supernatants were harvested 24 to 27 hours after 
electroporation and subjected to centrifugation at 3000 RPM (Sorvall rotor RTH-250) for 20 
minutes at 4˚C and frozen in 1-ml aliquots.  Virus stocks were titrated on BHK-21 cells as 
previously described (Simpson et al., 1996). 
 BHK-21 cells (ATTC CCL-10) were maintained at 37˚C in α-MEM (Gibco) 
supplemented with 10% donor calf serum, 10% tryptose phosphate broth, and 1% L-
glutamine, for a maximum of 10 passages. Single-step and multi-step in vitro growth curves 
were performed as previously described. Briefly, BHK-21 cells were plated at 105 cells/well 
in 24-well plates (Sarstedt) for 18 h at 37°C. Medium was removed, and wells were infected 
with virus in triplicate at a multiplicity of infection (MOI) of 5.0 or 0.01. Cells were 
incubated at 37°C for 1 h. Wells were then washed three times with 1 ml of PBS 
supplemented with 1% DCS and Ca2+-Mg2+. One milliliter of growth medium was then 
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added to each well, and cells were incubated at 37°C. Samples of supernatant were removed 
at various time points, with an equal volume of fresh medium added to maintain a constant 
volume within each well. Samples were frozen at 80°C until analysis by plaque assay. 
Construction of the full-length Girdwood clone.  The Girdwood infectious clone, pG100, 
was generated by RT-PCR amplification of the Girdwood genome from low cell culture 
passaged virus stocks.  The Girdwood genome was amplified as overlapping one to three kB 
fragments that spanned the genome, which were then introduced into the AR86 pS300 
infectious clone plasmid (Suthar et al., 2005) using restriction sites that are conserved 
between Girdwood and AR86.  The 5’ and 3’ untranslated regions (UTR) of this clone were 
maintained on the AR86 background (single nucleotide changes at positions 16 (T to C) and 
11558 (T to C)). The resulting clone, pG100, was sequenced to ensure that the cloned 
sequence matched the previously published Girdwood sequence (NCBI Accession No. 
U38304) (Simpson et al., 1996).  Several single amino acid differences were found in the 
Girdwood clone that differed from the published sequence (Simpson et al., 1996).  Several of 
these changes were present on multiple clones and changed a codon that was unique to 
Girdwood back to the SINV consensus sequence and therefore likely represent differences 
between our Girdwood isolate and the published sequence.  These changes are located at nt 
1721, 2200, 2407, 2496, 2498, 4588, 4780, 5524, 5526, 5527, 5704, 5705, 5824, 5826, 5843, 
6328, 6329, 6714 and were maintained within the clone.  In addition to these changes, PCR 
artifacts were found in the completed clone and nucleotide changes that resulted in coding 
changes were corrected either by recloning the fragment or by PCR mediated mutagenesis.  
There were also three non-coding nucleotide changes present at nucleotide position 536 (T to 
an A), 8639 (C to T), and 8985 (A to G).  These were not corrected and were instead used as 
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marker mutations to differentiate the cloned virus from the Girdwood natural isolate.  Other 
than the consensus sequence changes discussed above, the virus produced from pG100 has an 
amino acid sequence identical to that reported for Girdwood (Simpson et al., 1996).   
Specific Infectivity Assay.  Virus specific infectivity assays were performed as described by 
(Ryman et al., 2004)  Briefly, radiolabeled virus was prepared by infection of a BHK cell 
monolayer with an MOI of 2-3 followed by incubation with 10 µCi/ml [35S]-methionine 
(Amersham).  Virus was purified on two subsequent discontinuous 20%/60% sucrose 
gradients and concentrated by pelleting through 20% sucrose.  The BHK cell-specific 
infectivity (measured as PFU per count per minute [cpm]) was calculated for each virus 
preparation by plaque assay on BHK cells.  
Animal Studies.  Specific-pathogen-free timed pregnant CD-1 mice (13-15 days gestation) 
or six-week old female CD-1 mice were obtained from Charles River Breeding Laboratories 
(Raleigh, NC).  Mice that were born within a 12-hour period were pooled and divided 
randomly as 10-12 pups per litter.   Animal housing and care were in accordance with all 
University of North Carolina at Chapel Hill Institutional Animal Care and Use Committee 
guidelines.  Virulence studies were performed in 5, 8, or 14-day-old CD-1 mice by s.c 
inoculation in the ventral thorax with 103 PFU of virus diluted with diluent containing 
phosphate-buffered saline (PBS [pH 7.4]), supplemented with 1% donor calf serum (DCS) 
(Gibco).  Mock infected mice received diluent alone.   Mice were monitored daily for 
mortality and/or morbidity for a period of 21-days postinfection.  Six-week-old mice were 
anesthetized with either isoflourane (Halocarbon Laboratories) or ketamine supplemented 
with xylazine (Barber Med.) prior to intracranial (i.c.) inoculation with a standard dose of 103 
PFU of virus in diluent.  Mock infected mice received diluent alone.  Mice were monitored 
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daily for body weight and scored for disease signs as follows: 1= Ruffled fur and/or hunched 
body posture, 2= Mild hind-limb dysfunction, 3= Prominent hind-limb dysfunction, 4= 
Severe hind-limb dysfunction, 5= Paralysis of hind-limbs, and  6=  Terminal morbidity.  As 
required by the UNC-CH animal protocol, infected mice were euthanized during the 
experiment either when mice dropped to 30% of initial body weight or when mice exhibited 
severe disease signs.  For in vivo growth studies, 14-day-old mice were inoculated as 
described and sacrificed by exsanguination followed by perfusion with 10 ml of PBS.  
Tissues from these mice were harvested at  18, 36, 48, 60, 72, and 96 hours post infection 
and viral loads per gram or ml of tissue were determined in the the hind limb ankles, 
quadricep muscle, spleen, brain, and serum by plaque assay on BHK-21 cells.  Statistical 
analysis were performed using Students two-tailed t-test and differences were considered 
significant when p<0.05 (Instat 3.0).  Alternatively following exsanguination, mice were 
perfused with 4% paraformaldehyde and hind limbs were removed.  The hind limbs were 
decalcified for approximately two week in 4% paraformaldehyde and 8% EDTA.  Frozen 
sections were then prepared from the decalcified hind limbs.   
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Figure 2-1:  Relative specific infectivity of the Girdwood clone (G100), Girdwood 
natural isolate and TRSB. 
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Figure  2-1.  Relative specific infectivity of the Girdwood clone (G100), Girdwood 
natural isolate and TRSB.  Radiolabeled virus was prepared, diluted, and assayed for 
plaque formation on BHK-21 cell monolayers.  The specific infectivity (measured as 
PFU/cpm) was calculated for each of the viruses and the values were normalized to TRSB 
(100%).  The data shown are from one of three representative experiments. 
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Figure 2-2:  The Girdwood clone displays similar in vitro growth kinetics as that of the 
natural isolate.   
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Figure  2-2.  The Girdwood clone displays similar in vitro growth kinetics as that of the 
natural isolate.  Single-step (A) and multi-step (B) in vitro growth assays were performed in 
which BHK-21 cells were infected with the Girdwood clone (G100; solid circles) or the 
natural isolate (open circles) at an MOI of 5.0 or 0.01, respectively.  Samples of supernatant 
were removed at the indicated time points and evaluated for virus yield by plaque assay.  
Each point represents the average titer of three independent samples with the standard 
deviation.  The data shown are from one of three representative experiments.   
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Table 2-1:  Girdwood virulence in mice. 
Table 1
Suthar, Mehul et al.
42
14
8
5
Age (days)
0% (0)
100%
ND
ND
% Morbidity (DS)
i.c
s.c
s.c
s.c
Route
N/A0%N/A0%100%
N/A0%N/A0%0% (0)
AST (SD)AST (SD)
Girdwood Clone (G100)Girdwood Natural Isolate
8.3 (1.7)69.6%10.8 (3.1)45.5%ND
4.2 (1.2)100%4.4 (1.4)100%ND
% Mortality% Mortality% Morbidity (DS)
ND=Not Determined
DS= Clinical score as measured on peak day of disease
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Figure 2-3:  Girdwood infected mice show more severe disease signs than TR339.   
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Figure 2-3.  Girdwood infected mice show more severe disease signs than TR339.  
Groups of fourteen day-old CD-1 mice were infected s.c. in the ventral thorax with mock or 
103 PFU of Mock (closed circle; solid line), G100 (open circle; solid line), or TR339 (closed 
circle; dashed line).  Mice were monitored daily for (A) weight and (B) disease score.  Each 
data point represent an average for weight or disease score of infected mice at each timepoint 
(Mock=6, G100=11, TR339=10).  The data shown are from one of four representative 
experiments. 
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Figure 2-4:  Girdwood exhibits tropism for bone and joint-associated connective tissues. 
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Figure 2-4.  Girdwood exhibits tropism for bone and joint-associated connective tissues.  
Fourteen day-old CD-1 mice were infected s.c. in the ventral thorax with 103 PFU of G100-
egfp and ankle joint and foot bones were evaluated for virus-specific signal at 48 hours post-
infection.  (M= marrow, P= periosteum, T=tendon, B=Bone, Mu=Muscle).  Panels A, B, and 
C represent different locations within the foot and ankle joints of positive virus signal. 
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Figure 2-5:  Girdwood exhibits enhanced replication in peripheral tissues as compared 
to TR339.   
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Figure 2-5 
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Figure 2-5 
E.
0
1
2
3
4
5
6
7
12 24 36 48 60 72 84 96
Hours Post-Infection
PF
U/
m
l (L
o
g)
 
 108 
Figure 2-5.  Girdwood exhibits enhanced replication in peripheral tissues as compared 
to TR339.  Fourteen day-old CD-1 mice were infected s.c. in the ventral thorax with 103 
PFU of G100 (solid circle) or TR339 (open circle).  Mice were sacrificed by exsanguination 
at 18, 36, 48, 60, 72, and 96 hours post infection and perfused with PBS (pH7.4).  The hind 
limb (A) ankles, (B) quadricep muscle, (C) spleen, and (D) brain were removed, weighed, 
and titered by plaque assay on BHK-21 cells.  Serum (E) was collected and evaluated for 
viral load.  Each point represents the average titer from three mice per virus per time point 
along with the standard deviation (* p<0.05.).  The data shown represents one of three 
experiments.   
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ABSTRACT 
  Sindbis virus (SINV) infection of mice has provided valuable insight into viral and 
host factors that contribute to virus-induced neurologic disease.  In an effort to further define 
the viral genetic elements that contribute to adult mouse neurovirulence, the neurovirulent 
Sindbis-group virus strain AR86 was compared to the closely related (22 single amino acid 
coding changes and the presence or absence of an 18 amino acid sequence in nsP3 (positions 
386-403)), but avirulent Girdwood strain.  Initial studies using chimeric viruses demonstrated 
that genetic elements within the nonstructural and structural coding regions contributed to 
AR86 neurovirulence.  Detailed mapping studies identified three major determinants in the 
nonstructural region at nsP1 538 (Ile to Thr; avirulent to virulent), an 18 amino acid deletion 
in nsP3 (positions 386-403), and nsP3 537 (Opal to Cys; avirulent to virulent), as well as a 
single determinant in the structural genes at E2 243 (Leu to Ser; avirulent to virulent) that 
were essential for AR86 adult mouse neurovirulence.  Replacing these codons in AR86 with 
those found in Girdwood resulted in attenuation of AR86, while the four corresponding 
AR86 changes in the Girdwood genetic background increased virulence to the level of wild-
type AR86.  The attenuating mutations did not adversely effect viral replication in vitro and 
the attenuated viruses established infection in the brain and spinal cord as efficiently as the 
virulent viruses.  However, the virus containing the four virulence determinants grew to 
higher levels in the spinal cord at late times post-infection, suggesting that the virus 
containing the four attenuating determinants either fails to spread or are cleared more 
efficiently than the virus with the virulence determinants. 
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INTRODUCTION 
 Infection of mice with Sindbis-group viruses provides an excellent model for 
studying virus-induced neurological disease.  The outcome of SINV infection in the mouse 
model has been found to correlate with the age and strain of the animal, virus dose, route of 
inoculation, and the virus strain (5, 6, 13, 31).  Infection of neonatal mice with SINV results 
in a lethal disease characterized by elevated levels of proinflammatory cytokines and high 
viral titers in the muscle, brain and serum, in the absence of overt encephalitis (11, 26, 27).  
Increasing the age of the animal or infecting with an attenuated mutant virus results in a shift 
from the systemic disease towards a neurologic disease, however, most Sindbis-group viruses 
are avirulent in mice greater than 14 days of age (28).   
 Previous neurovirulence studies with Sindbis-group viruses have identified virulence 
determinants in both the E2 glycoprotein gene (29, 30) and the 5’ untranslated region (3, 12).  
Studies with the neuroadapted Sindbis virus (NSV) identified a His at amino acid position 55 
in the E2 glycoprotein that plays a major role in adult mouse neurovirulence (8, 30).  The 
mechanism underlying this change is not yet completely understood; however, E2 His 55 was 
shown to correlate with improved binding and entry into neuronal cells (30), increased levels 
of viral replication (2), and the ability to overcome the protective effect of bcl-2 
overexpression in neurons (15, 16).  Additionally, a single substitution of a G at position 8 in 
the 5' noncoding region of NSV was responsible for conferring neurovirulence in adult rats 
(12).   
 In addition to demonstrating the role of the structural genes in adult mouse 
neurovirulence, studies with the Sindbis-group virus S.A.AR86 (AR86), and Semliki Forest 
Virus (SFV) indicate that the viral nonstructural genes contribute to adult mouse 
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neurovirulence (9, 32, 33).  Studies with AR86 have shown that the presence of a Thr at 
position 538 in nsP1 plays an important role in contributing to adult mouse neurovirulence.  
Replacing this Thr of AR86 with an Ile, found in most Sindbis-group viruses, attenuates the 
virus, while introduction of the Thr into a non-neurovirulent laboratory strain of SINV lead 
to an increase in neurovirulence (9).  The introduction of the attenuating Ile at position 538 in 
nsP1 did not affect viral growth, as viruses that contained this change replicated as well as 
wild-type AR86 both in cell culture and in the brains of infected animals.  Furthermore, the 
presence of an Ile at position 538 accelerated processing of the nonstructural protein 
precursor (P123) into the mature nonstructural proteins, leading to earlier induction of viral 
26S RNA synthesis during infection (10).  In the case of SFV, mapping studies performed 
using virulent and avirulent strains demonstrated the importance of the nsP3 gene, including 
replacement of the opal termination codon (located within nsP3) with a sense codon, in 
reconstituting adult mouse neurovirulence (32, 33).   
  In this study, we utilized a newly generated clone of the Sindbis-group virus 
Girdwood to map determinants of adult mouse neurovirulence within AR86.  While AR86 
causes a lethal disease in adult mice, Girdwood is avirulent, even when administered 
intracranially.  However, these viruses differ by only 22 single amino acid coding changes, as 
well as the presence of an 18 amino acid sequence in nsP3 that are present in Girdwood, but 
are deleted from AR86.  Detailed mapping studies localized determinants to both the 
nonstructural and structural genes.  Furthermore, the virus containing the attenuating 
mutations did not adversely effect in vitro viral replication and the attenuated viruses 
established infection in the brain and spinal cord as efficiently as the virulent viruses.  
However, at late times post-infection, the virus containing the virulence determinants grew to 
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higher levels in the spinal cord, suggesting the virus containing the attenuating determinants 
either fail to spread or are cleared more efficiently than the virus with the virulence 
determinants.   
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MATERIALS AND METHODS 
Virus stocks and cell culture.  Plasmids containing the viral  cDNA are designated with the 
prefix “p” while the infectious virus derived from the cDNA clone does not contain the “p” 
designation; i.e., S300 represents virus derived from the plasmid pS300.  Clone pS300 was 
derived from AR86 RNA, and S300 is comparable to AR86 virus both in its growth and 
virulence properties (23).  Clone pS300 is identical to clone pS55 (23) except for a PmeI 
restriction site engineered at the 3’ end of the viral 3’UTR to facilitate generating chimeras 
with the Girdwood clone.  Virus derived from the Girdwood cDNA clone also exhibits in 
vitro and in vivo phenotypes similar to the Girdwood natural isolate (M. Suthar, manuscript 
in preparation).   
 Virus stocks were made as described previously (9).  Briefly, viral cDNA plasmids 
were linearized with PmeI and used as templates for the synthesis of full-length transcripts by 
using SP6-specific mMessage Machine in vitro transcription kits (Ambion).  Transcripts 
were electroporated into BHK-21 cells grown in α-minimal essential medium (α-MEM:  10% 
fetal calf serum [Gibco], 10% tryptose phosphate broth [Sigma], and 0.29 mg of L-glutamine 
per ml [Gibco]).  Supernatants were harvested 24 to 27 hours after electroporation and 
subjected to centrifugation at 3000 RPM (Sorvall rotor RTH-250) for 20 minutes at 4˚C and 
frozen in 1-ml aliquots.  Virus stocks were titrated on BHK-21 cells as previously described 
(23). 
 BHK-21 cells were maintained at 37˚C in α-MEM, for a maximum of 10 passages 
Single-step in vitro growth curves were performed as previously described (9). Briefly, 
BHK-21 cells were plated at 105 cells/well in 24-well plates (Sarstedt) for 18 h at 37°C. 
Medium was removed, and wells were infected with virus in triplicate at a multiplicity of 
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infection (MOI) of 5.0. Cells were incubated at 37°C for 1 h. Wells were then washed three 
times with 1 ml of room temperature PBS supplemented with 1% DCS and Ca2+-Mg2+. One 
milliliter of growth medium was then added to each well, and cells were incubated at 37°C. 
Samples of supernatant were removed at various time points, with an equal volume of fresh 
medium added to maintain a constant volume within each well. Samples were frozen at 
80°C until analysis by plaque assay. 
Construction of full-length cDNAs and chimeric viruses.  Standard recombinant DNA 
techniques were used to construct cDNA clones as previously described in (21).  The 
chimeric cDNA clone pS350, encoding the nsP1, nsP2, and nsP3 genes of Girdwood in the 
AR86 genome, was constructed by replacing the MfeI (nt 43) to BstBI (nt 6411) fragment of 
pS300 with that of pG100 (Fig. 1).  The chimeric cDNA clone pG106, encoding the 
structural genes of Girdwood in the AR86 genome, was constructed by exchanging the MfeI 
(nt 43) to BstBI (nt 6411) fragment of pG100 with that of pS300 (Fig. 1).   
Clone pS341 (changes of Ile to Val at position 648 and Leu to Glu at position 651 in 
nsP2), clone pS342 (Gly to Glu change at nsP3 position 344), and clone pS344 (Cys to Opal 
termination codon change at nsP3 position 537) were created by PCR-mediated site-directed 
mutagenesis on the wild-type pS300 background (Fig. 2).  Clone pS343, containing the 
Girdwood 18 amino acid region in nsP3 between positions 386-403, was constructed by 
replacing the SfiI (nt 5122) to AatII (nt 5285) fragment of pS300 with that of pG100.  
However, introduction of this region also included a single amino acid change of a Glu at 
nsP3 position 344, which was subsequently corrected to a Gly by primer-directed 
mutagenesis.   
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For the following panel of nonstructural chimeric cDNA clones, AR86 genomic 
fragments or point mutations were introduced into the chimeric virus pS350 (Fig. 3).  Clone 
pS351 was derived by replacing the thymidine with cytidine at nucleotide position 1672 
using PCR megaprimer mutagenesis (22), which replaced an Ile with a Thr codon at nsP1 
position 538.  Clone pS352 was made by replacing the adenine with a thymidine at 
nucleotide position 5793 to replace the opal termination codon at nsP3 position 537 with a 
Cys codon.  Clone pS353 was constructed by deleting the sequences between nucleotide 
positions 5257-5311, corresponding to amino acid positions 386 to 403 of nsP3 in Girdwood, 
by primer directed mutagenesis.  Clones pS354, pS355, pS356, and pS364, which contain 
different combinations of the changes at nsP1 position 538, nsP3 positions 386-403, and 
nsP3 position 537, were constructed by exchanging restriction fragments from clones pS351, 
pS352, pS353.   
For the panel of structural gene chimeric viruses listed in Fig. 4, AR86 genomic 
fragments or point mutations were introduced into the chimeric virus pG106.  The StuI-
BssHII fragment (nt 8110 to 9766) including most of the E2 coding region from clone pS300 
was introduced into clone pG106 to create the chimeric clone pG107, and the BssHII-PmeI 
fragment (nt 9766 to 11343), encompassing most of the E1 coding region of clone pS300, 
was introduced into clone pG106 to create chimeric clone pG108.  Clone pG117 was 
constructed by replacing the thymidine at position 9319 of pG106 with cytidine by PCR 
megaprimer mutagenesis, resulting in a coding change from a Ser to Leu at E2 position 243.  
Chimeric clone pG163 was constructed by primer-directed mutagenesis of pG100 as follows: 
substitution of thymidine for cytidine at nucleotide 1672 (Ile to Thr at nsP1 538), deletion of 
nucleotides between 5257-5311 (18 amino acid deletion from nsP3 386-403), substitution of 
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adenine for thymidine at nucleotide 5765 (Opal to Cys at nsP3 537), and thymidine for 
cytidine at nucleotide 9319 (Leu to Ser at E2 243).  The reciprocal set of changes were made 
in pS300 to create clone pS363.  Introduction of the various mutations were confirmed by 
sequencing at the University of North Carolina at Chapel Hill Genome Analysis Facility with 
a model 373A DNA sequencing apparatus (Applied Biosystems).    Chimeric virus stocks 
derived from full-length cDNAs were made as described above.      
Animal studies.  Specific-pathogen-free female CD-1 mice were obtained from Charles 
River Breeding Laboratories (Raleigh, NC).  Animal housing and care were in accordance 
with all University of North Carolina at Chapel Hill Institutional Animal Care and Use 
Committee guidelines.  Six-week-old mice were anesthetized with either isoflourane 
(Halocarbon Laboratories) or ketamine supplemented with xylazine (Barber Med.) prior to 
intracranial (i.c.) inoculation with a standard dose of 103 PFU of virus in diluent [phosphate-
buffered saline (PBS, pH 7.4)], supplemented with 1% donor calf serum (DCS, Gibco)).  
Mock infected mice received diluent alone.  Mice were monitored daily for body weight and 
scored for clinical signs as follows: 1= Ruffled fur and/or hunched body posture, 2= Mild 
hind-limb dysfunction, 3= Prominent hind-limb dysfunction, 4= Severe hind-limb 
dysfunction, 5= Paralysis of hind-limbs, and  6=  Terminal morbidity.  The average clinical 
score was calculated on day 5.  This day was chosen because by day 6 infected mice 
reproducibly showed severe disease progression and occasionally were euthanized, with 
death being recorded for the following day.  As required by the UNC-CH animal protocol, 
infected mice were euthanized during the experiment either when mice dropped below 30% 
of initial body weight or when mice exhibited severe disease signs.  Statistical analysis for 
mortality was performed using Fisher’s exact chi-squared test and differences were 
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considered significant when p<0.05 (Instat 3.0).  For the in vivo growth studies, mice were 
inoculated as described and sacrificed by exsanguination followed by perfusion with 10 ml of 
PBS at  6, 12, 24, 48, 72, 96, and 120 hours postinfection.  The whole brain was removed, 
weighed, and viral load assessed by plaque assay on BHK-21 cells (9, 23).  The spinal cord 
was removed, divided into thoracic and lumbar regions, weighed, and viral loads evaluated 
by plaque  assay on BHK-21 cells.   
 
RESULTS 
Neurovirulence determinants are localized within both the nonstructural and structural 
genes of AR86.   SINV adult mouse neurovirulence determinants have previously been 
found in the viral 5’ UTR and the E2 glycoprotein (12, 29).  In addition, previous studies 
with AR86 identified a single coding change at nsP1 position 538 that was essential for adult 
mouse neurovirulence (9).  In an effort to identify additional virulence determinants within 
AR86, comparisons were made between AR86 and Girdwood virus, a Sindbis-group virus 
that is closely related to AR86, but non-neurovirulent in adult mice.  To confirm 
neurovirulence phenotypes, mice were inoculated intracranially (i.c.) with 103 PFU of either 
S300 (AR86) or G100 (Girdwood) and monitored for virus-induced morbidity and mortality.  
Mice were observed daily and scored for clinical signs such as weight loss, ruffled fur, 
hunched body posture, hind-limb dysfunction (mild, moderate, and severe), paralysis of hind-
limbs, and terminal morbidity.  The average clinical score for each group was calculated 
from observations made on day 5.  Consistent with previous reports, S300 caused 100% 
morbidity and 100% mortality in 4 week-old mice, while G100 caused no detectable 
morbidity or mortality in the infected mice (Fig. 1A).  G100 and S300 differ at 22 single 
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amino acid positions and by the presence (G100) or absence (S300) of an 18 amino acid 
sequence in nsP3 (Table 1).  Given that the coding differences between S300 and G100 were 
distributed throughout the genome, our initial strategy involved defining whether the viral 
nonstructural or structural genes contained the major determinants of AR86 virulence.  
Therefore, two chimeras containing either the AR86 nonstructural coding region with the 
G100 structural genes (G106) or the G100 nonstructural genes with the AR86 structural 
genes (S350) were constructed and evaluated for virulence following i.c. infection of four 
week-old CD-1 mice.  G106 caused 91.7% mortality and 100% morbidity, while S350 
caused neither morbidity or mortality (Fig. 1A), though this virus grew as well as either wild-
type parent S300 or G100, both in vitro and in vivo (data not shown).  Furthermore, in vitro 
transcripts of pS300, pG100, pS350 and pG106 exhibited similar specific infectivities (data 
not shown).  These results strongly suggested that the major determinants of AR86 
neurovirulence were located in the nonstructural coding region.  However, when older mice 
(6 week-old) were inoculated i.c. with G106, only 26.1% mortality was observed, in 
comparison to 95.5% mortality with S300 (Fig. 1B).  Therefore, it was likely that 
determinants in both the nonstructural and structural genes were required for the full 
neurovirulence of AR86.   
 Since AR86 virulence determinants appeared to be located in both the structural and 
nonstructural coding regions, mapping of these virulence determinants were done separately, 
with the initial focus on the nonstructural region.  While it was possible that noncoding 
differences were at least partly responsible for the virulence differences between AR86 and 
Girdwood, the initial analysis focused on the coding differences, which were located in nsP1, 
nsP2, and nsP3, but not nsP4 (Table 1).  Previous analysis indicated that eight of the coding 
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differences, as well as the nsP3 deletion, were unique to AR86 when compared the known 
coding sequences of five non-virulent SINV (23).  Furthermore, in previous studies, the 
unique Thr at nsP1 538 of AR86 was shown to be essential for adult mouse neurovirulence, 
as viruses with Ile at this position no longer caused lethal disease in adult mice (9).  This 
suggested that the other coding changes that were unique to AR86 might be virulence 
determinants. Therefore each of the AR86 specific coding changes, with the exception of two 
changes at codons 442 and 446 in nsP3, were changed in the S300 background to the codon 
found at the corresponding position in Girdwood (clones pS341 and pS342).  The role of the 
18 amino acid deletion was also assessed by reintroducing the 18 amino acid sequence found 
at nsP3 positions 386 to 403 of Girdwood and the other non-neurovirulent SINV, back into 
the S300 clone (clone pS343), and an opal codon was introduced at nsP3 position 537 
(pS344).  The specific changes introduced into each clone was confirmed by sequencing.  
Viruses derived from these clones were evaluated for a loss of virulence following i.c. 
inoculation of 103 PFU into 6 week-old CD-1 mice.  In the process of performing this 
analysis it became apparent that the reported Arg codon at position 256 of nsP2 in the AR86 
infectious clone (23) was actually an Ala codon, which is present in all of the other SINV 
genomes.  Therefore, this position was dropped from our analysis.  Three changes at 
positions 648 and 651 of nsP2 (clone pS341) and at position 344 of nsP3 (clone pS342) did 
not appear to be major contributors to the adult mouse neurovirulence phenotype of AR86, 
since changing these codons to the corresponding codon found in Girdwood did not affect 
virulence in S300 (Fig. 2).  However, reintroduction of the 18 amino acid deletion in nsP3 
(clone pS343), or changing the unique Cys codon at nsP3 position 537 back to the opal 
termination codon (clone pS344) found in most non-neurovirulent SINV altered S300 
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virulence (Fig. 2).  In addition, both of these viruses exhibited equivalent growth kinetics to 
the wild-type S300 virus in vitro, suggesting that the decreased virulence was not simply due 
to a decrease in virus growth (data not shown).  These results suggested that in addition to 
nsP1 position 538 (9), additional AR86 virulence determinants included the 18 amino acid 
deletion in nsP3 and the Cys codon at nsP3 537, while the unique codons at nsP2 648 and 
651 or nsP3 344 did not appear to contribute to adult mouse virulence.  The role of nsP3 442 
and 446 was not addressed in this analysis, but the contribution of these determinants to 
virulence was evaluated in later studies (see below). 
Introduction of AR86 determinants into the non-virulent Girdwood background results 
in a gain of virulence.  Though mutation of nsP3 537 (Cys to Opal) or the reintroduction of 
the 18 amino acid deletion into nsP3 on the S300 background resulted in a loss of virulence, 
it was possible that rather than being true virulence determinants, these changes simply 
decreased virus fitness and thereby caused a subtle decrease in virus replication which 
affected virulence.  Therefore, a more rigorous test of whether these or other determinants 
within the nonstructural region were virulence determinants was performed by introducing 
changes into the non-neurovirulent Girdwood background (clone pG100) and assaying for a 
gain of virulence.  Since the AR86 nonstructural genes did not confer wild-type levels of 
virulence in the absence of the AR86 structural genes, all nonstructural mapping studies were 
performed using the clone pS350, which contained the Girdwood nonstructural region and 
the AR86 structural genes.  Therefore, if all of the nonstructural determinants of virulence 
were introduced into the pS350 clone, the resulting virus should exhibit a level of 
neurovirulence comparable to AR86.  As an initial step in this process, the three loci that 
were implicated in the S300 analysis (Fig. 2 and (9)) were analyzed in the S350 background 
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by introducing the codon found in the virulent AR86 virus back into the corresponding 
position in the Girdwood nonstructural region and looking for a gain of virulence (Fig. 3). 
 Introduction of a Thr codon in place of the Ile at nsP1 538 in the non-neurovirulent 
SINV TR339 was previously shown to increase virulence in 18 to 21 day old mice (9), which 
strongly suggests that this determinant plays a major role in adult mouse neurovirulence.  
When a Thr codon was placed at nsP1 538 of the ps350 clone, the resulting virus (S351) 
caused 100% morbidity, with a day 5 average clinical score of 2.2 and 16.7% mortality (Fig. 
3), compared to 27.3% morbidity (day 5 average clinical score of 0.4) and 0% mortality with 
the S350 virus.  A virus (S352) where the consensus opal termination codon at nsP3 position 
537 was replaced with the AR86 derived Cys codon caused 66.7% morbidity (day 5 average 
clinical score of 1.3), but no mortality (Fig. 3).  Likewise, deleting the 18 amino acids from 
position 386 to 403 in nsP3 of clone s350 (virus designated as S353) gave 78.6% morbidity 
(day 5 average clinical score of 1.2), but no mortality (Fig. 3).  Therefore, all three changes 
independently increased S350 virulence as determined by an increase in virus-induced 
morbidity, however none of the individual determinants were able to raise S350 virulence to 
the level observed with AR86 (clone S300).  Therefore, the individual coding changes were 
evaluated in combination.  Introduction of both the 18 amino acid deletion and the Cys codon 
at nsP3 position 537 of clone ps350 resulted in a virus (S364) that caused 91.7% morbidity 
(day 5 average clinical score of 1.5) and 6.7% mortality (Fig. 3).  However, when the Thr at 
nsP1 position 538 was introduced into clone pS350 in combination with either the 18 amino 
acid deletion (clone ps355) or the Cys codon at nsP3 position 537 (clone ps354), the resulting 
viruses were significantly more virulent than the parental S350 virus (27.3% morbidity, 0% 
mortality) (Fig. 3).  The S355 virus (Thr at nsP1 538, 18 amino acid deletion at nsP3 386-
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403) caused 100% morbidity and 65.4% mortality in 6 week-old mice, while the S354 virus 
(Thr at nsP1 538, Cys at nsP3 537) caused 100% morbidity and 76.9% mortality (Fig. 3).  
Finally, when all three changes were introduced into the same virus (clone pS356) the 
resulting virus caused 100% morbidity and 100% mortality in 6 week-old mice following i.c. 
inoculation.  Therefore, the Thr at nsP1 position 538, the 18 amino acid deletion from nsP3 
386 to 403, and the opal to Cys change at nsP3 527 are the major determinants of AR86 
neurovirulence within the AR86 nonstructural protein coding region.  Minor roles for other 
coding changes, such as nsP3 positions 442 and 446, or noncoding changes cannot be ruled 
out, however they were not necessary for the full adult mouse neurovirulence phenotype in 
the Girdwood background.  
Serine at Position 243 in the E2 glycoprotein is a major determinant of AR86 adult 
mouse neurovirulence.  Both the AR86 nonstructural coding region determinants and the 
AR86 structural genes were required for complete neurovirulence (Fig 1).  Therefore, studies 
were initiated to identify the structural gene determinants that contributed to adult mouse 
virulence.  Since complete virulence required the AR86 nonstructural coding region, all 
structural gene mapping studies were conducted using the G106 clone, which contains the 
AR86 nonstructural coding region and the Girdwood structural genes, and causes 87.0% 
morbidity (day 5 average clinical score of 2.0) and 26.1% mortality.  Gene segments or 
individual coding changes from the structural genes of wild-type AR86 (pS300) were 
introduced back into pG106 and the resulting viruses evaluated for increased virulence 
following i.c. inoculation of adult mice.  The AR86 and Girdwood structural genes contained 
5 coding differences, 1 in the E2 glycoprotein, 1 in the 6k protein, and 3 in the E1 
glycoprotein.  The relative contribution of the change in E2 versus the changes in the 6k/E1 
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protein coding regions were assessed using two chimeras where the E2 coding region or the 
6k/E1 coding region of AR86 was introduced into the G106 background.  When these viruses 
were evaluated for virulence, the virus with the AR86 E2 gene (G107) caused 100% 
morbidity and 82.4% mortality (Fig. 4), while the virus with the AR86 6k/E1 coding region 
caused 100% morbidity (day 5 average clinical score of 2.2) and 33.3% mortality (Fig. 4).  
While these results suggest that minor determinants of AR86 neurovirulence reside within 
the 6k/E1 coding region, it is clear that a major determinant of adult mouse neurovirulence 
was located in the E2 glycoprotein.  Since AR86 and Girdwood differ only at position 243 of 
E2, it was likely that this was the major determinant of adult mouse neurovirulence within 
the AR86 structural proteins.  This was directly tested by introducing the Ser codon at E2 
position 243 into the G106 clone to create the virus G117.  While G106 caused 87.0% 
morbidity (day 5 average clinical score of 2.0) and 26.1% mortality, clone G117 caused 
100% morbidity (day 5 average clinical score of 2.0) and 92.6% mortality, suggesting that 
the Ser at E2 position 243 was a major determinant of adult mouse neurovirulence (Fig. 4).  
Although the average peak clinical scores for G106 and G117 are the same on day 5, G117-
infected mice progress to show more severe disease and eventually die with an extended AST 
than G106.    
Determinants at nsP1 538, nsP3 386-430, nsP3 537, and E2 243 are able to confer an 
adult mouse neurovirulence phenotype in the Girdwood genetic background.  In order to 
determine whether the three nonstructural determinants and the Ser codon at E2 position 243 
were the major determinants of adult mouse neurovirulence in the AR86 virus, the four 
determinants were introduced into the G100 background.  While G100 caused no morbidity 
or mortality in six week-old mice, the virus G163, which was identical to G100 except for the 
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presence of an Ile to Thr change at nsP1 538, an 18 amino acid deletion from nsP3 positions 
386 to 403, an opal to Cys change at nsP3 537, and Leu to Ser change at E2 243, caused 
100% morbidity (day 5 average clinical score 3.0) and 84.6% mortality (Fig. 5).  For 
comparison, the same four changes were introduced into the S300 background, however, in 
this case the changes were Thr to Ile at nsP1 538, reconstitution of nsP3 codons 386 to 403, 
Cys to opal at nsP3 537, and Ser to Leu at E2 243.  This virus, which was designated S363, 
caused 71.4% morbidity (day 5 average clinical score of 0.9) and 0% mortality, in contrast to 
the parental S300 virus, which caused 100% morbidity (day 5 average clinical score of 3.1) 
and 95.5% mortality (Fig. 5).  These results show that introduction of the four AR86 
determinants back into the non-virulent Girdwood background resulted in a virus that 
exhibited neurovirulence that was comparable to AR86, demonstrating that these four 
changes play a major role in the adult mouse neurovirulence phenotype of AR86.  However, 
minor contribution from other coding or non-coding differences between Girdwood and 
AR86 cannot be ruled out.   
In vitro and in vivo growth analysis of the attenuated and virulent viruses.  The 
differences in virulence between the attenuated viruses (G100 or S363 chimera) and the 
virulent viruses (S300 or G163 chimera) could simply be explained by replication efficiency 
or the ability to successfully establish infection within neural tissues.  Therefore, a single-
step in vitro growth assay was performed for each virus in BHK-21 cells.  As shown in 
Figure 6A, the attenuated viruses grew at least as well as the virulent viruses at all time 
points tested.  Viral growth in brain and spinal cords of infected mice was evaluated next.  
Though G100 and S363 are significantly attenuated with regard to causing disease, both of 
these viruses grew at least as well as the virulent S300 and G163 viruses in the brains of 
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infected mice at all times post infection (Figure 6B).  Furthermore, when viral growth in the 
spinal cord was evaluated, viral titers were equivalent at 48 hours post infection, suggesting 
that both viruses were able to establish infection within the spinal cord.  However, at 96 
hours post infection, which is a time point when mice are starting to develop virus-induced 
disease signs, the virulent S300 virus exhibited significantly higher titers (p < 0.05) in the 
spinal cord than the attenuated S363 virus (Figure 6 C and D).  This suggests that the virus 
containing the four attenuating determinants are either defective in their ability to spread 
within the spinal cord or cleared more efficiently than the virus containing the four virulence 
determinants.  Additional studies to evaluate the extent of viral replication within these 
tissues will be required to address this question.       
 
DISCUSSION 
 The identification of the molecular determinants of alphavirus virulence represents an 
important step in understanding the pathogenesis of alphavirus-induced neurologic disease.  
The majority of studies looking at alphavirus neurovirulence determinants have identified the 
structural gene E2 and the 5’ UTR as major determinants of virulence in both neonatal and 
adult mice (3, 19, 29).  However, recent work with the Sindbis-group virus AR86 and 
Semliki forest virus (SFV) has demonstrated a role for the nonstructural genes in mediating 
alphavirus neurovirulence (9, 32, 33).  In this report, we describe the identification of four 
coding changes at nsP1 position 538, nsP3 position 537, an 18 amino acid deletion from nsP3 
386 to 403, and at E2 position 243 as major determinants of AR86 neurovirulence.  The fact 
that these four changes conferred adult mouse neurovirulence on a normally non-
neurovirulent SINV argues that these changes represent the major determinants of AR86 
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neurovirulence, although contributions from additional AR86 determinants cannot be ruled 
out.  It is also important to note that the neurovirulence determinants did not appear to simply 
affect viral replication  in vitro or in neural tissue at early times post-infection (Figure 6). 
However, studies in the spinal cord suggest that the attenuated viruses are either defective in 
spreading at late times in the infection, or may be cleared more efficiently than the virulent 
viruses (Figure 6).  Additional work is required to assess these possibilities and also 
determine whether the differences between the virulent and attenuated virus are spinal cord 
specific or simply a lack of sensitivity in detecting differences in the brain  by plaque assay.   
It is striking that all four of the identified AR86 neurovirulence determinants are, to 
our knowledge, unique to AR86, and not present in the published sequences of non-adult 
mouse neurovirulent SINV (23).  Furthermore, these determinants do not appear to be shared 
with other adult mouse neurovirulent SINV, such as the NSV strain (3, 19, 31).  This 
suggests that AR86 and NSV have evolved different strategies for causing neurologic disease 
in adult mice.  For instance, while the nonstructural gene determinants of AR86 are essential 
for neurovirulence in adult mice, the E2 243 change is only essential in mice greater than 4 
weeks of age (Figure 1).  In contrast, the structural genes of the NSV strain of Sindbis are the 
major determinants of adult mouse neurovirulence, with a His at E2 position 55 being 
particularly important (31).  There are several potential explanations for the differences in 
virulence determinants between AR86 and NSV, including passage histories and strain 
variation in the original viral isolates from which these neurovirulent viruses were derived.  
NSV was originally derived from the AR339 strain of Sindbis (7), while AR86 and 
Girdwood, which are closely related to each other, were isolated in South Africa.  In fact, 
Girdwood is one of the few SINV isolated from an infected human (20).  Therefore, it  is 
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possible that genetic differences between this strain and the South African Sindbis-group 
virus strains such as AR86 and Girdwood biased these viruses toward different types of 
virulence determinants.  NSV and AR86 were also placed under different types of selective 
pressure during their early passage.  NSV was derived from a virus that was passaged an 
unknown number of times in cell culture, and then selected through six rounds of passage in 
neonatal and weanling mice (7).  In contrast, AR86 was isolated from a mosquito pool, and 
subjected to 45 to 60 alternating rounds of intracranial passage in neonatal and weanling 
mice (34), with very limited exposure to cell culture prior to the generation of the infectious 
clone (23).  It is likely that these vastly different passage histories are in part responsible for 
the differences in virulence determinants between AR86 and NSV. 
While all four changes are essential for the complete mouse neurovirulence 
phenotype of AR86, it appears that the Thr at nsP1 538 plays a particularly important role.  
Previous studies have shown that changing the Thr at nsP1 538 in AR86 to the consensus Ile 
found in non-neurovirulent viruses results in a complete loss of virus-induced mortality, 
though this virus was still capable of causing disease (9).  Likewise, introduction of a Thr 
codon at nsP1 position 538 into S350 (which contains the AR86 structural genes in the 
Girdwood virus background), creating S351, did not result in a complete restoration of 
neurovirulence, but, a partial gain of virulence was observed (100% morbidity, 16.7% 
mortality, see Fig. 3)   As for the mechanism underlying the role for nsP1 538 in virulence, 
we have previously reported that substitution of the wild-type Thr with an Ile residue 
accelerates processing of the P123 polyprotein precursor into the mature nsP1, nsP2, and 
nsP3 proteins (10).  This coincided with a more rapid induction of 26S RNA synthesis 
contributing to earlier expression from the 26S promoter in infected cells, but did not 
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measurably affect the levels of viral minus- or plus-strand RNA synthesis (10).  The role of 
altered nonstructural polyprotein processing and/or accelerated induction of 26S RNA 
synthesis in adult mouse neurovirulence has yet to be determined.  They may be acting 
through one or more mechanisms, including induction of immune mediators by the earlier 
26S RNA expression, enhanced cytopathic effect due to high level expression of the viral 
structural genes, or differential effects on host macromolecular synthesis due to differences 
in the ratios of the nonstructural polyprotein precursor versus mature nonstructural proteins.   
 The 18 amino acid deletion between residues 386-403 in nsP3 is located within the C-
terminal region, which is highly variable between alphaviruses (as reviewed in reference 
(25)).  The function for the nsP3 protein has yet to be defined.  However, it has been shown 
to be a phosphoprotein that is required for the synthesis of both viral minus-strand and 
subgenomic RNA (14, 17).  With this in mind, it is interesting to note that the 18 amino acid 
deletion results in the removal of 7 Ser residues, which may affect the overall 
phosphorylation of nsP3.  Mutational analysis within the nonconserved C-terminal region of 
SINV nsP3 altered levels of viral minus-strand RNA synthesis, along with levels of nsP3 
phosphorylation (14).  Therefore, it will be important to assess the effect of the 18 amino acid 
deletion on viral minus-strand synthesis.  Recently, it was reported that mutations within the 
nsP3 gene of SFV, including a seven amino acid deletion within the C-terminal region, fully 
restored neurovirulence in adult mice (32), which suggests that nsP3 may contribute to the 
virulence of multiple alphaviruses.  However, more analysis is required to determine the 
exact role for the AR86 nsP3 in adult mouse neurovirulence. 
 While most alphaviruses encode an opal termination codon proximal to the 3’ end of 
the nsP3 gene, the Sindbis-group virus strain AR86 (23) and the SFV strain SFV4 carry a 
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sense codon, which has been shown to be an important contributor to neurovirulence in adult 
mice (23, 32, 33).  Tuittila et al. performed a detailed mapping study within the replicase 
genes using virulent and avirulent SFV strains and found that an Arg (virulent SFV4 strain) 
at nsP3 position 469, in place of the opal termination codon, was an important contributor to 
the adult mouse neurovirulence phenotype (32).  The mechanism of this change in 
pathogenesis is not well understood.  Translational readthrough of the opal termination codon 
occurs at a frequency of about 5-10% (as reviewed in reference (4)), leading to limiting 
quantities of the nsP4 protein relative to the other nonstructural proteins.  Interestingly, the 
nsP4 protein was found to be tightly regulated within infected cells, in that excess nsP4 was 
shown to be rapidly degraded by the N-end rule pathway (1).  It is also worth noting that a 
different nsP3 C-terminus is produced in viruses encoding either an opal termination codon 
or a sense codon.  In the presence of an opal termination codon, the predominate nsP3 C-
terminus is produced by the translational stop codon, while in the presence of a sense codon, 
an extra seven amino acids are added to the C-terminus of nsP3.  It is well known that the 
opal termination codon regulates both nonstructural polyprotein processing and viral RNA 
synthesis.  Li et al. replaced the opal termination codon of SINV with different sense codons 
and found increased levels of the nsP3/4 polyprotein precursor and in reduced levels of 
mature nsP3 early during infection (18).  This study also demonstrated that replacing the opal 
termination codon with a sense codon lead to reduced levels of both 49S genomic and 26S 
subgenomic viral RNA synthesis early during infection (18).  Based on these studies, it will 
be important to determine whether the Cys codon in AR86 affects neurovirulence through 
alterations of nonstructural polyprotein processing and/or viral RNA synthesis, which may 
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exert subtle effects on viral replication or affect an as yet to be defined interaction with the 
host. 
The neurovirulence determinant within the E2 glycoprotein at position 243, where 
AR86 encodes a unique serine residue, most likely affects early viral interactions with 
neurons or other cell types in the infected animal.  This change is near a region of E2 that is 
associated with receptor attachment, which raises the strong possibility that the Ser residue 
might affect virus/receptor interactions either through direct receptor interactions or by 
changing the conformation of the E2 glycoprotein (24).  This is supported by findings within 
the E2 glycoprotein of SINV virus, in that a Gly residue at position 172 enhanced viral 
binding to neuronal cells (29). Therefore, additional studies to evaluate the effect of Ser 
versus Leu at E2 position 243 on virus binding or infection of neurons may provide useful 
information on the role of this determinant in regulating viral infection of neurons or other 
cell types.  However, the lack of a clearly defined neuronal receptor for alphaviruses 
currently prevents a direct analysis of this determinant’s role in virus/receptor interactions.  
In conclusion, we have identified major determinants of SINV adult mouse 
neurovirulence using two closely related neurovirulent and non-neurovirulent Sindbis-group 
viruses.  These determinants are nsP1 position 538, a deletion in nsP3 between 386-403, 
nsP3 position 537, and E2 position 243.  Further studies are underway to determine whether 
these virulence determinants act by affecting viral RNA synthesis, cell tropism, or through 
some as yet undefined interaction with the infected host.  
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Table 3-1.  Amino acid sequence comparison between AR86 and Girdwood. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Footnote:   a)  AR86 amino acid numbering 
b) nsP3 18 amino acid deletion found in AR86 
c) First amino acid after 18 amino acid deletion 
Ile Val 30 6k 
Leu Ser 243* E2 
Ile Met 469 nsP1 
Leu 
Val 
Arg 
Cys 
Ile 
Asp 
Tyr 
Deletion 
Val 
Gly 
Lys 
Ile 
Glu 
Ala 
His 
Glu 
Thr 
Ile 
Thr 
AR86 
 
Ser 169 
Ala 112 
Lys 61  
E1 
Opal 537* 
Met 446 
Gly 442 
Asp 386 
 386-403* 
Ala 346 
Glu 344  
 
 
 
nsP3 
Glu 651 
Val 648 
Lys 634 
Arg 485 
Tyr 295 
Gln 218 
Ala 187 
Thr 30  
 
 
 
 
nsP2 
Ile 538  
Girdwood Amino Acid 
 Position 
Gene 
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Figure 3-1:  Both the nonstructural and structural genes of AR86 contain 
neurovirulence determinants.   
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Figure 3-1.  Both the nonstructural and structural genes of AR86 contain 
neurovirulence determinants.  A diagram of the Alphavirus genome organization is located 
at the top.   On the left are the names of the cDNAs encoding full-length virus, beginning 
with the parental strains, pS300 (WT AR86) and pG100 (WT Girdwood) followed by the 
chimeric viruses. The cDNA constructs are diagrammed to show the sequences derived from 
pS300 (shaded box) and pG100 (opened box).  The chimeric clone pS350 contains AR86 nt 
sequences between 1 to 6411 and the chimeric pG106 clone contains AR86 nt sequences 
from 6411 to 11343.  Groups (n= number of mice per group) of either (A) four week-old or 
(B) six week-old female CD-1 mice inoculated intracranially (i.c.) with 103 PFU of each 
virus and observed daily for clinical signs.  Virulence was assessed by morbidity (average 
clinical score (CS) on day 5), mortality, and average survival time (AST, days ± standard 
deviation [SD]).   
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Figure 3-2:  Mutational analysis of neurovirulence determinants within the 
nonstructural genes of AR86.   
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Figure 3-2.  Mutational analysis of neurovirulence determinants within the 
nonstructural genes of AR86.  The cDNA constructs are diagrammed to show sequences 
derived from AR86 (pS300) along with amino acids located in nsP2 at positions 648 and 651, 
and nsP3 position 344, 386-403, and 537.  Groups (n) of six week-old female CD-1 mice 
were inoculated i.c. with 103 PFU of either wild-type AR86 (S300) or each mutant virus and 
observed daily for clinical signs.  Virulence was assessed by morbidity (average clinical 
score (CS) on day 5), mortality, and AST (days ± standard deviation [SD]).  The mortalities 
for the mutant viruses S343 and S344 were statistically significant when compared to S300 
(p<0.05). 
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Figure 3-3:  AR86 neurovirulence determinants within the nonstructural genes.   
nsP1 nsP2 nsP3 nsP4 C E2 E1
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Figure 3-3.  AR86 neurovirulence determinants within the nonstructural genes.  The 
cDNA constructs are diagrammed to show the sequences derived from pS300 (shaded box) 
and pG100 (opened box) along with amino acids located in nsP1 at position 538 (Thr= pS300 
and Ile= pG100), nsP3 between positions 386-403 (del 386-403= pS300) and nsP3 at 
position 537 (Cys= pS300 and Opal= pG100).  All of the chimeric clones contain AR86 nt 
sequences between 6411 and 11343.  Groups (n) of six week-old female CD-1 mice were 
inoculated i.c. with 103 PFU of each virus and observed daily for clinical signs.  Virulence 
was measured by morbidity (average clinical score (CS) on day 5), mortality, and AST (days 
± standard deviation [SD]).  The mortalities for the chimeric viruses S354, S355, and S356 
were statistically significant when compared to the parental chimeric virus S350 (p<0.05). 
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Figure 3-4:  AR86 neurovirulence determinants within the structural genes.   
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Figure 3-4.  AR86 neurovirulence determinants within the structural genes.  The cDNA 
constructs are diagrammed to show the sequences derived from pS300 (shaded box) and 
pG100 (opened box) along with the amino acid located in E2 at position 243 (Ser= pS300 
and Leu = pG100).  All of the chimeric clones contain AR86 nt sequences between 1 and 
6411.  Groups (n) of six week-old female CD-1 mice were inoculated i.c. with 103 PFU of 
virus and observed daily for clinical signs.  Virulence was assessed by morbidity (average 
clinical score (CS) on day 5), mortality, and AST (days ± standard deviation [SD]).  The 
mortalities for the chimeric viruses G107 and G117 were statistically significant when 
compared to the parental chimeric virus G106 (p<0.05).   
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Figure 3-5:  Identification of the major determinants of neurovirulence within AR86.   
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Figure 3-5.  Identification of the major determinants of neurovirulence within AR86.  
The cDNA constructs are diagrammed to show the sequences derived from pS300 (shaded 
box) and pG100 (opened box) along with amino acids located in nsP1 at position 538 (Thr= 
pS300 and Ile= pG100), nsP3 between positions 386-403 (del 386-403= pS300), nsP3 at 
position 537 (Cys= pS300 and Opal= pG100), and E2 at position 243 (Ser= pS300 and Leu = 
pG100).  Groups (n) of six  week-old female CD-1 mice were inoculated i.c. with 103 PFU of 
virus and observed daily for clinical signs.   Virulence was measured by morbidity (average 
clinical score (CS) on day 5), mortality, and AST (days ± standard deviation [SD]).   
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Figure 3-6:  In vitro and in vivo growth analysis of virulent and attenuated viruses.   
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Figure 3-6. In vitro and in vivo growth analysis of virulent and attenuated viruses.  A. 
Single-step in vitro growth curve was performed on BHK-21 cells infected with S300 (solid 
line, closed circle), S363 (broken line, open circle), G100 (sold line, open square), or G163 
(broken line, closed square) at an MOI of 5.0.  Shown is a representative experiment where 
each point represents the average of three independent samples plus or minus the standard 
deviation.  B. Six-week-old female CD-1 mice were infected i.c. with 103 PFU of S300 (solid 
line, closed circle), S363 (broken line, open circle), G100 (sold line, open square), and G163 
(broken line, closed square).  Mice were sacrificed by exsanguination at 6 12, 24, 48, 72, 96, 
and 120 hours post infection and perfused with PBS (pH7.4).  The brain  was harvested and 
evaluated for viral load by plaque assay on BHK-21 cells.  The data shown represents one of 
three experiments for the brain. C and D. Six week old CD-1 mice were infected with S300 
(solid line, closed circle) or S363 (broken line, open circle) as in Figure 6B.  Mice were 
sacrificed at 48, 96, or 144 hours post-infection, perfused with PBS, and viral titers in the 
thoracic or lumbar spinal cord determined by plaque assay.  C. Viral titers in the thoracic 
spinal cord. n= 3 mice per time point and data shown represents one of two identical 
experiments.  D. Viral loads in the lumbar spinal cord.  Data was pooled from two 
experiments and n = 6 mice per time point.  Differences in viral loads in the thoracic and 
lumbar spinal cord at 96 hours post-infection are statistically significant (p<0.05) as 
measured by two-tailed student’s t test.   
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ABSTRACT 
A virulence determinant at nsP1 538 of the adult mouse virulent strain of Sindbis-group virus 
AR86, regulates viral nonstructural polyprotein processing, viral RNA synthesis, and adult 
mouse neurovirulence.  An attenuating mutation at nsP1 538 resulted in enhanced type I 
interferon (IFN) induction in vivo and in vitro.  Further characterization of this determinant 
demonstrated that its effects on type I IFN induction were independent of effects on virus-
mediated host cell transcription and translation.  Analysis of Interferon Regulator Factor-3 
(IRF-3), a key mediator of type I IFN induction, revealed that in the presence of the 
attenuating mutation at nsP1 538, more rapid IRF-3 phosphorylation and dimerization was 
observed as compared to wild-type virus.  The results from this study suggest that the nsP1 
538 locus modulates viral type I IFN induction and exerts a major influence on viral 
virulence. 
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INTRODUCTION 
 Alphaviruses are mosquito borne viruses that cause a range of human diseases, 
including encephalitis and severe arthritis/arthralgia.  Though Sindbis viruses (SINV) do not 
generally cause severe disease in humans, experimental SINV infection models in rodents 
have been used to identify viral determinants that contribute to virulence, and identify host 
factors that control infection and mediate viral clearance (11, 20, 41, 42, 49).  Such virulence 
determinants are distributed throughout the genome and their activities demonstrate an 
important role for the innate and adaptive immune response in controlling viral replication 
and virus-induced disease.  However, specific interactions between alphavirus virulence 
determinants and the host immune system have not been extensively studied. 
 The alphavirus nonstructural proteins constitute the viral RNA replicase and are 
translated as a polyprotein that is postranslationally processed to produce the mature 
nonstructural proteins, nsP1, nsP2, nsP3, and nsP4 (reviewed in reference (47)).  nsP1 
exhibits methyltransferase and guanyltransferase activity and is involved in viral RNA 
capping (2, 33).  nsP2 is a multifunctional protein exhibiting papain-like thiol proteolytic 
activity (19), nucleoside triphosphatase activity (39, 55), and helicase activity (15).  NsP3 is a 
phosphorylated protein that plays an essential role in viral minus-strand and subgenomic 
RNA synthesis; however, the functions of nsP3 are not well defined (24, 37, 56).  NsP4 
functions as the viral RNA-dependent RNA polymerase and was recently found to possess 
terminal adenylyltransferase activity (47, 51).  Processing of the nonstructural polyprotein 
regulates viral RNA synthesis.  The nsP123 polyprotein, in combination with nsP4, mediates 
viral minus strand synthesis (25, 26, 45), while processing of the nsP123 and nsP23 
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polyproteins into the mature nonstructural proteins leads to a shutoff of minus strand RNA 
synthesis and induction of viral positive strand genomic and 26S RNA synthesis (45, 48).   
 Control of alphavirus infection in vivo is mediated by components of both the innate 
and adaptive immune system (17, 18, 41, 52).  Type I IFN plays an essential role in the early 
control of alphavirus infection, with mice deficient in the type I IFN receptors being highly 
susceptible to normally nonpathogenic strains of SINV (41) or Venezuelan equine 
encephalitis virus (VEE) (57).  Other components of the adaptive immune response, 
including antibody, T cells, and IFN-γ contribute to the control and clearance of non-
pathogenic SINV strains (5, 6, 29), while T cells may contribute to virus-induced immune 
pathology with at least some neurovirulent SINV strains (23, 40). 
 Most SINV strains are nonpathogenic in adult mice; however, adult mouse virulent 
viruses, such as NSV and AR86 have been used to identify viral determinants that contribute 
to adult mouse virulence and/or neuroinvasion (10, 49, 54).  The major determinant of adult 
mouse virulence for the NSV strain is a determinant at E2 position 55, where a histidine 
codon is associated with increased virulence in adult mice (54).  Though the exact role of this 
determinant in promoting virus-induced disease is undefined, this determinant appears to 
enhance viral infection of neurons (9, 53), overcome the protective effect of bcl-2 
overexpression in neurons (27, 28), and modulate the adaptive immune response in 
promoting virus-induced disease (23, 40).  Virulence studies with the AR86 strain of Sindbis, 
which causes 90-100% mortality in mice greater than 6 weeks of age when delivered by the 
intracranial route (46), identified four major genetic determinants of adult mouse 
neurovirulence which localized to a Thr at nsP1 538, an 18 amino acid deletion from amino 
acids 386 to 403 in nsP3, Cys at nsP3 position 537, and Ser at E2 position 243.  Though all 
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four of these determinants are required for full adult mouse virulence, one determinant at 
nsP1 538 appeared to play a major role in promoting AR86 virulence (20, 49).  In 
comparison to an attenuating Ile codon at this position, the presence of the wild-type Thr 
codon exhibited delayed processing of the viral nonstructural polyprotein and delayed RNA 
synthesis from the 26S subgenomic promoter (21), however the actual mechanism(s) by 
which this determinant affects viral virulence is not currently understood. 
 Though the viral nonstructural proteins play an essential role in viral replication, their 
interactions with the host are less well defined.  Shutoff of host cell RNA and protein 
synthesis is mediated by the viral nonstructural proteins (16), with nsP2 believed to play a 
major role in this process through an undefined mechanism (12, 13, 16).  Host shutoff is 
thought to enhance viral replication by limiting competition for cellular translational 
machinery, while also limiting the ability of the infected cell to mount an antiviral response, 
including the production of type I IFN (11, 35).  However, the mechanisms by which the 
viral nonstructural proteins modify the host cell and promote viral virulence are still largely 
undetermined.   
 As described above, previous work from our laboratory has defined three 
determinants of adult mouse virulence within the nonstructural proteins of the AR86 strain of 
Sindbis (49), and one of these determinants, at nsP1 position 538, affects the kinetics of viral 
nonstructural protein processing and viral subgenomic RNA synthesis (21).  Based on 
importance of the virulence determinant at nsP1 position 538 and the role of type I IFN in 
controlling virus infection, we hypothesized that this virulence determinant modulates type I 
IFN induction.  In this report, we demonstrate that a virus with an attenuating mutation at 
nsP1 538 (Thr to Ile) is a potent inducer of type I IFN in vivo and in vitro.  Furthermore, this 
 155 
determinant did not affect the kinetics of viral host cell shutoff, but did affect the kinetics of 
IRF3 activation in the infected cell.  These results demonstrate that an alphavirus virulence 
determinant modulates type I IFN induction and suggests potential mechanisms for effects on 
virulence. 
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MATERIALS AND METHODS 
Viruses and cells.  Plasmids containing the viral  cDNA are designated with the prefix “p” 
while the infectious virus derived from the cDNA clone does not contain the “p” designation; 
i.e., S300 represents virus derived from the plasmid pS300.  Virus stocks were made as 
described previously (49).  Briefly, viral cDNA plasmids were linearized with PmeI and used 
as templates for the synthesis of full-length transcripts by using SP6-specific mMessage 
Machine in vitro transcription kits (Ambion).  Transcripts were electroporated into BHK-21 
cells grown in α-minimal essential medium (α-MEM:  10% fetal calf serum [Gibco], 10% 
tryptose phosphate broth [Sigma], and 0.29 mg of L-glutamine per ml [Gibco]).  
Supernatants were harvested 24 to 27 hours after electroporation and subjected to 
centrifugation at 3000 RPM (Sorvall rotor RTH-250) for 20 minutes at 4˚C and frozen in 1-
ml aliquots.  Virus stocks were titered on BHK-21 cells as previously described (46). 
 BHK-21 and L929 cells were maintained at 37˚C in α-MEM, for a maximum of 10 
passages.  A549 cells (ATCC) are human lung carcinoma cells and were grown in 
Dulbecco’s modified medium (DMEM) containing 10% fetal calf serum [Gibco], 0.29 mg of 
L-glutamine per ml [Gibco], and penicillin/streptomycin.  HEC-1B cells (ATCC) are human 
endometrial carcinoma cells and were used in this study to analyze IRF-3, since these cells 
are nonresponsive to IFN (8, 50).  HEC-1B cells were grown in MEM containing 10% fetal 
bovine serum, 0.29 mg of L-glutamine per ml [Gibco], and penicillin/streptomycin.  
Neuro2A cells (ATCC) are mouse neuroblastoma cells and were grown in MEM containing 
nonessential amino acids and 10% FBS.   
Examination of total RNA synthesis.  To examine host transcription, Neuro2A cells were 
mock infected (M), infected with S300, or S340 at an MOI of 10.0.  At 2, 5, 8, and 16 hours 
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post-infection, media was removed and replaced with complete α-MEM medium containing 
[3H]-uridine at 20 µCi/ml.  After 3 hours incubation at 37°C, cells were washed 1X in PBS 
and cells lysed with Trizol (Invitrogen) and RNA was isolated.  RNAs were denatured in 
glyoxal and dimethyl sulfoxide for one hour at 50°C and analyzed on a 0.8% agarose gel.  
The agarose gel was washed twice in methanol followed by overnight incubation in 2.5% 
2,5-diphenyloxazole (PPO) in methanol.  The gel was washed three times in ddH2O to 
precipitate the PPO, dried, and exposed to film (Kodak Biomax MR).  For quanititation, 18S 
rRNA and 28S rRNA fragment and the fragment corresponding to host cellular mRNA, as 
previously described (16), were excised from the dried gel and cpm’s were measured by 
liquid scintillation.   
Examination of protein synthesis.  To monitor protein synthesis with S300, S340- or mock-
infected cells, at various time-points post-infection, Neuro2A cell monolayers were washed 
with PBS and starved of methionine and cysteine by providing Minimum Essential Medium 
lacking methionine and cysteine (Sigma).  After 1 h incubation at 37°C, the medium was 
replaced with starvation medium supplemented with 33 µCi/mL 35S-methionine/35S-
cysteine (Pro-mix, Amersham Pharmacia).  Immediately following incubation for 1 h at 
37°C, monolayers were harvested in NP-40 lysis buffer as described above.  Equal volumes 
of lysate from each time point were separated on 10% SDS-PAGE gel.  The gels were fixed 
in a solution of 10% acetic acid and 40% methanol, dried, exposed to a Phosphorimaging 
screen, scanned using a Storm Phosphorimager (GE Healthcare) and analyzed using 
ImageQuant software (GE Healthcare).  Residual host cell protein synthesis was evaluated by 
measuring the amount of radioactivity detected in the protein band corresponding to actin 
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and normalized to the amount of radioactivity detected in the same protein band in mock 
infected cells.   
Animal studies.  Specific pathogen-free C57BL/6 mice were obtained from The Jackson 
Laboratory and bred in-house.  Specific pathogen-free six-week old female CD-1 mice were 
obtained from Charles River Breeding Laboratories (Raleigh, NC).  Animal housing and care 
were in accordance with all University of North Carolina at Chapel Hill Institutional Animal 
Care and Use Committee guidelines.  Six- to eight-week-old mice were anesthetized with 
ketamine supplemented with xylazine (Barber Med.) prior to intracranial (i.c.) inoculation 
with a standard dose of 103 PFU of virus in diluent [phosphate-buffered saline (PBS, pH 
7.4)], supplemented with 1% donor calf serum (DCS, Gibco)).  Mock infected mice received 
diluent alone.  At the indicated timepoints, mice were bled from the tail vein and sera was 
frozen at -80°C until analyzed for type I IFN by bioassay (see below). 
Type I IFN bioassay.  Type I IFN α/β were measured in cell culture supernatants and in sera 
using a biological assay as previously described.  Briefly, for a mouse IFN bioassay, L929 
cells were seeded at 3 x 104 cells/well in a 96 well plate one day prior to the addition of IFN 
standards or experimental samples.  Human IFN bioassay was performed in a similar manner 
except A549 cells were used.  Cell culture supernatant or mouse sera (diluted 1:10 in L929 
media) were centrifuged at 60,000 RPM for one hour at 4°C followed by acidification to a 
pH of 2.0 using hydrochloric acid (HCl).  Twenty-four hours later, supernatants and sera 
were neutralized with sodium hydroxide, after which cell culture supernatants were treated 
with UV light for 20 minutes to eliminate any residual virus.  Duplicate supernatants and sera 
samples were then applied to the 96-well plates in two-fold dilutions along with an NIH 
mouse- or human-specific IFN α/β standard.  The following day, EMCV challenge virus was 
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added to the cells in 50 ul/well at an MOI of  5.0.  Twenty-four hours later, 50% CPE was 
measured by blind scoring the wells  and IFN in the supernatant or sera was calculated based 
on the respective NIH IFN standard.  Statistical analysis were performed using Students two-
tailed t-test and differences were considered significant when p<0.05 (Instat 3.0).   
Native IRF-3 PAGE.  HEC-1B cells were plated at 5 x 105 cells/well and infected with 
mock (diluent), S300, or S340  at an MOI of 1.0 for 1 hour at 37°C.  After 1 hour of 
infection, HEC-1B media was added and cells were incubated at 37°C for the remainder of 
the infection.  At various times post-infection, cells were washed one time with PBS 
(phosphate buffered saline) and cell pellets were frozen at -80°C.  Whole cell extracts were 
prepared by mixing cells with NP-40 lysis buffer containing protease and phosphatase 
ihhibitors (50 mM Tris, pH 8.0, 150 mM NaCl, 1% Nonidet P-40, 5 mM EDTA, 10% 
glycerol, 30 mM NaF, 1.0 mM Na3VO4, 40 mM β-glycerophosphate, 0.1 mM 
phenylmethylsulfonyl fluoride, and 5 µg/ml of each leupeptin, pepstatin, and aprotinin) and 
centrifuged at 13,000 RPM at 4°C for 10 minutes.  Equal cell lysates (10 ul) were mixed on 
ice with a 2X loading buffer (125 mM Tris-Cl, pH 6.8, 30% glycerol, 0.002% bromphenol 
blue).  A 7.5% native PAGE was pre-run at 4°C for 30 minutes at 45 mA in gel running 
buffer (25 mM Tris-Cl, pH 8.4, 192 mM glycine, in the presence of or absence of 0.2% 
deoxycholate in the cathode and anode buffer, respectively).  Samples were loaded on the gel 
and run at 25 mA for 60 min at 4°C followed by transfer to polyvinylidene difluoride (PVDF) 
membranes.  After an hour of transfer, membranes were blocked for 1 hour at room 
temperature with PBS containing 0.1% Tween-20 (Sigma) (wash buffer) and 5% dry milk 
(blocking buffer).  The membrane was incubated in primary antibody overnight at 4°C with 
rabbit anti-IRF3 FL-425 (Santa Cruz, sc-9082) at 1:500.   After three washes, secondary 
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antibody was incubated for 1 hour at room temperature with anti-rabbit conjugated HRP at 
1:10,000 (Sigma) in blocking buffer.  The membrane was washed three times followed by 
detection of proteins was using ECL chemiluminescence (Amersham Biosciences). 
SDS-PAGE and Western Blot  Protein extracts were resolved on 10% SDS-PAGE followed 
by transfer to a PVDF membrane.  After an hour of transfer, membranes were blocked for 1 
hour at room temperature with blocking buffer.  Membranes were incubated in primary 
antibody (rabbit anti-IRF-3 FL-425,  and mouse anti-alpha-tubulin [Sigma]) diluted in 
blocking buffer overnight at 4°C. For detection of phosphorylated IRF-3, rabbit anti-IRF-396 
(anti-His5033; kindly provided by Dr. J. Hiscott) was diluted in wash buffer containing 5% 
bovine serum albumin and incubated overnight at 4°C.  Membranes were washed, incubated 
in the appropriate anti-rabbit or anti-mouse secondary antibodies, and proteins were detected 
as described earlier.    
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RESULTS  
The attenuated mutant S340 virus induces more type I IFN in cell culture.  The 
determinant at nsP1 538 has previously been characterized and profoundly affects adult 
mouse neurovirulence (20).  Introduction of an attenuating Ile codon (virus designated S340) 
in place of the virulence-associated Thr codon at nsP1 538 significantly reduced virulence.  
The attenuating Ile codon also accelerates processing of the nonstructural polyprotein 
precursor P1234, resulting in rapid induction of viral RNA synthesis from the viral 
subgenomic 26S promoter (21).  Since altered viral RNA synthesis may affect type I IFN 
induction and type I IFN plays a major role in controlling alphavirus infection, type I IFN 
induction by the mutant S340 virus was evaluated in cell culture.  L929 cells were mock 
infected or infected with S300 (wild-type) or S340 (mutant) at an MOI of 5.0.  At 18 hours 
post-infection, the supernatant was removed and assayed for type I IFN.  As shown in Figure 
1, the mutant S340 virus induced significantly more type I IFN than the wild-type S300 
virus.  While the mutant S340 virus exhibited IFN induction greater than 250 IU/ml, the 
wild-type S300 virus showed levels comparable to mock-infected cells.  Similar differences 
in IFN induction were observed in other cell types, including A549 (Fig. 1B), HeLa, and 
Neuro2A cells (data not shown). These results demonstrated that the presence of an 
attenuating mutation at nsP1 position 538 increases the ability of the virus to induce type I 
IFN. 
The attenuated mutant S340 virus induces a strong IFN response in vivo.  To determine 
whether the differential type I IFN induction between S300 or the mutant S340 virus also 
occurs in vivo,  type I IFN levels were measured in the serum of infected adult mice.  Six-
week old CD-1 (Fig. 2A) or C57BL/6 (Fig. 2B) were mock infected or infected with S300 or 
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S340 by the intracranial route (i.c.) and bled between 9 and 18 hours post-infection.  Serum 
type I IFN responses were measured using an IFN bioassay on L929 cells.  As shown in 
figure 2, serum from mice infected with the mutant S340 virus exhibited robust type I IFN 
levels compared to mice infected with the wild-type S300 virus.  In CD-1 mice, the mutant 
virus displayed higher levels of type I IFN between 12 and 18 hours post-infection as 
compared to the wild-type S300 virus.  Similarly, in the C57BL/6 mice, the mutant virus 
induced greater than 16,000 IU/ml IFN by 12 hours post-infection as compared to the wild-
type virus which induced levels comparable to mock infected mice.  Furthermore, wild-type 
S300 did not induce type I IFN up to 48 hours post-infection (data not shown), indicating that 
the wild-type virus was not simply delayed in the induction of type I IFN.  Interestingly, 
similar IFN differences were found in TLR3-/-, Myd88-/-, and TD-/- (PKR, RNaseL, MxA) 
between the wild-type and mutant viruses (data not shown), which indicates that the source 
of the IFN in the serum is most likely independent of the TLR3, Myd88, or PKR pathways.  
These results demonstrate that the mutant S340 virus induces more type I IFN in cultured 
cells and in vivo than the wild-type S300 virus, suggesting that this determinant plays a major 
role in modulating viral type I IFN induction.   
The mutant and wild-type S300 virus show similar kinetics of virus-induced host 
shutoff.  One potential explanation for the differences in IFN induction between the wild-
type and mutant viruses is that the mutant S340 virus may be impaired in its ability to shutoff 
host macromolecular synthesis, since mutations within nsP2 of a genetically related SINV, 
that impaired virus-induced host transcription and/or translation shutoff, led to increased type 
I IFN induction (16).  Therefore, virus-induced host shutoff was examined between the wild-
type S300 and mutant S340 viruses.  To examine kinetics of host transcription shutoff, 
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Neuro2A cells, a mouse neuroblastoma cell line, were mock infected or infected with S300 
or S340 at an MOI of 10.0.  At 2, 5, 8, or 16 hours postinfection, cells were incubated with 
media containing [3H]-uridine for 3 hours, RNA was isolated, and analyzed by agarose gel 
electrophoresis (Fig. 3).  Up to 8 hours post-infection, both viruses show similar kinetics of 
host transcription shutoff, as observed by the loss of host mRNA, 28S rRNA, and 18S rRNA.  
Interestingly, by 16 hours postinfection, wild-type S300 virus exhibited less efficient shutoff 
of host mRNA, 28S rRNA and 18S rRNA as compared to the mutant S340 virus.  This result 
strongly suggests that the enhanced type I IFN induction by the S340 virus is not due to a 
defect in host transcription shutoff.   
 To examine kinetics of host translation shutoff, Neuro2A cells were mock infected or 
infected with S300 or S340 at an MOI of 10.0.  At various times post-infection, cells were 
labeled with 35S-methionine/cysteiene for one hour and lysates collected and analyzed by 
SDS-PAGE (Fig. 4A).   By as early as 4 hours post-infection, both viruses exhibit greater 
than 50% shutoff of host protein synthesis and by 10 hours post-infection greater than 80% 
of host protein synthesis shutoff is observed.  Most importantly, when comparing the 42 kDa 
band, which corresponds to β-actin, the mutant S340 virus displayed similar kinetics of host 
protein shutoff as compared to wild-type S300 virus (Figure 4B).  Similar observations were 
also made in BHK-21 cells (data not shown).  These results demonstrate that the IFN 
induction by the mutant S340 virus is not simply due to defects in host transcription or 
translation shutoff and suggest that the determinant at nsP1 538 modulates host type I IFN 
induction by another mechanism.     
The mutant S340 virus induces early IRF-3 activation.   Although the results of 
Gorchakov et al. (16) suggest that virus-induced host shutoff plays an important role in 
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antagonizing type I IFN induction, the observation that the attenuated mutant S340 virus did 
not show defects in host cell shutoff suggests that the determinant at nsP1 position 538 
modulates type I IFN induction through a different mechanism.  IRF-3 activation is an 
essential step in type I IFN induction and is marked by phosphorylation of six serine residues 
grouped into two clusters (S385/386 and S396/398/402/405) (36, 44), which leads to 
dimerization, nuclear translocation, association with CBP/p300 and binding to the IFN-beta 
promoter (31, 43, 58).  Importantly, it has been reported by Preston et al. (38) that IRF-3 is 
capable of becoming activated independent of de novo host translation or transcription.  
Therefore, IRF-3 dimerization and phosphorylation were examined in HEC-1B cells.  HEC-
1B cells were mock infected or infected with S300 or S340 at an MOI of 1.0. Other cultures 
were infected with Sendai virus (SeV) to serve as the positive control for IRF-3 activation.  
At various times post-infection, lysates were collected and analyzed for IRF-3 dimerization 
by native PAGE and phosphorylation of IRF-3 by using a phospho-specific antibody for IRF-
3 (serine at position 396; Fig. 5).  By 6 hours postinfection, IRF-3 dimerization was apparent 
with the mutant S340 virus but not the wild-type S300 virus.  By 8 hours post-infection, the 
wild-type S300 virus showed slight activation of IRF-3; however, IRF-3 phosphorylation and 
dimerization levels were still lower than the mutant S340 virus.  These results suggest that 
the mutant S340 virus more rapidly induces IRF-3 activation than the wild-type S300 virus, 
and moreover that the determinant at nsP1 538 plays a major role in modulating type I IFN 
induction by AR86. 
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DISCUSSION 
 Type I IFN is an essential component of the host response to viral infection because it 
directly activates antiviral systems and modulates antiviral activities of other components of 
the host innate and adaptive immune systems.  However, a number of viruses have evolved 
mechanisms to antagonize or evade induction of a type I IFN response.  These mechanisms 
range from nonspecific effects, such as rapid shutoff of host cell macromolecular synthesis 
(1, 16), masking viral RNA from host cell sensory proteins (7, 34), or specific inhibition of 
host cell dsRNA sensors or signaling molecules that link these sensor molecules to 
transcription factors that regulate type I IFN transcription (3, 4, 30, 32).  Studies with SINV 
have demonstrated that host cell shutoff plays a major role in regulating viral type I IFN 
induction (16).  However, complete host cell shutoff does not occur until late in infection, 
which raises the question of whether alphaviruses utilize other mechanisms to suppress or 
avoid type I IFN responses prior to host cell shutoff.  In this report, we present evidence of a 
viral virulence determinant at nsP1 538 in the neurovirulent strain of SINV that modulates 
type I IFN induction without affecting host cell macromolecular synthesis.   
 While wild-type S300 virus exhibited reduced IFN induction in vitro and in vivo, the 
mutant S340 virus containing an Ile at nsP1 position 538 induced robust levels of type I IFN.  
Given that type I IFN plays a central role in regulating alphavirus-induced disease (41, 57), it 
is likely that the determinant at nsP1 538 affects viral virulence through effects on type I IFN 
induction.  Accordingly, the mutant S340 virus, which unlike wild-type S300 exhibited no 
mortality in WT 129Sv/Ev mice, shows 100% mortality in IFNα/βR-/- mice, which cannot 
respond to type I IFN (data not shown).  Interestingly, IFN induction by the mutant S340 
virus appeared to be independent of the Toll-like pathways, as TLR3-/- or Myd88-/- mice 
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infected with the mutant S340 virus induced comparable levels of type I IFN to that of wild-
type C57BL/6 mice (data not shown). 
 Using a genetically related SINV, Gorchakov et al. demonstrated that viruses with 
mutations resulting in defects in host translation or transcription shutoff induced more type I 
IFN (16).  Therefore, virus-induced host transcription and translation shutoff between wild-
type S300 and the mutant S340 virus were evaluated.  While both viruses exhibited similar 
overall kinetics of host transcription shutoff, the wild-type S300 virus exhibited defects in 
shutoff of cellular RNA polymerase I-dependent transcription at 16 hours postinfection (Fig. 
3).  Recently, mature nsP2 has been shown to be critical in the inhibition of RNA polymerase 
I- and II-dependent transcription (12, 13).  Thus, the differences in rRNA inhibition at late 
times postinfection between the wild-type and mutant AR86 viruses could possibly be due to 
differences in processing of the nonstructural polyprotein, where wild-type S300 has a more 
stable polyprotein than the mutant S340 virus (21).  Furthermore, our studies also 
demonstrated that the mutant S340 virus exhibited similar kinetics of host translation shutoff 
as compared to wild-type S300.  These results suggest that altered host cell shutoff is not the 
sole explanation for enhanced IFN induction by the mutant S340 virus.  This is further 
supported by the finding that the mutant S340 virus led to more rapid induction of IRF-3 
dimerization and phosphorylation, a step which is independent of de novo host protein 
synthesis and will not be affected by virus-induced host shutoff (38).   
 Therefore, the determinant at nsP1 538 affects type I IFN induction independently of 
virus-induced host shutoff, suggesting three possible mechanisms by which the determinant 
at nsP1 538 modulates type I IFN induction.  First, the wild-type S300 virus may 
downregulate or delay 26S promoter induction until virus-induced host shutoff is efficiently 
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able to antagonize type I IFN induction, and this effect is disrupted by the determinant at 
nsP1 538.  This would suggest that the subgenomic RNA may be a potential target for 
sensing by the host cell, a question which requires further investigation.  Second, Gitlin et al. 
has reported that RIG-I plays an important role in responding to SINV infection (14).  RIG-I 
interacts with 5’triphosphates on uncapped RNAs, and given that nsP1 and nsP2 proteins are 
involved in capping viral RNAs, it is possible that the determinant at nsP1 538 is altering the 
efficiency of capping viral genomic or subgenomic RNA (2, 22, 33, 39, 55).  Third, wild-
type S300 may actively suppress early type I IFN induction, and this effect is disrupted by 
the attenuating Ile at nsP1 538.  This scenario raises the possibility that alphaviruses employ 
a multi-step approach to blocking type I IFN induction, whereby a specific inhibitory effect 
is active early in infection, while a generalized host shutoff would block IFN synthesis late in 
infection.    
 Additional studies are underway to distinguish between these possibilities, and 
determine the mechanism by which AR86 virus mediates this effect.  In summary, we have 
demonstrated that wild-type S300 virus was a poor inducer of type I IFN, while the mutant 
S340 virus containing an attenuating Ile codon at nsP1 position 538 induces a robust type I 
IFN response in vitro and in vivo.  The altered type I IFN induction was independent of virus-
induced host translation or transcription shutoff, suggesting that the determinant at nsP1 538 
acts through a novel mechanism to modulate the host type I IFN response. 
 168 
ACKNOWLEDGEMENTS 
This research was supported by NIH research grants R01 AR47190 (M.T.H) and R01 
AI22186 (R.E.J).  We thank the members of the Carolina Vaccine Institute (CVI) and the 
Johnston and White Laboratory for helpful scientific discussions. We thank Wrennie 
Edwards for providing excellent technical support with cell culture.  We would also like to 
thank Dr. Charles M. Rice and Dr. Joe Marcotrigiano for excellent scientific discussion and 
technical help with the host transcription experiments.    
 
 169 
REFERENCES 
1. Ahmed, M., M. O. McKenzie, S. Puckett, M. Hojnacki, L. Poliquin, and D. S. Lyles. 
2003. Ability of the matrix protein of vesicular stomatitis virus to suppress beta 
interferon gene expression is genetically correlated with the inhibition of host RNA 
and protein synthesis. J Virol 77:4646-57. 
2. Ahola, T., and L. Kaariainen. 1995. Reaction in alphavirus mRNA capping: 
formation of a covalent complex of nonstructural protein nsP1 with 7-methyl-GMP. 
Proc Natl Acad Sci U S A 92:507-11. 
3. Andrejeva, J., K. S. Childs, D. F. Young, T. S. Carlos, N. Stock, S. Goodbourn, and 
R. E. Randall. 2004. The V proteins of paramyxoviruses bind the IFN-inducible RNA 
helicase, mda-5, and inhibit its activation of the IFN-beta promoter. Proc Natl Acad 
Sci U S A 101:17264-9. 
4. Basler, C. F., A. Mikulasova, L. Martinez-Sobrido, J. Paragas, E. Muhlberger, M. 
Bray, H. D. Klenk, P. Palese, and A. Garcia-Sastre. 2003. The Ebola virus VP35 
protein inhibits activation of interferon regulatory factor 3. J Virol 77:7945-56. 
5. Binder, G. K., and D. E. Griffin. 2001. Interferon-gamma-mediated site-specific 
clearance of alphavirus from CNS neurons. Science 293:303-6. 
6. Burdeinick-Kerr, R., and D. E. Griffin. 2005. Gamma interferon-dependent, 
noncytolytic clearance of sindbis virus infection from neurons in vitro. J Virol 
79:5374-85. 
7. Cardenas, W. B., Y. M. Loo, M. Gale, Jr., A. L. Hartman, C. R. Kimberlin, L. 
Martinez-Sobrido, E. O. Saphire, and C. F. Basler. 2006. Ebola virus VP35 protein 
binds double-stranded RNA and inhibits alpha/beta interferon production induced by 
RIG-I signaling. J Virol 80:5168-78. 
8. Chen, H. Y., T. Sato, A. Fuse, T. Kuwata, and J. Content. 1981. Resistance to 
interferon of a human adenocarcinoma cell line, HEC-1, and its sensitivity to natural 
killer cell action. J Gen Virol 52:177-81. 
9. Dropulic, L. K., J. M. Hardwick, and D. E. Griffin. 1997. A single amino acid change 
in the E2 glycoprotein of Sindbis virus confers neurovirulence by altering an early 
step of virus replication. J Virol 71:6100-5. 
 170 
10. Dubuisson, J., S. Lustig, N. Ruggli, Y. Akov, and C. M. Rice. 1997. Genetic 
determinants of Sindbis virus neuroinvasiveness. J Virol 71:2636-46. 
11. Frolova, E. I., R. Z. Fayzulin, S. H. Cook, D. E. Griffin, C. M. Rice, and I. Frolov. 
2002. Roles of nonstructural protein nsP2 and Alpha/Beta interferons in determining 
the outcome of Sindbis virus infection. J Virol 76:11254-64. 
12. Garmashova, N., R. Gorchakov, E. Frolova, and I. Frolov. 2006. Sindbis virus 
nonstructural protein nsP2 is cytotoxic and inhibits cellular transcription. J Virol 
80:5686-96. 
13. Garmashova, N., R. Gorchakov, E. Volkova, S. Paessler, E. Frolova, and I. Frolov. 
2006. The Old World and New World alphaviruses use different virus-specific 
proteins for induction of the transcriptional shutoff. J Virol. 
14. Gitlin, L., W. Barchet, S. Gilfillan, M. Cella, B. Beutler, R. A. Flavell, M. S. 
Diamond, and M. Colonna. 2006. Essential role of mda-5 in type I IFN responses to 
polyriboinosinic:polyribocytidylic acid and encephalomyocarditis picornavirus. Proc 
Natl Acad Sci U S A 103:8459-64. 
15. Gomez de Cedron, M., N. Ehsani, M. L. Mikkola, J. A. Garcia, and L. Kaariainen. 
1999. RNA helicase activity of Semliki Forest virus replicase protein NSP2. FEBS 
Lett 448:19-22. 
16. Gorchakov, R., E. Frolova, and I. Frolov. 2005. Inhibition of transcription and 
translation in Sindbis virus-infected cells. J Virol 79:9397-409. 
17. Griffin, D., B. Levine, W. Tyor, S. Ubol, and P. Despres. 1997. The role of antibody 
in recovery from alphavirus encephalitis. Immunol Rev 159:155-61. 
18. Griffin, D. E. 1976. Role of the immune response in age-dependent resistance of mice 
to encephalitis due to Sindbis virus. J Infect Dis 133:456-64. 
19. Hardy, W. R., and J. H. Strauss. 1989. Processing the nonstructural polyproteins of 
sindbis virus: nonstructural proteinase is in the C-terminal half of nsP2 and functions 
both in cis and in trans. J Virol 63:4653-64. 
 171 
20. Heise, M. T., D. A. Simpson, and R. E. Johnston. 2000. A single amino acid change 
in nsP1 attenuates neurovirulence of the Sindbis-group alphavirus S.A.AR86. J Virol 
74:4207-13. 
21. Heise, M. T., L. J. White, D. A. Simpson, C. Leonard, K. A. Bernard, R. B. Meeker, 
and R. E. Johnston. 2003. An attenuating mutation in nsP1 of the Sindbis-group virus 
S.A.AR86 accelerates nonstructural protein processing and up-regulates viral 26S 
RNA synthesis. J Virol 77:1149-56. 
22. Hornung, V., J. Ellegast, S. Kim, K. Brzozka, A. Jung, H. Kato, H. Poeck, S. Akira, 
K. K. Conzelmann, M. Schlee, S. Endres, and G. Hartmann. 2006. 5'-Triphosphate 
RNA is the ligand for RIG-I. Science 314:994-7. 
23. Kimura, T., and D. E. Griffin. 2003. Extensive immune-mediated hippocampal 
damage in mice surviving infection with neuroadapted Sindbis virus. Virology 
311:28-39. 
24. LaStarza, M. W., J. A. Lemm, and C. M. Rice. 1994. Genetic analysis of the nsP3 
region of Sindbis virus: evidence for roles in minus-strand and subgenomic RNA 
synthesis. J Virol 68:5781-91. 
25. Lemm, J. A., and C. M. Rice. 1993. Roles of nonstructural polyproteins and cleavage 
products in regulating Sindbis virus RNA replication and transcription. J Virol 
67:1916-26. 
26. Lemm, J. A., T. Rumenapf, E. G. Strauss, J. H. Strauss, and C. M. Rice. 1994. 
Polypeptide requirements for assembly of functional Sindbis virus replication 
complexes: a model for the temporal regulation of minus- and plus-strand RNA 
synthesis. Embo J 13:2925-34. 
27. Levine, B., J. E. Goldman, H. H. Jiang, D. E. Griffin, and J. M. Hardwick. 1996. Bc1-
2 protects mice against fatal alphavirus encephalitis. Proc Natl Acad Sci U S A 
93:4810-5. 
28. Levine, B., and D. E. Griffin. 1993. Molecular analysis of neurovirulent strains of 
Sindbis virus that evolve during persistent infection of scid mice. J Virol 67:6872-5. 
29. Levine, B., J. M. Hardwick, B. D. Trapp, T. O. Crawford, R. C. Bollinger, and D. E. 
Griffin. 1991. Antibody-mediated clearance of alphavirus infection from neurons. 
Science 254:856-60. 
 172 
30. Li, K., E. Foy, J. C. Ferreon, M. Nakamura, A. C. Ferreon, M. Ikeda, S. C. Ray, M. 
Gale, Jr., and S. M. Lemon. 2005. Immune evasion by hepatitis C virus NS3/4A 
protease-mediated cleavage of the Toll-like receptor 3 adaptor protein TRIF. Proc 
Natl Acad Sci U S A 102:2992-7. 
31. Lin, R., C. Heylbroeck, P. M. Pitha, and J. Hiscott. 1998. Virus-dependent 
phosphorylation of the IRF-3 transcription factor regulates nuclear translocation, 
transactivation potential, and proteasome-mediated degradation. Mol Cell Biol 
18:2986-96. 
32. Loo, Y. M., D. M. Owen, K. Li, A. K. Erickson, C. L. Johnson, P. M. Fish, D. S. 
Carney, T. Wang, H. Ishida, M. Yoneyama, T. Fujita, T. Saito, W. M. Lee, C. H. 
Hagedorn, D. T. Lau, S. A. Weinman, S. M. Lemon, and M. Gale, Jr. 2006. Viral and 
therapeutic control of IFN-beta promoter stimulator 1 during hepatitis C virus 
infection. Proc Natl Acad Sci U S A 103:6001-6. 
33. Mi, S., R. Durbin, H. V. Huang, C. M. Rice, and V. Stollar. 1989. Association of the 
Sindbis virus RNA methyltransferase activity with the nonstructural protein nsP1. 
Virology 170:385-91. 
34. Mibayashi, M., L. Martinez-Sobrido, Y. M. Loo, W. B. Cardenas, M. Gale, Jr., and 
A. Garcia-Sastre. 2007. Inhibition of retinoic acid-inducible gene I-mediated 
induction of beta interferon by the NS1 protein of influenza A virus. J Virol 81:514-
24. 
35. Montgomery, S. A., P. Berglund, C. W. Beard, and R. E. Johnston. 2006. Ribosomal 
protein S6 associates with alphavirus nonstructural protein 2 and mediates expression 
from alphavirus messages. J Virol 80:7729-39. 
36. Mori, M., M. Yoneyama, T. Ito, K. Takahashi, F. Inagaki, and T. Fujita. 2004. 
Identification of Ser-386 of interferon regulatory factor 3 as critical target for 
inducible phosphorylation that determines activation. J Biol Chem 279:9698-702. 
37. Peranen, J., K. Takkinen, N. Kalkkinen, and L. Kaariainen. 1988. Semliki Forest 
virus-specific non-structural protein nsP3 is a phosphoprotein. J Gen Virol 69 ( Pt 
9):2165-78. 
38. Preston, C. M., A. N. Harman, and M. J. Nicholl. 2001. Activation of interferon 
response factor-3 in human cells infected with herpes simplex virus type 1 or human 
cytomegalovirus. J Virol 75:8909-16. 
 173 
39. Rikkonen, M., J. Peranen, and L. Kaariainen. 1994. ATPase and GTPase activities 
associated with Semliki Forest virus nonstructural protein nsP2. J Virol 68:5804-10. 
40. Rowell, J. F., and D. E. Griffin. 2002. Contribution of T cells to mortality in 
neurovirulent Sindbis virus encephalomyelitis. J Neuroimmunol 127:106-14. 
41. Ryman, K. D., W. B. Klimstra, K. B. Nguyen, C. A. Biron, and R. E. Johnston. 2000. 
Alpha/beta interferon protects adult mice from fatal Sindbis virus infection and is an 
important determinant of cell and tissue tropism. J Virol 74:3366-78. 
42. Ryman, K. D., L. J. White, R. E. Johnston, and W. B. Klimstra. 2002. Effects of 
PKR/RNase L-dependent and alternative antiviral pathways on alphavirus replication 
and pathogenesis. Viral Immunol 15:53-76. 
43. Sato, M., N. Tanaka, N. Hata, E. Oda, and T. Taniguchi. 1998. Involvement of the 
IRF family transcription factor IRF-3 in virus-induced activation of the IFN-beta 
gene. FEBS Lett 425:112-6. 
44. Servant, M. J., N. Grandvaux, B. R. tenOever, D. Duguay, R. Lin, and J. Hiscott. 
2003. Identification of the minimal phosphoacceptor site required for in vivo 
activation of interferon regulatory factor 3 in response to virus and double-stranded 
RNA. J Biol Chem 278:9441-7. 
45. Shirako, Y., and J. H. Strauss. 1994. Regulation of Sindbis virus RNA replication: 
uncleaved P123 and nsP4 function in minus-strand RNA synthesis, whereas cleaved 
products from P123 are required for efficient plus-strand RNA synthesis. J Virol 
68:1874-85. 
46. Simpson, D. A., N. L. Davis, S. C. Lin, D. Russell, and R. E. Johnston. 1996. 
Complete nucleotide sequence and full-length cDNA clone of S.A.AR86 a South 
African alphavirus related to Sindbis. Virology 222:464-9. 
47. Strauss, J. H., and E. G. Strauss. 1994. The alphaviruses: gene expression, replication, 
and evolution. Microbiol Rev 58:491-562. 
48. Suopanki, J., D. L. Sawicki, S. G. Sawicki, and L. Kaariainen. 1998. Regulation of 
alphavirus 26S mRNA transcription by replicase component nsP2. J Gen Virol 79 ( Pt 
2):309-19. 
 174 
49. Suthar, M. S., R. Shabman, K. Madric, C. Lambeth, and M. T. Heise. 2005. 
Identification of adult mouse neurovirulence determinants of the Sindbis virus strain 
AR86. J Virol 79:4219-28. 
50. Talon, J., C. M. Horvath, R. Polley, C. F. Basler, T. Muster, P. Palese, and A. Garcia-
Sastre. 2000. Activation of interferon regulatory factor 3 is inhibited by the influenza 
A virus NS1 protein. J Virol 74:7989-96. 
51. Tomar, S., R. W. Hardy, J. L. Smith, and R. J. Kuhn. 2006. Catalytic core of 
alphavirus nonstructural protein nsP4 possesses terminal adenylyltransferase activity. 
J Virol 80:9962-9. 
52. Trgovcich, J., J. F. Aronson, J. C. Eldridge, and R. E. Johnston. 1999. TNFalpha, 
interferon, and stress response induction as a function of age-related susceptibility to 
fatal Sindbis virus infection of mice. Virology 263:339-48. 
53. Tucker, P. C., S. H. Lee, N. Bui, D. Martinie, and D. E. Griffin. 1997. Amino acid 
changes in the Sindbis virus E2 glycoprotein that increase neurovirulence improve 
entry into neuroblastoma cells. J Virol 71:6106-12. 
54. Tucker, P. C., E. G. Strauss, R. J. Kuhn, J. H. Strauss, and D. E. Griffin. 1993. Viral 
determinants of age-dependent virulence of Sindbis virus for mice. J Virol 67:4605-
10. 
55. Vasiljeva, L., A. Merits, P. Auvinen, and L. Kaariainen. 2000. Identification of a 
novel function of the alphavirus capping apparatus. RNA 5'-triphosphatase activity of 
Nsp2. J Biol Chem 275:17281-7. 
56. Wang, Y. F., S. G. Sawicki, and D. L. Sawicki. 1994. Alphavirus nsP3 functions to 
form replication complexes transcribing negative-strand RNA. J Virol 68:6466-75. 
57. White, L. J., J. G. Wang, N. L. Davis, and R. E. Johnston. 2001. Role of alpha/beta 
interferon in Venezuelan equine encephalitis virus pathogenesis: effect of an 
attenuating mutation in the 5' untranslated region. J Virol 75:3706-18. 
58. Yoneyama, M., W. Suhara, Y. Fukuhara, M. Fukuda, E. Nishida, and T. Fujita. 1998. 
Direct triggering of the type I interferon system by virus infection: activation of a 
transcription factor complex containing IRF-3 and CBP/p300. Embo J 17:1087-95. 
 175 
Figure 4-1:  The mutant S340 virus induces more type I IFN in cell culture.   
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Figure 4-1. The mutant S340 virus induces more type I IFN in cell culture.  (A) L929 or 
(B) A549 cells were infected with mock, wild-type AR86 (S300) or mutant AR86 (S340; Ile 
at nsP1 position 538) at an MOI of 5.0 and supernatants were harvested at 18 hours post-
infection.  Supernatents were subjected to an IFN bioassay on L929 or A549 cells, as 
described in the Materials and Methods.  Each bar represents the average of triplicate 
samples and standard deviation was calculated (*p<0.05). 
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Figure 4-2:  The mutant S340 virus induces a robust type I IFN response in vivo.   
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Figure 4-2. The mutant S340 virus induces a robust type I IFN response in vivo.  Groups 
of six-week old (n=3) (A) CD-1  or (B) C57BL/6 mice were infected with PBS alone, S300 
(wild-type AR86) or S340 (mutant AR86; Ile at nsP1 position 538) at 1x103 PFU via the 
intracranial (i.c.) route.  Serum was harvested by tail vein bleeding at (A) 9, 12, and 18 hours 
post-infection or (B) 12 hours post-infection and was subjected to a L929 mouse IFN 
bioassay, as described in the Materials and Methods.  Each bar represents an individual 
animal (Mock- white, S300- grey, S340- hatched).  The data shown are representative of 
three independent experiments. 
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Figure 4-3:  The mutant S340 virus exhibits similar kinetics of host cell transcription 
shutoff as compared to wild-type S300 virus.   
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Figure 4-3.  The mutant S340 virus exhibits similar kinetics of host cell transcription 
shutoff as compared to wild-type S300 virus.  (A) Neuro-2A cells were mock infected (M) 
or infected with S300 (wild-type AR86) or S340 (mutant AR86) at an MOI of 10.0.  At the 
timepoints indicated, media was removed and replaced with complete α-MEM medium 
containing [3H]-uridine at 20 µCi/ml.  After 3 hours incubation at 37°C, cells were washed 
1X in PBS, RNAs were isolated using Trizol and RNAs were analyzed by agarose gel 
electrophoresis as described in the Materials and Methods.  (B) Residual host cell 
transcription was measured by excising fragments from the dried gel followed by liquid 
scintillation counting.  The data are reported as counts per minute normalized to the amount 
of radioactivity detected in the same band in mock infected cells.  The data shown are 
representative of two independent experiments.    
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Figure 4-4:  The mutant S340 virus shuts off host cell translation with similar kinetics 
as the wild-type S300 virus. 
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Figure 4-4.  The mutant S340 virus shuts off host cell translation with similar kinetics 
as the wild-type S300 virus. (A) Neuro-2A cells were mock infected (M) or infected with 
S300 (wild-type AR86) or S340 (mutant AR86) at an MOI of 10.0.  Cells were labeled with 
35S Met/Cys for 1 hour at the time points indicated and cell lysates were analyzed by PAGE.  
(B) Residual host cell protein synthesis was evaluated by measuring the amount of 
radioactivity detected in the protein band corresponding to actin (as marked by the arrow) 
and normalized to the amount of radioactivity detected in the same protein band in mock 
infected cells (S300- solid line; S340- dashed line).  The data shown are representative of 
three independent experiments. 
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Figure 4-5:  The mutant AR86 virus induces earlier IRF-3 activation.   
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Figure 4-5. The mutant AR86 virus induces earlier IRF-3 activation.  HEC-1B cells were 
infected with mock (1-4), Sendai virus (5-8), S300 (wild-type AR86; 9-12) or S340 (mutant 
AR86; 13-16) at an MOI of 1.0 and at the indicated timepoints, cells were washed one time 
with PBS and whole cell extracts were prepared by mixing cells with NP-40 lysis buffer 
containing protease and phosphatase inhibitors.  Native PAGE (upper panel) and SDS-PAGE 
western blots (lower panels) were performed as described in the Materials and Methods.  
Blots shown are representative of three independent experiments.  
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ABSTRACT 
 Many viruses have evolved strategies to interfere with type I interferon induction and 
promote viral virulence.  Alphaviruses have been shown to inhibit type I IFN induction by 
virus-mediated shutoff of host cell macromolecular synthesis.  However, whether 
alphaviruses possess specific mechanisms to inhibit host type I IFN induction signaling is not 
known.  We have recently shown that the adult mouse neurovirulent Sindbis-group virus 
AR86 inhibits type I IFN induction by inhibiting Interferon Regulatory Factor-3 (IRF-3) 
activation early during infection.  In this study, we extend these findings and show that while 
AR86 genomic RNA is efficiently recognized by RIG-I, AR86 virus actively antagonizes 
IRF-3 activation early during infection.  Furthermore, the viral nonstructural proteins (nsPs) 
inhibited RIG-I and Mda5 signaling when expressed independently of virus infection.  
Strikingly, co-expression of the viral nsPs proteins led to the loss of RIG-I, Mda5, and IRF-3 
expression in a manner that was dependent on the nsP2 protease.  These results demonstrate 
that the viral nonstructural proteins specifically antagonize the type I IFN induction signaling 
pathway and suggest that the virus may directly target components of the type I IFN 
induction signaling pathway. 
 187 
INTRODUCTION 
 Alphaviruses are mosquito borne viruses that are a significant human pathogen, 
causing disease ranging from encephalitis to arthritis.  Sindbis viruses (SINV) are one of the 
best model systems for studying alphavirus interactions with the host.  SINV have been well 
characterized at the molecular level and cause diseases in mice ranging from a shock-like 
inflammatory response syndrome (SIRS) in young mice to lethal encephalitis in adult mice 
(15, 16, 30).  SINV pathogenesis models have been used to define specific viral and host 
factors that regulate virus-induced disease.  One of the most important components of the 
innate antiviral response is the type I IFN system.  Deficiency in IFN signaling significantly 
increases sensitivity to SINV infection (24, 25). However, relatively little is known about 
how these viruses interact with the host cell to initiate and/or avoid type I IFN response.  
Virus-induced shutoff of host cell macromolecular synthesis has been shown to inhibit type I 
IFN induction signaling, however, whether these viruses specifically antagonize type I IFN 
induction has not been evaluated.   
 Type I IFN induction is initiated upon recognition of viral products by host cell 
pattern recognition receptors (PRRs), specifically Toll-like receptors (TLRs) and recently 
identified retinoic acid inducible gene-I (RIG-I) and melanoma differentiation antigen 5 
(Mda5) (21).  While TLR7 and TLR3 recognize single-stranded (ssRNA) and double-
stranded RNA (dsRNA) within the endosomal compartment, respectively, dsRNA in the 
cytoplasm is recognized by RIG-I and Mda5 (13, 34).  Upon binding dsRNA substrates, 
TLR3 and RIG-I/Mda5 recruit their respective adaptor proteins, Toll/IL-1 receptor (TIR)-
domain containing adaptor inducing IFN-β (TRIF) and IPS-1/MAVS/Cardif/VISA via the 
caspase recruitment domain leading to activation of IFN regulator factor-3 (IRF-3), Nuclear 
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factor kappa B (NF-κB), ATF2/c-Jun and formation of the enhancesome complex that binds 
to the promoter region of the IFN-β gene and activates transcription (21).   
 Alphaviruses contain a single-stranded positive-sense RNA genome of approximately 
11.5 kb in length that encodes for the nonstructural proteins in the 5’ two-thirds of the 
genome and the structural proteins in the remaining one-third.  The nonstructural proteins are 
translated as a polyprotein that are postranslationally processed to produce the mature 
nonstructural proteins, nsP1, nsP2, nsP3, and nsP4.  While the nsP polyprotein precursors 
and mature nsPs are mainly involved in viral RNA synthesis, they have also been shown to 
modulate the host antiviral response through specific virus-host interactions.  The  nsP2 
protein has been well-studied and shown play an important role in antagonizing the host 
antiviral response through shutoff of host macromolecular synthesis.  Introducing mutations 
in the carboxy-terminus of nsP2,  which render it defective in host translation or transcription 
shutoff, correlated with increased type I IFN induction (6, 9).  Furthermore, mature nsP2 has 
been implicated in causing cytopathic effect in cells, most likely attributed to its ability to 
shutoff host RNA polymerase I and RNA polymerase II transcription (7).   
 Recent studies with the adult mouse neurovirulent AR86 virus has demonstrated that 
a virulence determinant at nsP1 position 538 modulates type I IFN induction.  Introduction of 
an Ile for the virulence-associated Thr codon at this position attenuated virulence and 
resulted in induction of a type I IFN response (10, Suthar, M.S. and Heise, M.T., 
unpublished).  In addition to virus-induced shutoff of host macromolecular synthesis, AR86 
virus inhibits type I IFN induction through an additional mechanism by inhibiting IRF-3 
activation early during infection.  This study further demonstrates the importance of the viral 
nsPs in modulating the host antiviral response through specific virus-host interactions.  
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Therefore, we hypothesized that the AR86 viral nsPs specifically antagonize components of 
the type I IFN signaling pathway upstream of IRF-3.   
 In this study, we demonstrate that RIG-I efficiently recognizes AR86 virus  genomic 
RNA.  Although the viral RNA is capable of being recognized, AR86 was found to actively 
antagonize IRF-3 activation in infected cells.  Since the viral nonstructural proteins are 
known to play a major role in regulating viral type I IFN induction, we evaluated whether the 
AR86 nonstructural proteins were antagonizing the RIG-I/Mda5-mediated signaling 
pathway.  These studies demonstrate that the AR86 nonstructural proteins interfered with 
RIG-I and Mda5 mediated IFN-β induction through a mechanism that requires a functional 
nsP2 protease.  We also found that RIG-I, Mda5, and IRF-3 expression were rapidly lost in 
the presence of the viral nonstructural proteins.  This work demonstrates a novel role for the 
alphavirus nonstructural proteins in blocking IFN induction and suggests that the viral nsP2 
protease may directly target components of the type I IFN induction signaling pathway.   
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MATERIALS AND METHODS 
 
Viruses and cell lines.  Virus stocks were made as described previously (30).  Briefly, viral 
cDNA plasmids were linearized with PmeI and used as templates for the synthesis of full-
length transcripts by using SP6-specific mMessage Machine in vitro transcription kits 
(Ambion).  Transcripts were electroporated into BHK-21 cells grown in α-minimal essential 
medium (α-MEM:  10% fetal calf serum [Invitrogen], 10% tryptose phosphate broth [Sigma], 
and 0.29 mg of L-glutamine per ml [Invitrogen]).  Supernatants were harvested 24 hours after 
electroporation and subjected to centrifugation at 3000 RPM (Sorvall rotor RTH-250) for 20 
minutes at 4˚C and frozen in 1-ml aliquots.  Virus stocks were titrated on BHK-21 cells as 
previously described (28). 
 BHK-21 cells were maintained in α-MEM, for a maximum of 10 passages.  Human 
embryonic kidney (HEK) 293 cells (ATCC) were maintained in Dulbecco's MEM containing 
10% fetal bovine serum [Invitrogen], 0.29 mg of L-glutamine per ml [Gibco], and 1x 
penicillin/streptomycin [Invitrogen].  HEC-1B cells (ATCC) are human endometrial 
carcinoma cells and were used in this study to analyze IRF-3, since these cells are 
nonresponsive to IFN (5, 31).  HEC-1B cells were grown in MEM containing 10% fetal 
bovine serum, 0.29 mg of L-glutamine per ml [Gibco], and penicillin/streptomycin. 
Plasmid Constructs.  Standard recombinant DNA techniques were used to construct cDNA 
clones.  To construct the AR86 nsP1234 construct, replicon plasmid pRep89-egfp was 
digested with MfeI and NotI, which encompasses nsP1234, and cloned into pcDNA3.1+ 
(Invitrogen) digested with EcoRI and NotI.  To construct nsP123, PCR-mediated site-
directed mutagenesis of the nsP1234 construct was modified to create the authentic cleaved 
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end of nsP3.  To construct the protease defective nsP expression plasmids, a mutation of a 
Cys codon at nsP2 481 to a Gly codon was engineered by site-directed mutagenesis (clones 
are designated as P2C481G).  Flag-tagged nsP plasmids were constructed by inserting a 
FLAG-tag amino acid sequence (DYKDADDDK) upstream of nsP1.  The reporter construct 
p56-luc was kindly provided by Dr. G.Sen.  The reporter plasmid 3X-KB-luc and pcDNA-
FLAG-p65 expression plasmids were a kind gift from Dr. A.Baldwin.  The reporter plasmid 
pIFN-β-Luc and pcDNA-FLAG-IRF-3 expression plasmids were a kind gift from Dr. 
J.Pagano.  pcDNA3.1+-egfp was purchased from Invitrogen.  RIG-I, and Mda5 expression 
plasmids were constructed as described by (1, 34). Briefly, HEK293 cells were treated with 
IFN-β for 24 hours, RNA was isolated and RT-PCR was performed using oligo dT primers 
(Invitrogen) or Mda5 specific primers for first strand synthesis following Promega’s AMV-
RT (HC) protocol.  FLAG-RIG-I and FLAG-Mda5 were assembled by overlap extension 
PCR and cloned into pcDNA3.1+.  FLAG-constituitively active RIG-I expression plasmid 
was constructed by PCR amplification of the CARD domains of RIG-I and cloned into 
pcDNA3.1+.  All plasmids were confirmed by sequencing at the University of North 
Carolina at Chapel Hill Genome Analysis Facility with a model 373A DNA sequencing 
apparatus (Applied Biosystems).     
Native IRF-3 PAGE.  HEC-1B cells were plated at 5 x 105 cells/well and infected with 
mock (diluent), S300, or S340  at an MOI of 1.0 for 1 hour at 37°C.  After 1 hour of 
infection, the inoculum was removed and HEC-1B media was added to the cells and were 
incubated at 37°C for the remainder of the infection.  At 1, 2, and 4 hours post-infection, 
cells were mock transfected or transfected with 100 poly-(I:C) using Lipofectamine 2000 
(Invitrogen) and harvested 2 hours post-transfection.  Cells were washed one time with PBS 
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(phosphate buffered saline) and cell pellets were frozen at -80°C.  Whole cell extracts were 
prepared by mixing cells with RIPA lysis buffer containing protease inhibitors (5 µg/ml of 
each leupeptin, pepstatin, and aprotinin) and centrifuged at 13,000 RPM at 4°C for 10 
minutes.  Equal cell lysates (10 ul) were mixed on ice with a 2X loading buffer (125 mM 
Tris-Cl, pH 6.8, 30% glycerol, 0.002% bromphenol blue).  A 7.5% native PAGE was pre-run 
at 4°C for 30 minutes at 45 mA in gel running buffer (25 mM Tris-Cl, pH 8.4, 192 mM 
glycine, in the presence of or absence of 0.2% deoxycholate in the cathode and anode buffer, 
respectively).  Samples were loaded on the gel and run at 25 mA for 60 min at 4°C followed 
by transfer to polyvinylidene difluoride (PVDF) membranes.  After an hour of transfer, 
membranes were blocked for 1 hour at room temperature with PBS containing 0.1% Tween-
20 (Sigma) (wash buffer) and 5% dry milk (blocking buffer).  The membrane was incubated 
in primary antibody overnight at 4°C with rabbit anti-IRF3 FL-425 (Santa Cruz, sc-9082) at 
1:500.   After three washes, secondary antibody was incubated for 1 hour at room 
temperature with anti-rabbit conjugated HRP at 1:10,000 (Sigma) in blocking buffer.  The 
membrane was washed three times followed by detection of proteins was using ECL 
chemiluminescence (Amersham Biosciences). 
SDS-PAGE and Western Blot.  Western blot analysis was performed as previously 
described (22).  Samples were quantitated using Bradford assay and equal protein was loaded 
onto SDS-PAGE gel followed by transfer to polyvinylidene difluoride (PVDF) membranes.  
After an hour of transfer, membranes were blocked for 1 hour at room temperature with PBS 
containing 0.1% Tween-20 (Sigma) (wash buffer) and 5% dry milk (blocking buffer).  Blots 
were stained with rabbit anti-RIG-I (dilution 1:15,000), mouse anti-Flag (1:1000), rabbit anti-
gfp (1:500), rabbit anti-nsP1 (1:10,000) (generously provided by Dr.C.Rice) , and rabbit anti-
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IRF3-FL425 (1:500) (Santa Cruz Biotechnology; sc-9082) in blocking buffer.  After three 
washes, secondary antibody was incubated for 1 hour at room temperature with anti-rabbit 
conjugated HRP at 1:6,000 (Amersham Biosciences) or anti-mouse conjugated HRP at 
1:2500 (Amersham Biosciences) in blocking buffer.  The membrane was washed three times 
followed by detection of proteins using ECL chemiluminescence (Amersham Biosciences). 
RNA transcription and virion RNA isolation.  RNA transcriptions were performed as 
previously described ((30).  Briefly, viral cDNA plasmids were linearized with PmeI and 
used as templates for the synthesis of full-length transcripts by using SP6-specific mMessage 
Machine in vitro transcription kits (Ambion).  RNAs were isolated as described in the 
manufacturer’s protocol.  Virion RNA was extracted from 1 x 107 PFU of purified virus 
using the MagMax Viral RNA Isolation Kit (Ambion) and RNAs were resuspended in 50 ul 
of nuclease-free water.   
Luciferase Assay.  HEK293 cells (6 x 104 cells per well in 48-well plates) were transfected 
in triplicate with the indicated expression vectors using Fugene6 [Roche] at 3 ul per ug of 
plasmid DNA.  Where indicated, in vitro transcript RNA, virion RNA, or Poly-(I:C) were 
subsequently transfected using Lipofectamine 2000 [Invitrogen] and cells were lysed with 
1X Cell Culture Lysis Reagent (Promega) and assayed for luciferase activity.  Where 
indicated, relative luciferase activity was normalized to total protein and multiplied by a 
factor of 10 and reported as normalized relative luciferase units.    
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RESULTS 
 
AR86 viral RNA is more efficiently recognized by RIG-I than Mda5.  Recent work by 
several groups have shown that RIG-I and Mda5 vary in their specificity for recognizing 
RNA viruses.  While RIG-I has been shown to be critical for recognizing Influenza virus, 
Sendai virus, Vesicular Stomatitis virus, Hepatitis C virus, and Japanese encephalitis virus, 
Mda5, on the other hand, has been shown to be critical for recognizing Encephalomyocarditis 
virus (8, 14).  In addition, Mda5 was reportedly not critical for responding to SINV infection 
(8).   
 To further evaluate the specificities of RIG-I and Mda5 for recognizing SINV RNA, 
HEK293 cells were co-transfected with an IFN-β promoter reporter plasmid expressing the 
luciferase gene along with either RIG-I or Mda5 expression plasmids.  Twenty-four hours 
post-transfection, cells were subsequently transfected with various RNA inducers, including 
carrier RNA, poly-(I:C), AR86 virion-derived RNA, and in vitro transcribed full-length wild-
type AR86 viral RNA, followed by measuring luciferase activity seven hours post-
stimulation (Fig. 1).  RIG-I and Mda5 efficiently responded to poly-(I:C), however, RIG-I 
was more efficient than Mda5 in responding to RNA extracted from virions or full-length 
virus RNA derived from in vitro transcription.   
 Due to the complexities of transfecting replication competent viral RNA into cells, a 
mutation within nsP2 (Cys to Gly at position 481), which has been shown to ablate nsP2 
protease function and viral RNA synthesis (29), was engineered into the full-length 
infectious clone of AR86.  In vitro transcripts from this clone were transfected into cells 
under the same conditions and similar specificities were observed as that of in vitro 
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transcripts derived from that of the wild-type AR86 infectious clone.  The results from this 
study demonstrate that RIG-I, and partially Mda5, are capable of responding to SINV RNA. 
AR86 virus infection inhibits dsRNA-induced IRF-3 activation.  Previous studies from 
our laboratory have shown AR86 virus inhibits activation of IRF-3 early during infection, 
suggesting that AR86 virus is either actively suppressing type I IFN induction or evading 
type I IFN induction.   Therefore, we determined whether AR86 can block activation of IRF-
3 induced from an exogenous source of dsRNA.  HEC-1B cells were infected with AR86 at 
an MOI of 1.0 and poly-(I:C) was transfected into cells at 1, 2, and 4 hours post-infection and 
cells were harvested 2 hours post-transfection (equivalent to 3, 4, and 6 hours post-infection, 
respectively).  As shown in Figure 2, early during infection, AR86 virus inhibited IRF-3 
dimerization upon treatment with poly-(I:C) in contrast to mock infected cells, which 
exhibited normal IRF-3 dimerization (compare lanes 2 and 4).  This result suggests that 
AR86 virus is able to actively antagonize the type I IFN induction signaling pathway.   
AR86 nsPs inhibit RIG-I and Mda5 mediated IFN-β promoter activity.  Though RIG-I 
clearly recognizes AR86 genomic RNA (Fig. 1), the fact that AR86 infected cells were 
refractory to poly-(I:C)-induced IRF-3 activation suggests that AR86 is interfering with type 
I IFN induction.  Since the viral nonstructural proteins have previously been implicated in 
modulating the type I IFN response, we directly evaluated whether the AR86 nsPs blocked 
RIG-I/Mda5-mediated type I IFN induction.  To evaluate this, HEK293 cells were 
transfected with the IFN-β-luc reporter plasmid, RIG-I or Mda5 expression plasmids, and a 
nsP1234 expression plasmid.  Cells were subsequently transfected with poly-(I:C) and 
luciferase activity was measured (Fig. 3).  In the context of vector alone, poly-(I:C) exhibited 
strong induction of RIG-I or Mda5-mediated IFN-β promoter activity.  In contrast, 
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expression of nsP1234 efficiently inhibited RIG-I- and Mda5-mediated IFN-β promoter 
activity.   
 The AR86 viral nonstructural proteins are translated as a single polyprotein 
(nsP1234), however, nsP4 is rapidly cleaved off so that the major polyprotein precursor at 
early times post-infection is nsP123.  Therefore, we next determined whether nsP123 is able 
to inhibit RIG-I or Mda5 mediated IFN-β promoter activity (Fig. 3).  Similar to the findings 
with nsP1234, nsP123 was found to efficiently inhibit RIG-I and Mda5-mediated IFN-β 
promoter activity.  These results demonstrate that the AR86 nonstructural proteins, 
independent of nsP4, are able to inhibit the IFN-β induction signaling pathway.   
AR86 nsPs inhibit RIG-I-mediated IFN-β signaling.   We next determined if the viral nsPs 
were antagonizing the ability of RIG-I to recognize dsRNA through its DExD/H box helicase 
domain or antagonizing downstream signaling through its N-terminal CARD domains.  
Ectopic expression of the RIG-I N-terminal CARD domains has been shown to induce IFN-β 
signaling independent of a dsRNA substrate (19, 33, 34).  Therefore, HEK293 cells were co-
transfected with the IFN-β-luc reporter plasmid, constituitively active RIG-I expression 
plasmid, and nsP1234 (Fig. 4).  In the presence of an empty plasmid transfection control, 
constituitively active RIG-I exhibited robust IFN-β promoter activity, while expression of 
wild-type AR86 nsPs completely abrogated IFN-β promoter activity.  This result suggests 
that the AR86 viral nonstructural proteins are either directly antagonizing RIG-I signaling or 
downstream RIG-I-mediated signaling.     
Viral nsP2 protease function is required for antagonizing RIG-I.  Recent reports have 
implicated viral proteases as playing an important role in modulating type I IFN induction.  
The SINV nsP2 protease reportedly plays an important role in the induction of cell death (7). 
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In addition, the Hepatitis C virus NS3/4A protease has been shown to antagonize the IFN-β 
signaling pathway through cleavage of the TLR3-adaptor protein TRIF and the RIG-I/Mda5 
adaptor protein IPS-1 (18, 20).   
 Based on these findings, we next determined whether the nsP2 protease functions in 
antagonizing the RIG-I- or Mda5-activated IFN-β signaling pathway.  A mutation within the 
nsP2 protease active site at position 481 from a Cys to Gly (P2C481G) was introduced into 
the nsP123 expression plasmid to ablate proteolytic processing of the nonstructural 
polyprotein (29).  HEK293 cells were co-transfected with the IFN-β-luc reporter plasmid, 
RIG-I or Mda5 expression plasmids, and nsP123 P2C481G expression plasmid.  Cells were 
subsequently transfected with poly-(I:C) and luciferase activity was measured.  In contrast to 
the wild-type AR86 nsPs (Fig. 5), the viral nonstructural proteins containing a defective nsP2 
protease were unable to downregulate RIG-I or Mda5 mediated IFN-β promoter activity (Fig. 
5A and 5B, respectively).  Moreover, expression of the nsP123 P2C481G had no effect on 
constituitively active RIG-I mediated IFN-β promoter activity (Fig. 5C).  This result suggests 
that the AR86 nonstructural proteins antagonize type I IFN induction through a novel 
mechanism that is dependent on the viral nsP2 protease.   
AR86 nsPs inhibit RIG-I/IRF-3 specific pathway, but not p65.  Upon binding  dsRNA 
substrate, the RIG-I CARD domains interact with the CARD domains of the mitochondrial-
associated adaptor protein IPS-1/MAVS/Cardif/VISA and leads to the activation of IRF-3 
and NF-κB, two components of the enhancesome complex required for IFN-β transcription 
(12).  We next determined whether the AR86 viral nonstructural proteins are antagonizing 
RIG-I signaling to IPS-1/MAVS/Cardif/VISA or antagonizing signaling downstream of IPS-
1/MAVS/Cardif/VISA.  To evaluate this, HEK293 cells were co-transfected with either an 
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IFN-β-luc reporter plasmid, an IRF-3 specific reporter plasmid (p56-luc) or an NF-κB 
specific reporter plasmid (3X-kB-luc), along with a MAVS expression plasmid, and empty 
vector, AR86 nsP1234 or nsP1234 P2C481G expression plasmids.  As shown in Figure 6, 
expression of the wild-type AR86 nsPs efficiently inhibited MAVS-mediated IFN-β 
promoter activity and this was dependent on the nsP2 protease.  Moreover, the AR86 nsPs 
exhibited strong inhibition of MAVS-mediated IRF-3 promoter activity (2.7-fold induction) 
as compared to empty vector control (35-fold induction) or nsP1234 P2C481G (114-fold 
induction).  Furthermore, the wild-type AR86 nsPs inhibited MAVS-mediated NF-κB 
promoter activity (5-fold induction) as compared to empty vector control (21-fold induction) 
or nsP1234 P2C481G (62-fold induction).  This result suggests that the AR86 nsPs are 
antagonizing MAVS-mediated signaling to IRF-3 and NF-κB in an nsP2-protease dependent 
manner.     
 While the AR86 nsPs inhibited MAVS-mediated signaling, it appeared as though the 
AR86 nsPs were exerting greater inhibition on IRF-3 promoter activity as compared to NF-
κB promoter activity.  To further evaluate virus interactions with the type I IFN induction 
signaling pathway, we next directly evaluated the effect the AR86 nsPs have on IRF-3 and 
NF-κB activity.  To evaluate this, HEK293 cells were co-transfected with either an IRF-3 
specific reporter plasmid (p56-luc) or an NF-κB specific reporter plasmid (3X-κB-luc), along 
with IRF-3 or p65 expression plasmids, and empty vector, AR86 nsP1234 or nsP1234 
P2C481G expression plasmids.  Expression of the wild-type AR86 nsPs efficiently inhibited 
IRF-3-mediated IRF-3 promoter activity (1-fold induction) as compared to empty vector 
control (9.4 fold induction) and nsP1234 P2C481G (11.6 fold induction).  In contrast, 
expression of the wild-type AR86 nsPs showed no inhibition of p65-mediated NF-κB 
 199 
promoter activity, demonstrating the AR86 nsPs have no effect NF-κB activity.  These 
results demonstrate that the AR86 nsPs are antagonizing IRF-3 activity and confirm our 
earlier findings that AR86 virus actively suppresses IRF-3 activation in infected cells (Fig. 
2).   
AR86 nsPs leads to loss of RIG-I, Mda5, and IRF3 expression.  Due to the fact that 
expression of the wild-type AR86 nsPs led to strong inhibition of RIG-I, Mda5, and IRF-3 
activities and this was dependent on a functional nsP2 protease, we next determined whether 
the viral nonstructural proteins were affecting expression of the various components of the 
type I IFN induction signaling pathway.  To evaluate this, HEK293 cells were co-transfected 
with either empty vector, wild-type nsP123, or nsP123 P2C481G along with RIG-I, Mda5, 
constituitively active RIG-I, MAVS, IRF-3, and p65.  Twenty-four hours post-transfection, 
cell lysates were collected and analyzed for protein expression (Fig. 7)  In the presence of 
wild-type nsP123, RIG-I, Mda5, constituitively active RIG-I, and IRF-3 exhibit nearly 
complete loss of expression.  However, co-expression of wild-type nsP123 with MAVS or 
the p65 subunit of NF-κB exhibited slightly reduced or normal expression levels, 
respectively.  Furthermore, normal expression levels were observed when the wild-type 
nsP123 were co-expressed with egfp (data not shown).  Consistent with its lack of inhibiting 
reporter activity, nsP123 P2C481G expression did not effect the expression of any of the 
signaling proteins.  This result demonstrates that the viral nonstructural proteins are 
specifically targeting IFN-β signaling proteins and this is dependent on a functional nsP2 
protease.   
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DISCUSSION 
 The innate and adaptive arms of the immune system play critical roles in controlling 
early virus replication, viral clearance, and establishing long-term protection from re-
infection (11, 27).  Type I IFN is the first line of defense during virus infection and is 
responsible for deterring virus replication and spread within the host (17, 23, 32).  Many 
viruses have evolved strategies to interfere with type I IFN induction to promote viral 
virulence.  Our laboratory has previously demonstrated that a single virulence determinant at 
nsP1 538 modulates type I IFN induction by altering IRF-3 activation.  In the presence of a 
virulence-associated Thr at nsP1 538, wild-type AR86 exhibited reduced type I IFN 
induction and delayed IRF-3 activation early during infection.  This indicated that the AR86 
nonstructural proteins were interacting with components of the type I IFN signaling pathway 
and blocking IRF-3 activation early during infection.   In this report, we provide evidence 
that AR86 genomic RNA is capable of being recognized by RIG-I and Mda5, but that this 
effect is blocked by the viral nonstructural proteins ability to antagonize RIG-I, Mda5, and 
IRF-3 expression, through a viral nsP2 protease-dependent mechanism. 
 Studying host protein interactions with the alphavirus nonstructural proteins can be 
difficult, in part, due to their specific role in viral RNA synthesis.  To circumvent this issue, 
the viral nonstructural proteins were expressed independent of the context of virus infection 
using a CMV-promoter based overexpression plasmid.  Although this has been shown to be a 
viable alternative to studying virus-host interactions (7, 22), several concerns can be raised 
by overexpression of the viral nonstructural proteins, including nsP2-induced cell death and 
host transcription/translation shutoff.  However, in our studies, we failed to observe cell 
death while expressing the viral nsPs up to 72 hours post-transfection (data not shown).  
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Furthermore, several lines of evidence argue against the issue that overexpression of the viral 
nsPs are inducing host cell shutoff.  First, co-expression of the viral nsPs with the p65 
subunit of NF-κB or egfp (data not shown) did not alter protein or RNA expression levels 
(Fig. 5 and data not shown, respectively).  Secondly, p65-medated 3X-κB promoter activity 
was unaltered in the presence of the viral nsPs, which suggests that the viral nsPs specifically 
target steps in the IFN induction pathway rather than inducing a generalized host cell shutoff.   
 Perhaps, one of the most intriguing observations was that while wild-type AR86 nsPs 
efficiently induced the loss of RIG-I, Mda5, and IRF-3 expression, the nsPs containing a 
defective nsP2 protease were unable to block RIG-I, Mda5, or IRF-3 activity or reduce 
protein stability.  This strongly suggests a novel role for the viral protease in antagonizing 
type I IFN induction and raises two possibilities by which the protease is affecting protein 
expression.  First, the viral nsP2 is targeting and cleaving RIG-I and Mda5.  One such 
examples is the finding that the Hepatitis C virus NS3/4A protease cleaves the 
mitochondrial-associated adaptor protein IPS-1 and the TLR-adaptor protein TRIF to 
antagonize type I IFN induction (18, 20).  Examination of the amino acid sequences for RIG-
I and Mda5 revealed nsP1/2 and nsP2/3 virus-like cleavage sites within the proteins, 
respectively.  This suggests that AR86, which has been shown to have a stable nsP123 early 
during infection, is able to efficiently target host proteins containing nsP1/2 virus-like 
cleavage sites, such as RIG-I.  As the nsP123 precursor polyprotein is processed into nsP23, 
this polyprotein would be able to efficiently target host proteins that contain nsP2/3 virus-like 
cleavage sites, such as Mda5.  However, further studies are required to determine if these 
host proteins are truly targets of the viral nsP2 protease.  These finding would demonstrate an 
important role for the early nonstructural polyproteins and viral protease in antagonizing the 
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host type I IFN response.  This raises the possibility that viruses, not only alphaviruses but 
any virus containing a protease, would be able to target host proteins for cleavage.   
 Another possibility for the observed loss of RIG-I, Mda5, and IRF-3 expression is 
that the viral nsPs could be targeting these proteins for degradation.  Recently, it has been 
reported that the Classic swine fever virus N(pro) protein and Rotavirus nonstructural protein 
NSP1 target endogenous IRF-3 for degradation in a proteasome-dependent manner (3, 4).  It 
is well known that activated IRF-3 is efficiently targeted to the host proteasome through the 
function of peptidylprolyl isomerase Pin1 (26), however, the mechanism of degrading 
endogenous IRF-3 is not known.  Mda5 has recently been shown to be cleaved during 
poliovirus infection and this appeared to be mediated by the induction of apoptosis during 
virus infection (2).  These findings imply that the host cell has efficient mechanism to 
downregulate expression of components of the type I IFN signaling pathway.  The ability of 
a virus to target these negative regulating pathways would be a mechanism to completely 
abrogate the ability of the host cell to respond to virus infection.  Therefore, it will be 
interesting to determine if the viral nsPs interact with and target these components for 
degradation or induce a negative regulator within the host cell that efficiently targets these 
proteins for degradation. 
 In summary, we have demonstrated that AR86 viral RNA is recognized by RIG-I and 
Mda5 and that the viral nonstructural proteins antagonize type I IFN induction by reducing 
the stability of RIG-I, Mda5 and IRF-3.  Perhaps most importantly, we demonstrated an 
important role for the viral nsP2 protease in antagonizing type I IFN induction signaling.  
Further studies are underway to investigate the mechanism by which the AR86 nonstructural 
proteins mediate these effects.    
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Figure 5-1:  RIG-I is more efficient in responding to AR86 viral RNA than Mda5.   
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Figure 5-1.  RIG-I is more efficient in responding to AR86 viral RNA than Mda5.  
HEK293 cells were co-transfected with the IFN-β-luc reporter plasmid (50 ng), (A) RIG-I 
(50 ng) or (B) Mda5 (50 ng) expression plasmids.  After 24 hours, cells were transfected with 
carrier RNA, 8 ng of poly-(I:C), AR86 virion RNA (undiluted, 1:10, 1:100), 1 ug wild-type 
txp RNA, or 1 ug P2C481G AR86 transcript (Txp) RNA and luciferase activity was 
measured after seven hours post-stimulation.  Each bar represents an average of triplicate 
samples normalized to total protein and standard deviation was calculated.  The data shown 
are representative of three independent experiments.   
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Figure 5-2:  AR86 virus blocks poly-(I:C)-mediated IRF-3 activation.   
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Figure 5-2.  AR86 virus blocks poly-(I:C)-mediated IRF-3 activation.  HEC-1B cells 
were mock infected or infected with wild-type AR86 at an MOI of 1.0 in duplicate followed 
by mock transfections or transfections with 100 ng poly-(I:C) at one (lanes 1-4), two (lanes 
5-8), or four (lanes 9-12) hours post-infection.  Two hours post-transfection, cells were 
harvested and lysates were analyzed for IRF-3 dimerization by Native PAGE.   
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Figure 5-3:  The AR86 nsPs inhibit RIG-I and Mda5 mediated IFN-β promoter activity.   
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Figure 5-3.  The AR86 nsPs inhibit RIG-I and Mda5 mediated IFN-β promoter activity.  
HEK293 cells were co-transfected with the IFN-β-luc reporter plasmid (50 ng), empty vector, 
nsP1234 (200 ng) or nsP123 (200 ng) expression plasmids, and (A) RIG-I (50 ng) or (B) 
Mda5 (50 ng) expression plasmids.  After twenty-four hours of incubation, cells were 
subsequently mock transfected or transfected with 8 ng of poly-(I:C) and luciferase activity 
was measured seven hours after post-stimulation.  Each bar represents an average of triplicate 
samples normalized to total protein and standard deviation was calculated.  The data shown 
are representative of three independent experiments.    
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Figure 5-4:  The AR86 nsPs inhibit constituitively active RIG-I mediated IFN-β 
promoter activity.   
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Figure 5-4.  The AR86 nsPs inhibit constituitively active RIG-I mediated IFN-β 
promoter activity.  HEK293 cells were co-transfected with the IFN-β-luc reporter plasmid 
(50 ng), constituitively active RIG-I (100 ng) or empty vector control (100 ng), and empty 
vector or nsP123 (200 ng) expression plasmids.  Twenty-four hours post-transfection 
luciferase activity was measured.  Each bar represents an average of triplicate samples and 
standard deviation was calculated.  The data shown are representative of three independent 
experiments.    
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Figure 5-5:  The protease function of nsP2 is critical in antagonizing RIG-I and Mda5 
mediated IFN-β promoter activity.   
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Figure 5-5.  The protease function of nsP2 is critical in antagonizing RIG-I and Mda5 
mediated IFN-β promoter activity.  HEK293 cells were co-transfected with the IFN-β-luc 
reporter plasmid (50 ng), empty vector, or nsP123 P2C481G (200 ng) expression plasmids, 
and (A) RIG-I (50 ng) or (B) Mda5 (50 ng) expression plasmids.  After twenty-four hours of 
incubation, cells were subsequently mock transfected or transfected with 8 ng of poly-(I:C) 
and luciferase activity was measured seven hours after post-stimulation.  (C) HEK293 cells 
were co-transfected with the IFN-β-luc reporter plasmid (50 ng), constituitively active RIG-I 
(100 ng) or empty vector control (100 ng), and empty vector or nsP123 P2C481G (200 ng) 
expression plasmids.  Twenty-four hours post-transfection luciferase activity was measured.  
Each bar represents an average of triplicate samples normalized to total protein and standard 
deviation was calculated.  The data shown are representative of three independent 
experiments.    
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Figure 5-6:  AR86 nsPs inhibit MAVS/IRF-3 signaling pathway. 
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Figure 5-6.  AR86 nsPs inhibit MAVS/IRF-3 signaling pathway.  (A) HEK293 cells were 
co-transfected with either IFN-β-luc reporter plasmid (50 ng), p56-luc reporter or 3X-κB 
reporter plasmids (50 ng), empty vector, nsP1234, or nsP1234 P2C481G, and empty vector 
or MAVS expression plasmid (100 ng). (B)  Transfections were performed in a similar 
manner except IRF-3 was used as the inducer and p56-luc promoter activity was measured.  
(C)  Transfections were performed in a similar manner except p65 was used as the inducer 
and 3X-κB-luc promoter activity was measured.  Twenty-four hours post-transfection 
luciferase activity was measured.  Each bar represents an average of triplicate samples 
normalized to cells induced with an empty vector.  The data shown are representative of three 
independent experiments.    
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Figure 5-7:  Expression of AR86 nsPs induces the loss of RIG-I, Mda5, and IRF-3 
expression.   
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Figure 5-7.  Expression of AR86 nsPs induces the loss of RIG-I, Mda5, and IRF-3 
expression.  HEK293 cells were co-transfected with empty vector, nsP123, nsP123 
P2C481G (1 ug) and either RIG-I, Mda5, constituitively active RIG-I, MAVS, IRF-3, or p65 
(500 ng).  Cells were lysed after twenty-four hours and protein expression was evaluated by 
western blot as described in the Materials and Methods.  The data shown are representative 
of three independent experiments.    
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Girdwood virus-induced arthralgia in mice  
 We hypothesized that the Sindbis-group virus strain Girdwood, that is associated with 
infectious arthralgia in humans, would be useful for studying the pathogenesis of bone and 
joint disease in a mouse model.  While arthritogenic alphaviruses are a significant cause of 
human disease, the mechanisms underlying alphavirus-induced arthritis and arthralgia in 
humans are not well understood.  In order to better understand the pathogenesis of 
arthritogenic alphaviruses, improved animals models are needed to dissect the pathogenesis 
of these diseases.  Currently, two mouse models have been described for studying the 
pathogenesis of  alphavirus-induced arthritis and myositis.  One study has shown that the 
Sindbis-group virus strain AR86 replicates in joint associated tissues of adult mice (20).  
However, no virus-induced disease was observed, which limits the potential of this model for 
studying the pathogenesis of SINV-induced arthralgia.  Furthermore, Morrison et al. has 
described a mouse model of RRV-induced arthritis/myositis; however, unlike RRV, which 
causes inflammatory arthritis in humans, SINV, such as Ockelbo, Pogosta, and Girdwood 
cause arthralgias without overt inflammation (19, 26, 38).  It is therefore likely that the 
pathogenesis of arthritis associated viruses will differ from arthralgia-associated viruses.   
 It is thought that direct virus replication within the affected joints contributes to the 
development of alphavirus-induced arthritis/arthralgia in humans.  This is largely based on 
studies with RRV, where viral RNA and viral antigen-positive cells have been isolated from 
the knee joint and synovium effusions of afflicted individuals (13, 46).  RRV has been shown 
to replicate to high levels in synovial tissues of infected mice and in hind limb skeletal 
muscle (38), In support of this, our studies demonstrated that joint-associated tissues and 
skeletal muscle of mice were major sites of replication for the arthralgia-associated Sindbis-
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group virus strain Girdwood.  Perhaps most importantly, we found that the arthralgia-
associated Girdwood virus replicates to higher titers in joint and muscle tissues than the 
prototypic TR339 strain of SINV, which has not been linked to arthralgia in humans.  This 
result is particularly striking in that both viruses replicated to equivalent titers in the CNS, 
which suggests that the arthralgia-associated Girdwood virus may either exhibit an enhanced 
tropism for extraneural tissues, or an enhanced ability to replicate in cells within these 
tissues.  Either of these possibilities may have an important impact on our understanding of 
the pathogenesis of alphavirus-induced arthritis/arthralgia, since this would suggest that 
specific viral determinants contribute to the ability of arthralgia-associated viruses to target to 
and/or replicate within joints or associated connective tissues.  This in turn raises the 
possibility of mapping genetic determinants within the cloned Girdwood virus that contribute 
to the enhanced replication within muscle and joint tissues.  The availability of molecular 
clones of Girdwood and TR339 viruses, which can be readily used to create a set of chimeras 
to map the determinants of bone/joint tropism, provides a set of tools that could be used to 
significantly enhance our understanding of the viral and host factors that contribute the 
development of arthritis/arthralgia following alphavirus infection.  
             The mechanisms underlying alphavirus-induced arthralgia are poorly understood, 
since the joint pain induced by SINV lack the inflammation that presumably mediates the 
arthritic symptoms caused by viruses such as RRV (19, 42).  Infection of 14 day-old mice 
with Girdwood virus did result in a transient hind limb dysfunction which is similar to that 
seen with RRV-infected mice (data not shown; (38), respectively).  Though we cannot rule 
out a role for neurologic effects, several lines of evidence from this study suggest that this 
disease is due to direct viral replication within muscle and joint-associated tissues within the 
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limb, rather than virus-induced nerve damage within the CNS.  This includes the observed 
transient nature of the disease, with infected mice recovering full use of their hind limbs after 
the resolution of the viral infection.  Though it is possible for mice to regain partial hind limb 
function following virus-induced damage of the CNS (48), it is unlikely that the affected 
animals would regain full function as rapidly as the those in our study if the hind limb 
dysfunction were due to nerve damage.  Furthermore, while Girdwood virus replicated to 
higher titers than TR339 virus in joint and muscle tissues and caused more severe disease, 
both viruses replicated to similar titers in the CNS.  Hematoxylin and eosin stained brain and 
spinal cord sections revealed no overt neuronal damage during the course of infection (data 
not shown).  This result supports the hypothesis that direct viral replication by the arthralgia-
associated Girdwood virus is responsible for the hind limb dysfunction, though additional 
studies are needed to address this issue in greater detail.  However, even if the hind limb 
disease proves to be due to virus-induced damage to the CNS, this mouse model should still 
be useful for identifying viral genetic factors that promote replication within joint-associated 
tissues. 
  
The genetic determinants of the adult mouse neurovirulent AR86 virus 
 SINV infection of mice has provided valuable insight into the viral and host factors 
that contribute to virus-induced neurologic disease.  The identification of molecular 
determinants of alphavirus virulence represent an important step in understanding the 
pathogenesis of alphavirus-induced neurologic disease.  While the Sindbis-group virus strain 
AR86 causes a lethal disease in adult mice, the closely related Girdwood strain is avirulent 
(21, 44, 48).  These two strains differ by only 22 amino acid coding changes plus an 18 
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amino acid deletion within nsP3 (44).  We hypothesized that the avirulent Girdwood virus 
will aid in the identification of genetic determinants of adult mouse neurovirulence within the 
AR86 virus.  Initial studies using chimeric viruses demonstrated that genetic elements within 
the nonstructural and structural regions contribute to AR86 neurovirulence.  Detailed 
mapping studies identified four major genetic determinants of adult mouse virulence that 
localized to nsP1 position 538 (Ile to Thr; avirulent to virulent), an 18 amino acid deletion 
from nsP3 386 to 403, nsP3 position 537 (Opal to Cys; avirulent to virulent), and E2 position 
243 (Leu to Ser; avirulent to virulent).  The fact that these four changes conferred adult 
mouse neurovirulence on a normally non-neurovirulent SINV (Girdwood) clearly argued that 
these changes represent the major determinants of AR86 neurovirulence, although 
contributions from additional AR86 determinants cannot be ruled out.  
 These findings are unique in that all four of the identified AR86 neurovirulence 
determinants are not present in published sequences of any other adult mouse neurovirulent 
SINV, such as neuroadapted Sindbis virus (NSV).  This suggests that AR86 and NSV have 
evolved different mechanisms for causing neurologic disease in adult mice.  Previous 
neurovirulence studies with NSV have shown the importance for regions within the E2 
glycoprotein and the 5’ untranslated region (UTR) in contributing to virus-induced 
neurologic disease.  Within the E2 glycoprotein, a His at position 55 in the E2 glycoprotein 
was found to play a major role in adult mouse neurovirulence (18, 50).  The mechanism 
underlying this change is not yet completely understood; however, E2 His 55 was shown to 
correlate with improved binding and entry into neuronal cells (50), increased levels of viral 
replication (12), and the ability to overcome the protective effect of bcl-2 overexpression in 
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neurons (28, 29).  Additionally, a single substitution of a G at position 8 in the 5' noncoding 
region of NSV was responsible for conferring neurovirulence in adult rats (25).   
While all four changes are essential for the complete mouse neurovirulence 
phenotype of AR86, it appears that the Thr at nsP1 538 plays a particularly important role.  
Previous studies with this determinants have shown that changing the Thr at nsP1 538 in 
AR86 to the consensus Ile found in non-neurovirulent viruses resulted in a complete loss of 
virus-induced mortality, though this virus was still capable of causing disease, albeit less 
severe (21). 
One of the unique findings in our mapping studies was that the other two 
nonstructural virulence determinants (18 amino acid deletion and nsP3 537) showed very 
little effect on adult mouse neurovirulence when introduced, either individually or in 
combination, into an attenuated chimeric virus.  However, combining the Thr at nsP1 538 
with either of the two nsP3 virulence determinants resulted in a synergistic effect on adult 
mouse neurovirulence.  This indicates that the nsP1 538 determinant is interacting with the 
18 amino acid deletion and nsP3 537 determinants.  As for the mechanism underlying the 
role for nsP1 538 in virulence, we have previously reported that substitution of the wild-type 
Thr with an Ile residue accelerates processing of the P123 polyprotein precursor into the 
mature nsP1, nsP2, and nsP3 proteins (22).  This coincided with a more rapid induction of 
26S RNA synthesis contributing to earlier expression from the 26S promoter in infected 
cells, but did not measurably affect the levels of viral minus- or plus-strand RNA synthesis 
(22).  Based on the difference in nsP polyprotein processing, this raises the possibility that 
the two nsP3 virulence determinants enhance adult mouse neurovirulence only when there 
are more stable nonstructural polyprotein precursors present during infection.  In addition to 
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the modulating nsP polyprotein processing and viral RNA synthesis, this determinant was 
found to modulate type I IFN induction.  Details of this finding are discussed in more detail 
in the next section.  
 The 18 amino acid deletion between residues 386-403 in nsP3 is located within the 
highly variable C-terminal region of the protein (as reviewed in reference (47)).  One of the 
intriguing features of this 18 amino acid region is that Girdwood virus, which was originally 
isolated in South Africa (34), has the same set of amino acid residues within this region as 
that of other SINV strains, including the infectious clone for the original AR339 strain 
(TRSB), which was isolated near Egypt, Cairo (35, 54).  This indicates that this 18 amino 
acid domain is highly conserved amongst SINV.  While the function for the nsP3 protein has 
yet to be defined, it has been shown to be a phosphoprotein that is required for the synthesis 
of both viral minus-strand and subgenomic RNA (27, 30).  It is interesting to note that the 18 
amino acid deletion within AR86 results in the removal of 7 Ser residue and 1 Thr residue, 
which may affect the overall phosphorylation of nsP3.  Mutational analysis within the C-
terminal region of nsP3, which included this 18 amino acid domain, altered levels of viral 
minus-strand RNA synthesis and levels of nsP3 phosphorylation (27).  It will be intriguing to 
determine if the Ser/Thr residues are important or whether the specific amino acid sequence 
within the 18 amino acid region is important.  Due to the fact that nsP3 can tolerate insertions 
of green fluorescent protein (GFP), red fluorescent protein (RFP), or luciferase protein within 
the C-terminal region, this suggests that the specific amino acid sequence within the 18 
amino acid region may not be as important as the Ser/Thr residues (8, 10, 14).   
 In addition to its role in viral RNA synthesis, nsP3 has been shown to interact with 
several host proteins during the course of virus infection.  Cristea et al. has demonstrated that 
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early during infection nsP3 transiently interacts with Ras-GTPase activating protein (G3BP), 
a nuclear transport factor, while late in infection, nsP3 interacts with 14-3-3, a cellular 
protein which interacts with phosphorylated proteins and regulates various host cell 
processes (10).  In addition, Frolova et al. demonstrated that nsP3 forms higher ordered 
structures during infection and similarly found that nsP3 interacts with 14-3-3 late in 
infection (14).  While the importance of these nsP3-host protein interactions are not yet 
defined, it does demonstrate that nsP3 is not exclusively involved in viral RNA synthesis.  It 
will be interesting to determine the effect this 18 amino acid region plays in altering the 
efficiency of these interactions. 
 While most alphaviruses encode an opal termination codon proximal to the 3’ end of 
the nsP3 gene, the Sindbis-group virus strain AR86 (44) and the Semliki Forest virus (SFV) 
strain SFV4 carry a cysteine and arginine sense codon, respectively (44, 51, 52).  Tuittila and 
colleagues performed a detailed mapping study within the replicase genes using virulent and 
avirulent SFV strains and found that an Arg (virulent SFV4 strain) in place of the opal 
termination codon at nsP3 position 469 was an important contributor to adult mouse 
neurovirulence (51).   
 While the mechanism of this determinant in viral pathogenesis is not well understood, 
studies have characterized the role of the opal termination codon in regulating nonstructural 
polyprotein processing and viral RNA synthesis.  Translational read-through of the opal 
termination codon occurs at a frequency of about 5-10% (as reviewed in reference (17)), 
leading to limiting quantities of nsP4 relative to the other nonstructural proteins.  Li et al. 
replaced the opal termination codon of SINV with different sense codons and found 
increased levels of the nsP3/4 polyprotein precursor and reduced levels of mature nsP3 early 
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during infection (31).  A different C-terminus of nsP3 is produced in viruses encoding either 
an opal termination codon or a sense codon.  In the presence of an opal termination codon, 
the predominate nsP3 protein form consists of a C-terminus produced by translational stop at 
nsP3 537.  In contrast, in the presence of a sense codon, the predominate nsP3 protein is 
formed by cleavage at the nsP3/nsP4 site, which results in the addition of an extra seven 
amino acids to the C-terminus of nsP3 (47).  Furthermore, replacing the opal termination 
codon with a sense codon reduced levels of both 49S genomic and 26S subgenomic viral 
RNA synthesis early during infection (31).  Based on these findings, it will be important to 
determine whether the Cys sense codon in AR86 affects neurovirulence through alterations 
of nonstructural polyprotein processing and/or viral RNA synthesis.   Additionally, it will be 
interesting to study the relevance of the nsP34 precursor polyprotein in viral RNA synthesis 
or modulating virus-host interactions.   
The neurovirulence determinant within the E2 glycoprotein at position 243, in which 
AR86 encodes a unique serine residue, is likely affecting viral interactions with neurons or 
other cell types in the infected animal.  This hypothesis is based on the fact that E2 is 
involved in host cell receptor interactions and this particular change is near a region of the E2 
glycoprotein that is thought to be involved in direct contact with host receptors (39, 45).  This 
raises the strong possibility that the Ser residue might affect virus/receptor interactions by 
either altering the efficiency of receptor interaction or by changing the conformation of the 
E2 glycoprotein.  This is supported by findings within the E2 glycoprotein of other SINV, in 
which a Gly residue at position 172 enhanced viral binding to neuronal cells or a His residue 
at position 55 improved binding, entry, and replication in neuronal cells (12, 49, 50).  
Preliminary evidence from our laboratory showed no difference in the infectivity of neuronal 
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cells.  However, this determinant did appear to alter the infectivity of astrocytes, in which the 
attenuating Leu exhibited higher infectivity than the virulent Ser residue (Suthar, M.S. and 
Heise, M.T., unpublished data).  This preliminary finding, if true, would have some 
important implications on viral pathogenesis.  Astrocytes are the major glial cell within the 
CNS and are critical in the formation and maintenance of the blood-brain barrier, antigen 
presentation to CD4+ T cells through expression of major histocompatibility complex II 
(MHC class II), and induction of proinflammatory cytokines and chemokines such as type I 
IFN, IL-6, IP-10, IL-1, RANTES, and TNF-α (11).  This would imply that infection of this 
cell type may result in the induction of a strong proinflammatory response which would 
ultimately restrict virus replication and spread within the CNS.  It will be interesting to 
determine if this virulence determinant also shows differences in infectivity of microglial 
cells, which are the resident macrophages within the CNS.  Therefore, additional studies to 
evaluate the effect of the Ser versus Leu at E2 position 243 on virus binding or infection of 
neurons, astrocytes, or microglial cells may provide useful information on the role of this 
determinant in regulating viral infection.  However, the lack of a clearly defined receptor for 
alphaviruses currently hinders a direct analysis of this determinant’s role in virus/receptor 
interactions. 
 
AR86 virus antagonism of type I IFN induction 
Type I IFN is an essential component of the host response to viral infection because it 
directly activates antiviral effects and modulates antiviral activities of other components of 
the host innate and adaptive immune systems.  However, a number of viruses have evolved 
mechanisms to antagonize or evade induction of a type I IFN response.  These mechanisms 
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range from nonspecific effects, such as shutoff of host cell macromolecular synthesis (1, 16), 
masking viral RNA from host cell sensory proteins (9, 37), or specific inhibition of host cell 
dsRNA sensors or signaling molecules that link these sensor molecules to transcription 
factors that regulate type I IFN transcription (3, 6, 32, 33).   
 Although studies with SINV and other alphaviruses have demonstrated that host cell 
shutoff plays a major role in regulating viral type I IFN induction (16), we found that in our 
studies with AR86, the virulence determinant at nsP1 538 modulates type I IFN induction 
through an additional mechanism by altering the activation of Interferon Regulatory Factor-3 
(IRF-3).  We found that while wild-type AR86 virus exhibits reduced IFN induction in vitro 
or in vivo, a mutant AR86 virus containing the attenuating Ile at nsP1 position 538, induced 
robust levels of type I IFN.  While these two viruses did not differ in their kinetics of host 
translation of transcription shutoff, the mutant AR86 virus exhibited more rapid induction of 
IRF-3 dimerization and phosphorylation, a step which is independent of de novo host protein 
synthesis and is not affected by virus-induced host shutoff.  To further support this finding, it 
will be important to evaluate type I IFN induction and virulence in IRF3-/- mice.  
 Since the determinant at nsP1 538 affects type I IFN induction in addition to effects 
on host cell macromolecular synthesis, this raises three possible mechanisms by which the 
determinant at nsP1 538 modulates type I IFN induction.  One possibility is that wild-type 
S300 virus intentionally delays RNA synthesis from the 26S promoter until late in infection 
and this effect is disrupted by the determinant at nsP1 538.  This would suggest that the 
subgenomic RNA may be a potential target for sensing by the host cell.  A recent report by 
Gitlin et al., suggested that RIG-I plays an important role in responding to SINV infection 
(15).   Secondly, based on the recent finding that RIG-I has been shown to interact with 
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5’triphosphates on uncapped RNAs and given that virus nsP1 and nsP2 proteins are involved 
capping viral RNAs, it is possible that the determinant at nsP1 538 is altering the efficiency 
of capping viral genomic or subgenomic RNA (2, 23, 36, 41, 53).  Thirdly, wild-type AR86 
nonstructural proteins may actively suppress early type I IFN induction through direct 
interaction with host type I IFN signaling component(s), and this effect is disrupted by the 
attenuating Ile at nsP1 538.  This scenario raises the possibility that alphaviruses employ a 
multi-step approach to blocking type I IFN induction, where a specific inhibitory effect is 
active early in infection, while a generalized host shutoff would block IFN synthesis late in 
infection.   
 Given the role of the SINV nonstructural proteins in modulating type I IFN induction, 
we hypothesized that the AR86 nonstructural proteins were actively suppressing the type I 
IFN response.  Towards this end, we investigated the role of the two host cell cytoplasmic 
sensors of dsRNA, RIG-I and Mda5, during SINV infection.  We found that AR86 genomic 
RNA is capable of being recognized by RIG-I and Mda5.  In future studies, it will be 
interesting to determine the region of the viral genome RIG-I is recognizing and whether the 
subgenomic RNA is more efficiently recognized by RIG-I than full-length genomic RNA.   
 Although the AR86 genomic RNA is capable of being recognized by RIG-I, type I 
IFN induction is blocked by the viral nonstructural proteins.  We found that RIG-I, Mda5, 
and IRF-3 expression were rapidly lost in the presence of the viral nonstructural proteins in a 
viral nsP2 protease-dependent manner. This result suggests a novel role for the viral nsP2 
protease in antagonizing type I IFN induction and raises two possibilities by which the 
protease is effecting protein expression.  The first is the idea that the viral nsP2 protease is 
targeting and cleaving RIG-I and Mda5.  Examination of the amino acid sequences for RIG-I 
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and Mda5 revealed nsP1/2 and nsP2/3 virus-like cleavage sites within the proteins, 
respectively.  The cleavage preferences for nsP2 depend on its context with the other 
nonstructural proteins (as reviewed in  reference (47)).  Briefly, cleavage at the nsP1/2 site 
occurs only by the nsP123 polyprotein and inhibiting the nsP1/2 cleavage site blocked 
cleavage at nsP2/3 by the nsP123 polyprotein.   Furthermore, the nsP23 polyprotein is 
responsible for cleaving the nsP2/3 site.  The relevance of the cleavage site preferences on 
type I IFN induction is demonstrated by the finding that a Thr at nsP1 538 exhibits delayed 
nsP processing early during infection.  This would imply that wild-type AR86, which has 
been shown to have a stable nsP123 early during infection, is able to efficiently target host 
proteins that contain nsP1/2 virus-like cleavage sites, such as RIG-I.  As the nsP123 
precursor polyprotein is processed into nsP23, this polyprotein would be able to efficiently 
target host proteins that contain nsP2/3 virus-like cleavage sites, such as Mda5.   
 In addition to RIG-I and Mda5, we have identified other host cell proteins that 
regulate type I IFN induction that contain virus-like cleavage sites, including the 
mitochondrial associated adaptor protein IPS-1, containing an nsP2/3 like site, and histone 
deacetylase 6 (HDAC6), containing an nsP1/2 like site.  The adaptor protein IPS-1, also 
known as MAVS, Cardif, and VISA, interacts with activated RIG-I and Mda5, via their 
respective CARD domains, to activate IFN-β gene transcription (24).  While HDAC-1 and 
HDAC-8 were found to function as repressors of viral type I IFN infection, HDAC6 was 
found to function as a co-activator of IRF-3 dependent transcription (40).  While targeted 
cleavage of these proteins would be an efficient means of antagonizing the host cell antiviral 
response, further studies are required to determine if these host proteins are targets of the 
viral nsP2 protease.  These studies would include identification of the potential cleaved target 
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protein fragments when co-expressed with the viral nsPs or during virus infection.  
Moreover, this raises the possibility that targeting host proteins by viral proteases may be a 
general viral immune evasion strategy.  One such example is the observation that the 
Hepatitis C virus NS3/4A protease cleaves the mitochondrial-associated adaptor protein IPS-
1 and the TLR-adaptor protein TRIF to antagonize type I IFN induction (32, 33).     
 Another possibility for the observed loss of RIG-I, Mda5, and IRF-3 expression is 
that the viral nsPs could be targeting these proteins for degradation.  Recently, it has been 
reported that the Classic swine fever virus N(pro) protein and Rotavirus nonstructural protein 
NSP1 target endogenous IRF-3 for degradation in a proteasome-dependent manner (5, 7).  It 
is well known that activated IRF-3 is efficiently targeted to the host proteasome through the 
function of peptidylprolyl isomerase Pin-1 (43), however, the mechanism of degrading 
endogenous IRF-3 is not known.  Mda5 has recently been shown to be cleaved during 
poliovirus infection and this appeared to be mediated by the induction of apoptosis during 
virus infection (4).  These findings imply that the host cell has efficient mechanism to 
downregulate expression of components of the type I IFN signaling pathway.  The ability of 
a virus to target these negative regulatory pathways would be a mechanism to completely 
abrogate the ability of the host cell to respond to virus infection.  Therefore, it will be 
interesting to determine if the viral nsPs interact with and target these components for 
degradation or induce a negative regulator within the host cell that efficiently targets these 
proteins for degradation. 
  
 These studies have provided significant insight into the viral and host factors that 
mediate alphavirus-induced disease and the mechanisms underlying alphavirus pathogenesis.  
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SINV infection of mice is one of the best characterized model systems for studying virus-
induced diseases.  These studies have shown the spectrum of diseases SINV can cause in 
mice, ranging from virus-induced arthralgia to virus-induced neurologic disease.  Identifying 
the viral determinants responsible for modulating virus-induced neurologic disease provides 
the fundamental basis for future studies characterizing the mechanism of these determinants.  
Undoubtedly, future studies with the Sindbis-group virus strains Girdwood and AR86 will 
unveil novel mechanisms through which these viruses modulate the host antiviral response. 
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